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1. Introduction 
1.1. Stroke 
Stroke is a cerebrovascular disease, consequence of the 
alteration of normal cerebral blood flow, which results in a 
transient or permanent deficit of the function of one or 
more parts of the brain. This alteration of normal cerebral 
blood flow induces metabolic or biochemical alterations 
and would lead to cell death, and consequently, the 
alteration of the nervous system. The World Health 
Organization (WHO) has defined stroke as the fast clinical 
development of focal signs of alteration of cerebral 
function without any other apparent origin than the 
vascular one.[1] 
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Focusing on the nature of the lesion, stroke can be 
classified in two main groups, ischemic and hemorrhagic 
stroke. However, alternative classifications of this 
cerebrovascular disease can be used looking at other 
parameters such as stroke subtype, progression profile, 
neuroimaging characteristics, size and topography of the 
lesion, nature, and the mechanisms of induction and 
etiology.[2,3] 
1.1.1. Ischemic Stroke 
Ischemic stroke is the most common type of stroke, and 
represents about the 80% of all strokes.[2,4-6] This term 
includes also all those secondary encephalic alterations 
that lead to a failure of blood supply. Depending on the 
size and the affected territory, the classification is: focal 
brain ischemia, if affects one part of the brain, or global 
brain ischemia when the whole brain is injured. Among the 
focal brain ischemias, we can differentiate between 
transient ischemic attack (TIA) and cerebral infarction. TIA is 
defined as the focal or monocular cerebral dysfunction 
with symptoms that last for less than 24 hours, whose origin is 
a vascular insufficiency caused by an arterial thrombus or 
embolism, associated to arterial, cardiac or hematologic 
disease.[7] TIA patients present higher risk of subsequent 
major stroke (cerebral infarct) and other vascular episodes, 
mainly coronary, and the outcome of each individual is 
extraordinarily variable. 
Attending to the etiology, the different ischemic stroke 
subtypes can be divided,[6]  
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o Atherothrombotic infarction: (~20%) Generally 
middle or large sized infarcts with cortical, 
subcortical, carotid or vertebro-basilar topography, 
in patients with presence of one or several 
cerebrovascular risk factors. It is imperative the 
presence of clinically generalized atherosclerosis, or 
the demonstration of occlusion or stenosis (> 50% 
occlusion or <50% plus two or more vascular risk 
factors) in cerebral arteries, with an established 
correlation to the patient’s clinic. 
o Lacunar infarction or small vessel disease: (~25%) 
small sized infarct (<15 mm of diameter), localized in 
the distribution territory of the penetrating arterioles. 
Although micro-atheromatosis and lipohialinosis of 
penetrating arterioles are the most frequent 
pathologic substrate in lacunar infarcts, other less 
frequent potential causes are cardiac embolism, 
arterial embolism, infectious arthritis or prothrombotic 
state. 
o Cardioembolic infarction: (~20%) generally medium 
(1.5-3 cm of diameter) or large (>3 cm of diameter) 
sized infarcts, with symptoms frequently started 
during awakening. It is mandatory the presence of a 
demonstrated embolic origin, and the absence of 
significant concomitant arterial occlusion or stenosis. 
o Infarction of undetermined etiology: (~30%)  brain 
infarcts of medium or large size with more than two 
potential etiologies or unknown origin. 
o Other causes (~5%) 
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1.1.2. Biochemistry of cerebral ischemia 
The acute obstruction of one of the large brain arteries 
induces an instantaneous reduction of blood flow in the 
corresponding irrigation area (focal ischemia). But that 
reduction of blood supply is not homogeneous in the 
affected area, and can change within minutes or hours, 
especially if blood supply is reinstated.[8] 
Two regions can be distinguished: The ischemic core is the 
portion of tissue closest to the affected blood vessel and 
where the ischemia becomes severe, and the so-called 
penumbra, where the reduction of blood flow is less severe, 
due to the blood supply carried out by collateral arteries of 
the non-ischemic neighbor tissue.[9] The impact of brain 
ischemia will depend on the level of the artery occlusion 
and duration of the reduction of blood flow, that is why 
time is a very important parameter in this disease. 
After the onset of brain ischemia, a sequence of molecular 
events are triggered in the short and the long term, initiated 
with an energetic failure in cells, related to the interruption 
of oxidative phosphorylation processes and the deficient 
production of adenosine tri-phosphate (ATP) (Figure 1). The 
cessation of transmembrane ionic gradients due to the 
failure of sodium-potassium-ATPase pumps, and other ATP-
dependent ionic pumps, is the key step of the 
physiopathological mechanisms in stroke, especially of cell 
death in the ischemic core, when the vascular occlusion 
lasts for few minutes.[10] Neurons and glial cells suffer an 
extreme depolarization because of the entrance of sodium, 
chloride, calcium and water into the cytoplasm,[11] and in 
addition, potassium leaves the cell, inducing a sudden 
increment of its extracellular levels.[12] The energetic failure 
and the associated ionic changes, originate an increment 
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in glutamate, a hyperexcitability of N-methyl- D-aspartate 
glutamatergic receptors (NMDA), and of -amino- 3-
hydroxy-5-methyl-4-isoxazol propionic acid receptors 
(AMPA), which induces an even higher increase of 
intracellular calcium (Figure 2).[13-15] 
 
Figure 1: Sequence of main physiopathological events in cerebral 
ischemia. 
The increase of intracellular calcium does not exclusively 
depend on the activation of glutamate receptors, but also 
in the stimulation of calcium voltage-dependent channels. 
Hyperexcitability causes a depolarization phenomenon in 
the periphery of the infarct, which increases the energetic 
cost while the membrane tries to re-polarize itself.[9,16,17] 
Calcium increment, together with acidosis and peri-infarct 
depolarization, contributes to initiate the damage, and 
after it, inflammation and activation of apoptotic 
phenomena contribute to increment the lesion.[15,18] 
During ischemia, and particularly during reperfusion, free 
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radicals are generated. These are highly reactive species 
produced at the initial and late stages of brain ischemia, 
following different physiopathological mechanisms. In first 
place, oxygen reactive species are produced by the 
metabolism of arachidonic acid and the activity of 
neuronal Nitric Oxide (NO) synthase (nNOS). During 
intermediate stages, free oxygen radicals are provided by 
the infiltration of neutrophils in the ischemic area. At later 
stages, they are produced via the synthesis and activation 
of inducible NO synthase enzymes (iNOS) and 
cycloxigenase-2(COX-2).[19,20]  
 
Figure 2: Glutamate role on the stimulation of AMPA and NMDA 
receptors. 
Ischemic stroke triggers a series of complex molecular 
events, where the activation and the expression of genes 
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are included. Some of those events arise from the 
immediate reaction of neurons to damage,[21] and others 
are associated to cellular processes that determine the 
near fate of the affected neurons[22], or coordinate the 
repair mechanisms of tissues.[23,24] 
However, ischemic cellular death can take place in two 
different ways. The most common one is necrosis,[25] which 
is the result of the acute energetic failure, and it is 
characterized by morphology changes and, in the end, 
cellular lysis, which also triggers inflammatory processes.[26] 
On the other hand, apoptotic or programmed cell death 
can be observed when energy-dependent intracellular 
mechanisms are activated, leading to cell 
degradation.[18,27] 
1.1.3. The peri-infarct region 
The introduction of the concept of ischemic penumbra by 
Astrup[10], and its subsequent development, has been 
crucial for the consideration of ischemic stroke from a 
preventable catastrophe to a treatable disease. The time is 
brain aphorism, and the consideration that stroke is a 
neurological emergency, as a result of the ischemic 
penumbra concept, has allowed patients to profit from fast 
attention by trained medical staff and specialized stroke 
units. The penumbra is classically defined as the 
hypoperfused tissue surrounding the ischemic core, where 
blood flow is too low to maintain electric activity but 
sufficient to preserve ion channels. However, this area is 
subjected to waves of deleterious metabolic processes 
propagated from the core to the neighboring tissue, 
including excitotoxicity, spreading depression, oxidative 
stress, and inflammatory response, which lead to the 
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expansion of the ischemic core and the subsequent 
worsening clinical outcome. 
The most relevant definition of ischemic penumbra for 
clinical practice is based on neuroimaging techniques. It is 
widely accepted that brain tissue with reduced blood 
perfusion, as seen in MR perfusion-weighted imaging (PWI) 
but not included into the lesion core, as seen in MR diffusion 
weighted imaging (DWI), indicates potentially salvageable 
tissue. Thus, the combination of PWI and DWI images has 
led to the PWI/DWI mismatch concept.[28] Although it is 
generally accepted that hyperintense signal on DWI 
represents the lesion core, quantitative measurements of 
apparent diffusion coefficients (ADC) reveal that during 
ischemia, ADC values decline before energy metabolism 
fails, indicating that the increase in DWI signal intensity is not 
restricted to the infarct core[29]. Therefore, the 
discrimination between penumbra and infarct core by DWI 
is not always clear, because DWI signal increases in both 
sites. In addition, PWI-detectable flow decrease is 
pathophysiologically relevant only when interferes with the 
adequate oxygen supply to the tissue. Thus, the PWI/DWI 
mismatch includes not only the penumbra periphery, but 
also surrounding intact tissue.[28] Nowadays, neuroscientists 
are able to delineate the ischemic penumbra using 
alternatives to this hemodynamic concept. Among others, 
tissue hypoxia can be determined by MR spectroscopy, 
anoxic depolarization depicted by manganese enhanced 
MRI, tissue acidosis shown by pH-weighted MRI, and others. 
However, none of these methodologies is able to provide 
clear-cut threshold values to differentiate among ischemic 
core, penumbra, and surrounding intact brain tissue by 
themselves, and a multimodality approach is generally 
recommended.[28,29] Most of these MRI-based methods 
are unfortunately restricted to experimental models and 
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state-of-the-art brain imaging systems, and must be fully 
validated for the human brain before they can be 
translated into clinical practice.[30] 
Although the definition of the penumbra by imaging 
techniques is currently of great value, in clinical terms an 
alternative definition of “tissue-at-risk”, that is generally 
called peri-infarct region, may be more suitable for the 
development of new therapeutic approaches in stroke. The 
peri-infarct region is defined as a no men’s land between 
the infarct core, with a front of toxic mediators of damage 
spreading out from it, and the healthy tissue, from where 
tissue’s healing and repair mediators are trying to access to 
the affected but still viable tissue (Figure 3). It is clear that 
the peri-infarct definition and spatiotemporal dynamics do 
not necessarily match the specifications of the ischemic 
penumbra.  
 
Figure 3: Peri-infarct region defined as the battlefield between mediators 
of damage, from the infarct core, and mediators of healing and repair 
from normal tissue. (Adapted from [31]) 
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1.1.4. Therapeutic approaches for the treatment 
of stroke 
1.1.4.1. Thrombolysis and neuro-interventionism 
Pharmacological or mechanical (thrombectomy) 
thrombolysis are the strategies that report higher benefits for 
the patient, in terms of neurological outcome. The most 
common thrombolytic agent is the recombinant tissue 
plasminogen activator or rt-PA. Both therapies have pushed 
for the creation of stroke units inside hospitals, which have 
improved the management of stroke patients. Nevertheless 
only 3-7% of stroke patients are currently treated by these 
procedures. Such reduced numbers may be due to 
different factors, including the narrow therapeutic window 
and the high risks of hemorrhage transformation. Current 
neuroprotective strategies are required to work at both 
stages, by widening the therapeutic window and by 
reducing the associated risk factors.[32-36] The therapeutic 
window associated with intravenous thrombolytic treatment 
is 4.5 hours. The extension of this window may be possible by 
selecting candidate patients with a large penumbral area 
(the area of the brain susceptible to damage unless 
otherwise protected within the first 24-48 hours).[37] 
In addition, reperfusion is associated with a higher rate of 
hemorrhagic events and the maintenance of the blood-
brain barrier integrity (i.e. with metalloproteinase inhibitors), 
fluid homeostasis (by regulating aquaporin and inhibiting 
endothellin) and disabling free radicals after a reperfusion 
treatment, makes neuroprotective strategies during the 
acute phase of a stroke difficult to be viable.[38] An early 
treatment with anti-excitatory drugs or induction of 
hypothermia could also help to maintain the penumbra for 
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extended periods of time, hence extending the therapeutic 
window for reperfusion.[39] 
1.1.4.2. Neuroprotection 
Neuroprotection is a term that conglomerates a variety of 
strategies focused in reducing cell death after an ischemic 
event, without affecting tissue reperfusion. So far, a plethora 
of compounds have been proposed to block the pathway 
leading to ischemia-induced cell death at different steps. 
Most of these compounds have shown positive effects in 
experimental studies, although none of them have shown a 
clear beneficial effect in clinical studies.[40,41] 
Neuroprotective drugs can be classified into different 
groups, regarding their action mechanism. 
a. Calcium blockers 
Calcium plays an important role in stroke pathophysiology. 
The blockage of calcium channels stops neuronal calcium 
intake, hence reducing cell death. Nimodipine is an 
example of this family of compounds. With more than 200 
published experimental studies, only half of them proved 
the efficacy of the drug. None of the members of this family 
of compounds have demonstrated a clear neuroprotective 
activity on clinical studies.[42,43] Among the reasons for this 
fact, overall the studies that generated positive results, 
animals were mostly treated within the first 15 minutes post-
ischemia, which is not translatable to the clinical settings. 
b. Glutamate antagonists 
Glutamate is the main excitatory amino acid in the central 
nervous system. After an ischemic event, an excitotoxic 
response is generated leading to cell death. Glutamate 
activates NMDA and AMPA receptors. NMDA receptors 
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mediate cellular calcium and sodium intake. Several non-
competitive blocking drugs against NMDA receptors have 
been synthesized, such as MK-801 (dizocilpine), which was 
used as a neuroprotective compound and rendered 
positive results in animal models of stroke. Nevertheless, the 
subsequent clinical trial had to be stopped due to adverse 
effects.[44] 
NMDA competitive antagonist drugs have been also 
synthesized and used in animal models of stroke, like CGS 
19755 (Selfotel) and GV15526 (Gavestinel). Although both 
compounds produced encouraging results in experimental 
studies, but they showed no effect in clinical trials.[45,46] 
Natural NMDA antagonists, such as magnesium, have also 
been used as neuroprotective compounds. Magnesium 
sulphate has showed a brain infarct reduction up to 60% in 
animal models, treated even 6 hours after ischemia onset. 
Once again, these results showed no effect in clinical 
trials.[47] 
As for NMDA, AMPA receptors have also been targeted for 
neuroprotective strategies. AMPA antagonists like ZK200755 
have shown moderate neuroprotective effects in animal 
models. Results of its clinical trials have never been 
published.[38,42,48] 
c. Plasmatic glutamate grabbers 
Under normal physiologic conditions, glutamate present at 
the synaptic junction is captured by neurons and astrocytes 
through specific excitatory amino-acid transporters (EAATs). 
Nonetheless, under ischemic conditions these transporters 
do not function properly, and the massive release of this 
molecule lead to an accumulation of glutamate in the 
extracellular space.  
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EAATs are also present at the luminal side of endothelial 
cells in brain capillaries, and facilitate the passing of 
glutamate from the brain to blood. In this sense, it has been 
recently published that the increase of glutamate gradients 
between brain and blood facilitates the dumping of 
glutamate from the extracellular space to circulating 
blood, offering in this way an alternative strategy to protect 
brain cells during ischemia. Those strategies are based on 
metabolizing plasmatic glutamate by the action of the 
resident enzyme glutamate-oxaloacetate transaminase 
(GOT). This neuroprotective strategy has been successfully 
tested in animal models by our research group, leading to a 
significant reduction on brain infarct volume in animal 
models of stroke. In parallel, an association between 
elevated levels of GOT on blood and good outcome after 
stroke has been found in two clinical retrospective studies, 
pointing to the potential translationality of this 
neuroprotective strategy to the clinical setting.[49-52] 
d. Antioxidants 
Oxidative stress is another mechanism implicated on cell 
death after an ischemic event. Antioxidants could therefore 
play a role as neuroprotective drugs. The most successful 
antioxidant tested has been NXY-059. This drug reduced 
brain infarct by 66% in animal models, when injected 5 
hours after occlusion. The first clinical trial generated 
positive results, improving patient’s functional outcome. 
However a second clinical trial showed negative results. 
[53-55] 
e. Phospholipid precursors: citicoline 
Citicoline or CDP-choline is a precursor on the synthesis of 
phosphate-choline, which is integrated in the membrane of 
neurons. It has been shown that citicoline inhibits 
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norepinephrine and dopamine levels on the CNS, and 
restores mitochondrial ATPase activity.[56] 
On animal models citicoline lowered phospholipase 2 
activation after brain ischemia, reducing arachidonic acid 
formation and hence the production of free radicals; 
therefore inhibiting oxidative stress. Another effects claimed 
for this drug are its capacity to reduce excitotoxicity and 
the stimulation of brain plasticity.[57] 
In preclinical studies, the treatment with citicoline 
immediately after reperfusion led to an improvement on 
functional deficits after a period of 28 days. A pool-data 
analysis published in 2002 showed a 33% increment in 
complete recovery after mild or severe stroke (NIHSS ≥ 8) 
when the treatment was started within the first 24 hours and 
maintained for 6 weeks.[40,58-60] 
f. Nitric oxide pathway transduction regulators 
One example of this kind of drugs is Lubezol, a compound 
capable of deregulate the glutamate-induced nitric oxide 
synthase pathway. This compound has shown hippocampal 
neuroprotection from nitric oxide toxicity. In experimental 
studies it has shown a 50 % infarct volume reduction upon 
injecting the drug 3 hours after ischemia induction. 
Nevertheless no clinical trial rendered positive results, and 
one of them was cancelled due to the mortality increase 
experimented in the treated group.[44] Several studies 
have been performed using other neuroprotective agents 
such as leukocyte inhibitors (Enlimomab), neuronal 
potassium channel activators (BMS-204352), membrane 
fluidity modifiers (Piracetam), opioid antagonists 
(Namefene), growth factors employed as intracellular 
calcium regulators (FGF), and much more. None of them 
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have shown the definitive efficacy of pharmacological 
neuroprotection.[44] 
1.1.4.3. Neurorepair 
Neurorepair strategies involve the restoration of brain 
function, either by regeneration of damaged cerebral 
tissue (neurogereneration) or by the establishment of 
alternative neural pathways or synapses (brain plasticity). 
However, therapeutic window for those therapies is wider 
than for thrombolytic or neuroprotective approaches. The 
aim of the treatments for neurological function recovery 
after stroke is not restricted to neurons; it is more focused on 
the neurovascular unit, including procedures that enhance 
synaptogenesis and angiogenesis. Thus, neurorepair 
treatments may use stem cells, pro-neurogenic, pro-
angiogenic and/or pro-synaptogenic drug delivery. 
a. Neurogenesis after brain ischemia 
In the adult brain there are niches for the production of 
neural stem cells,[61] localized in the subventricular region 
of the lateral ventricles (SVZ) and the dentate gyrus of the 
hippocampus (Figure 4). Under normal physiological 
conditions, the neuroblasts produced in the SVZ migrate to 
the olfactory bulb to differentiate in new neurons. After the 
induction of focal brain ischemia in the rat, an increase in 
neuroblast formation occurs in the ipsilateral hemisphere, 
and these neuroblasts migrate to regions surrounding the 
lesion.[62] This effect has been also shown in humans.[63] 
The enhancement of endogenous neurorepair mechanisms 
is one of the main goals on new therapies for the treatment 
of stroke. 
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Figure 4: The SVZ–OB system (OB, olfactory bulb). Schematic sagital view 
of the adult rodent brain with the OB to the left and the cerebellum (CB) 
to the right. The SVZ is along the lateral wall of the lateral ventricle (LV, 
blue). New neurons are constantly produced throughout the SVZ. The 
young neurons become aligned into long chains (red lines) that form a 
complex network of interconnected paths throughout the SVZ. Many of 
these chains in the anterior SVZ connect with the RMS, which leads young 
neurons into the core of the olfactory bulb. Within the olfactory bulb, cells 
disperse radially (dotted lines) as individual cells and complete their 
differentiation into granule and periglomerular interneurons. NC, 
Neocortex; cc, corpus callosum. (Taken from[61]) 
Even though newborn cells are recruited after an ischemic 
insult, most of them do not get integrated into neuronal 
circuits. Several strategies have been used to enhance 
endogenous neurogenesis. Thus, a great number of newly 
differentiated neurons would be available, increasing the 
chance of survival and integration in neuronal networks, 
therefore improving functional recovery. Both cellular and 
pharmacological therapies have been used to achieve this 
goal by activating the phosphatidylinositol-3-kinase (PI3-
Akt) pathway. This pathway is involved in cell survival, 
proliferation, differentiation and migration.[64]  
b. Angiogenesis after brain ischemia 
The development of the cerebral vascular system occurs 
mainly due to angiogenic processes. During adult life, 
endothelial cell proliferation ceases under normal 
physiological conditions. However, after an ischemic event 
brain capillaries surrounding the lesion proliferate, and new 
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vessels are formed between 2 and 28 days after the onset 
of stroke. [65-68] 
The angiogenic process involves a multi-step procedure 
that comprises endothelial cell proliferation and migration, 
tubule formation, branching and anastomosis. Vascular 
Endothelial Growth Factor (VEGF) and its receptor (VEGFR2) 
initiate the angiogenic process, being angiopoietin 1 and 2 
and their receptor (TIE-2) responsible for the maturation, 
stabilization and vascular remodeling [69]. VEGF and VEGF2 
expression promotes vascular ramification, and the newly 
formed vessels are highly permeable. Meanwhile 
angiopoietins and TIE2 expression stimulate vessel 
maturation leading to the formation of fully functional brain 
blood vessels. VEGF treatment or therapies focused in 
producing VEGF, VEGF2, angiopoietin or TIE2 expression 
could increase the angiogenesis in the peri-infarct region.  
The angiogenic process is essential for brain recovery after 
cerebral ischemia. In experimental studies both cellular and 
pharmacological therapies have been used to increase 
angiogenesis, promoting the functional recovery of 
ischemic animals.[70] 
c. Neurogenesis & angiogenesis 
Neurogenesis and angiogenesis after cerebral ischemia are 
not separated processes. Neurogenesis in the peri-infarct 
region cannot occur without angiogenesis, since the 
ultimate is responsible for restoring the oxygen and nutrient 
supply. Furthermore, endothelial cells produce growth 
factors that allow the neurons to survive, and that regulate 
metabolic activity of neural precursors. Endothelial cells 
secrete Stromal Cell-Derived Factor-1 (SDF-1), VEGF and 
Matrix Metalloproteinases (MMPs) that induce and facilitate 
neural progenitor cell migration to the injured site. On the 
 32 
 
other hand, neural progenitor cells overexpress 
angiopoietin 2 and VEGFR2 leading to an increase in 
angiogenesis.[71] 
Several in vitro and in vivo studies have shown the 
relationship between angiogenesis and neurogenesis. 
[71,72]. In animal models of ischemia, Tie2 inhibitors not only 
reduce angiogenesis, but also neuroblast migration to the 
peri-infarct area. On the other hand, neural progenitor cell 
grafted in the infarct region have demonstrated the 
induction of angiogenesis. These and other studies have 
reported that neurogenesis and angiogenesis are highly 
connected, and both promote neural remodeling and 
improve neurologic function after brain ischemia.[73,74] 
d. The role of oligodendrocytes, astrocytes and axons in 
neurorepair 
In the brain parenchyma there are not only neurons, but 
other cellular components as well (Figure 5). 
Oligodendrocytes, astrocytes and the development of 
functional axons are also involved on neurorepair. After an 
ischemic event, astrocytes proliferate forming a glial scar 
that surrounds the lesion and release proteoglycans that 
inhibit axonal growth. Hence there should be mechanisms 
for reducing glial scar formation, and also to stimulate 
axonal growth, leading to an efficient neurorepair.[75] 
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Figure 5: Cell structure of brain parenchyma (Adapted from [76]) 
 
1.2. Stem cell therapy 
Research on stem cell therapies has been increasing from 
the last 40 years. This kind of therapies are specially 
attractive because stem cells interact directly to brain 
parenchyma cells whereas classical or pharmacological 
treatments depend on their pharmacokinetic profiles.[62] In 
this way, stem cells have emerged with a double role, not 
only as the key for revealing the insights of the 
neuroscience as well as new promising therapies for stroke, 
due to their self-renewal and multipotentiality 
properties.[77] However, the mechanisms mediating 
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ischemic stroke recovery using stem cells are still poorly 
understood.[78]  
One of the potential mechanisms of stem cell therapy is cell 
replacement. Early studies have reported that after stem 
cell transplantation the number of grafted cells 
differentiated into mature neurons formed can vary. The 
origin of this variation lies in the source of the stem cell and 
also in the injection site. In this way, in recent preclinical 
studies, 34-60% of the injected cells were Neural Stem Cells 
(NSCs),[79] 30% Embryonic Stem Cells (ESCs)[80] or 2-20% for 
Mesenchymal Stem Cells (MSCs).[81,82] But sometimes, 
grafted cells remain undifferentiated close to the injury site, 
releasing growth and trophic factors [83,84] or even without 
entering the Cerebral Nervous System (CNS) inducing also 
benefits after stroke.[85] Regardless of this effect, this 
systemic cell administration can provoke that administered 
cells stay also in other organs, like spleen or liver, interacting 
with other cells from the immune system and leading into 
modulatory functions,[86] reducing at the same time, the 
post-ischemic inflammatory damage in stroke. [87-89] 
Nevertheless, apart from cell replacement, enhanced 
trophic support and immunomodulatory response, there are 
endogenous brain repair processes that stem cell can 
stimulate, such as angiogenesis, neurogenesis, 
synaptogenesis and white matter remodeling [62,90-93] 
inducing neurorestorative effects after ischemia.  
In contrast to other pathologies, in stroke there is affected 
more than one brain cell population, involving also vascular 
cells in the ischemic region. This heterogeneity means that 
not only functional neuronal connections have to be 
reestablished; the vascular system has to be restored as 
well. In consequence, there is not an unique type of stem 
cells for stroke therapy, many of them have been tested 
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demonstrating beneficial effects: Embryonic Stem Cells 
(ESCs),[94-96] Neural Stem Cells (NSCs),[91,97,98] Induced 
Pluripotent Stem Cells (iPSCs),[99,100] Human Umbilical 
Cord Blood Cells (HUCBCs)[101,102] and Mesenchymal 
Stem Cells (MSCs). [82,103,104] Recent studies with iPSCs 
have shown powerful new opportunities for modeling 
human diseases offering hope for personalized 
regenerative cell therapies. However, the field is racing 
ahead, and some researchers are pausing to evaluate 
whether induced pluripotent stem cells are indeed the true 
equivalents of embryonic stem cells and whether subtle 
differences between these cells might affect their research 
applications and therapeutic potential.[105,106] 
But, there are several parameters to take into account to 
elucidate the effective time point for stem cell therapy in 
preclinical or even clinical studies. An important factor to 
be considered is the use of autologous versus allogenic 
stem cells. The term autologous is referred to those from the 
same individual who is going to receive the treatment 
whereas allogenic cells are related to a donor. In spite of 
this, the less lineage specific the cells are, the less chances 
to have an immune response,[107] in fact, for example 
MSCs which can be harvested from a variety of 
mesenchymal tissues have different immune response 
depending on their origin.[108] Additionally to the immune 
response, several cases of tumorigenicity have been 
reported after stem cells therapies from different stem cell 
types. [109,110] 
Very few preclinical studies have compared different routes 
of administration, and the choice among them depends on 
the organ target. First studies for cerebrovascular diseases 
explored the intraparechymal route with the main goal of 
determine the feasibility of replacing lost neurons and 
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rebuilding neural circuits,[111] meanwhile later studies 
showed that stem cells were not only able to survive after 
injection, as well as proliferate, differentiate and even 
migrate to the site of the injury.[112,113] However, 
intraparenchymal cell delivery normally is not the first 
choice because the injection is focused in one region and 
to reach that point it is necessary to damage brain tissue. 
On the other hand, vascular routes, intravenous (i.v.) and 
intra-arterial (i.a.), solve these pitfalls and they are 
becoming the most common cell delivery method. Tail vein, 
femoral and jugular veins are the most common ones for 
stem cell administration. Several groups have demonstrated 
that i.v. administration can reduce infarct size or induce 
functional recovery [82,101] when administrated 24h after 
stroke. Later studies also studied the biodistribution after i.v. 
injection and found out that depend on the cell type, 
between 1-5% of the injected cells reached arterial 
circulation.[114] One of the most interesting i.v. applications 
was for NSCs delivery. It’s known that this kind of stem cells 
has the ability to differentiate into neurons, astrocytes and 
oligodendrocytes. At the early beginning of stem cell 
therapies their repairing mechanisms were assumed to be 
related to rebuild the neural structure, but in recent years it 
has been observed that the injured brain environment is not 
optimal for cell integration, so the recovery works through 
growth factor mediation or anti-immflamatory processes. 
[115]  Nevertheless, it seems that if the brain is the target, it 
would be desirable to reach it with the most of the injected 
cells, and to achieve it the best delivery route is the i.a. 
administration. The first study showed that 21% of the 
injected Bone Marrow Stem Cells (BMSCs) were observed in 
the affected hemisphere, and this was also related with 
functional recovery in behavioral tests but not as an infarct 
volume reduction in the treated group. However, 
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administration route efficiency is also conditioned by the 
safety of the procedure and attending to this, i.a. 
administration has shown higher mortality than i.v. delivery. 
In a recent study, 41% of the animals died after an i.a. 
injection compared to 8% for i.v. delivery.[116] That’s why 
this delivery route has been more explored recently and 
many studies have developed different injection strategies 
to minimize the risks.[117-120] 
All these promising preclinical results progressed into early 
clinical trials of stem cell therapy in stroke. The effectiveness 
of different types of stem cells and delivery routes is also 
reflected in clinical studies which are exploring different 
combinations. So far, there is four published clinical trials of 
intracerebral cell therapy for stroke and one that is still 
ongoing,[121-123] one of intravenously administration 
[115,124-126] and three following intra-arterial delivery. [127-
129] The main goals of these clinical trials were to 
demonstrate the safety and feasibility of stem cell therapy 
using different types of stem cells and routes of 
administration. Published results have reported that there 
were not enough patients enrolled in these studies to show 
benefits in terms of functional recovery after the treatment, 
but all of them demonstrated that stem cells are a 
promising, feasible and safe therapy for stroke.  
However, the optimal conditions for applying stem cell 
therapies are still under discussion, fundamental questions 
related to cell type, characterization and dosage, 
therapeutic timing versus toxicity, or the relationship 
between biodistribution, fate and outcome are still on the 
bench, and preclinical studies should answer it first.  
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1.2.1. Mesenchymal Stem Cells 
The term mesenchyme is related to embryonic connective 
tissue, derived from mesoderm, that can be differentiated 
into hematopoietic and connective tissue. Mesenchymal 
Stem Cells (MSCs) can be derived from almost all tissues in 
the body (Figure 6): bone marrow, placenta, muscle, skin, 
adipose tissue, umbilical cord, etc.[130] 
The bone marrow derived cells (BM-MSCs) is the most 
studied type of MSCs. [131]  They express a number of 
markers, none of which unfortunately are specific to MSCs, 
being CD73+, CD90+, CD105+, CD11b-, CD14-, CD19-, CD79a-
, CD34-, CD45- and HLA-DR. It is generally agreed that rat 
MSCs do not express hematopoietic markers, as CD45, 
however cultured MSCs are uniformly and strongly positive 
for CD105, CD90 and CD73, regardless their passage or 
time in culture.  MSCs can be differentiated into several cell 
types in vitro and can be expanded in vitro. These two 
properties make the mesenchymal stem cells attractive as 
a powerful source for tissue repair.[132,133] Moreover, MSCs 
have the potential to differentiate into adypocites, 
chondroblasts and osteoblasts[134] and their ability to be 
differentiated into myocytes, neuronal and glial cells has 
been already reported.[135-137] 
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Figure 6: MSCs differentiation into different cell types. 
MSCs are one of the best candidates for regenerative 
therapies, also in stroke, not only due to their 
multipotientiality, but mainly because their ability of 
releasing growth factors and their immunomodulatory 
abilities.[131] Several mechanisms of action of these cells in 
the ischemic brain have been described, mechanisms like 
transdifferentiation into cells of neural lineage[138-141] 
induction of neurogenesis,[142-144] angiogenesis,[142-144] 
synaptogenesis,[145] activation of endogenous restorative 
processes by producing cytokines and trophic 
factors,[142,146-148] regulating the Cerebral Blood Flow 
(CBF) and the Blood Brain Barrier (BBB),[146] and other 
neuroprotective mechanisms like the reduction of 
apoptosis, immflamation, demyelination and the increase 
of astrocyte survival.[101,142,143,149] Many preclinical 
studies reported functional recovery and infarct volume 
reduction after ischemic stroke, [131] which facilitates the 
leap into clinical trials.  
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1.2.2. Strengthen of endogenous stem cells and 
stroke recovery 
Several studies in rodents and also in humans have reported 
that after a stroke event there is an endogenous stem cells 
migration towards the site of damage to contribute to the 
functional recovery.[150,151] These neural stem cells and 
their progeny activation and migration occur till the cells 
are integrated forming new functional neurons.[152,153] 
However, this endogenous contribution is not enough to 
overcome the consequences after stroke.  
Several groups have demonstrated that direct 
administration of growth factors can enhance these 
endogenous processes like migration of NPCs, neurogenesis 
and angiogenesis. Factors such as vascular Endothelial 
Growth Factor (VEGF),[154-156] Epidermal Growth Factor 
(EGF),[157] Fibroblast Growth Factor (FGF) and 
Erythropoietin (EPO)[158] have been proved in stroke 
models with functional benefits. Moreover, the stimulation 
of the NPCs without affecting other cell types is being 
investigated. There are some approaches for this purpose 
by focalizing different treatments as poly(ethylene glycol) 
nano/microparticles carrying biomolecules[159] direct brain 
injection of functionalized hydrogel[158] or intraventricular 
infusion of biomolecules.[160]  
Nevertheless, there is another way of growth factors 
delivery: stem cells. If the matter is target the proximity of 
the injury, as it has been specified at the beginning of this 
section, intra-arterial route of administration is the most 
efficient in terms of cell engraftment. But this binding can 
be also enhanced either by selecting a specific population 
of cells that endogenously express adhesion molecule or by 
modifying them to induce their expression.[161]  However, it 
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is still necessary to demonstrate if those cells which have 
been bound to the endothelium, are able to migrate and 
target stroke lesions.  
1.3. Animal models of ischemic stroke 
Stroke is a focal neurologic deficit caused by an alteration 
in the cerebral blood circulation. Animal models for 
cerebral ischemia have been used for over 150 years trying 
to mimic the human pathology,[162] improving our 
understanding of the physiopathology of this disease. 
Numerous preclinical studies, mostly with neuroprotective 
drugs, have shown promising results for the treatment of 
stroke, however not all positive experimental outcomes 
were transferred to patients, in terms of a phase III clinical 
study so far.[163,164] However, the success of stroke studies 
in animals depends on the choice of the experimental 
model species. An inadequate selection of the specie 
and/or the experimental model may lead to limitations that 
compromise results and analysis.[165,166]   
Numerous animal species have been used to study stroke, 
although the most common are rodents, due to the ease 
for inducing the cerebral ischemia, ease to monitor 
physiologic conditions and the reduced costs to obtain and 
maintain the animals for long periods of time.[163,166] We 
may not forget that in animal models of cerebral ischemia, 
most of variables are controlled in laboratory experiments 
and these conditions are quite different compared to a 
human going through a ischemic stroke process.[165]  
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Among rodents, the arterial and nerve supply of the rat is 
essentially similar to that of humans,[167] so rat is an 
appropriate animal for preclinical studies of brain ischemia. 
Firstly, and for a better understanding of cerebral ischemic 
models, it is necessary to have an anatomic knowledge 
about cerebral circulation in the rat. Basically, the head 
blood circulation depends on two systems: the carotid and 
the vertebrobasilar systems.[168] 
o Carotid system. Right and left common carotid 
arteries (CCA) supply the head and the neck. Left 
arises from the arch of the aorta and right common 
artery is a continuation of the innominate artery. 
Each common carotid yields two branches, the 
external and internal carotid, both follow the same 
general direction to the head. External carotid (ECA) 
leads to occipital, superior thyroid, ascending 
pharyngeal, lingual and ascending palatine, 
meanwhile internal carotid artery (ICA) continues to 
reach the base of the skull. On its way to the brain, it 
branches into pterygopalatine (PPA) artery, which 
corresponds to a portion of the internal maxillary 
branch of the external carotid artery in humans. The 
cerebral portion of the internal carotid artery 
branches into the posterior communicating artery 
(PCoA), hypothalamic artery, anterior choroid artery, 
middle cerebral artery (MCA) and anterior cerebral 
artery (ACA). The main branch of posterior 
communicating artery is the posterior cerebral artery 
(PCA), which supplies the surface of the brain 
hemisphere, including the medial and lateral 
surfaces of the occipital lobe.  
o Vertebrobasilar system: vertebral arteries arise from 
the anterior surface of the subclavian artery. When 
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entering the skull, both vertebral arteries join to form 
the basilar artery (BA). This artery is anastomosed to 
posterior communicating arteries from the carotid 
system.  
Arteries from carotid and vertebrobasilar systems form a 
circle of communicating arteries, which protects the brain 
when the blood flow circulation is interrupted. This arterial 
circle, present in humans and also in rats, is called circle of 
Willis. The circle of Willis in rats is a buttonhole-like structure, 
formed by the anterior cerebral and posterior 
communicating arteries. Normally, another extra artery, the 
anterior communicating artery (ACA), bridges anterior 
cerebral arteries from both hemispheres closing the circle, 
however is quite common that the circle is not complete. 
Probably one of the most interesting things about the circle 
of Willis is that the blood flow circulation is overlapped, i.e., 
if one of the main arteries is occluded, the distal smaller 
arteries that it supplies can receive blood from other 
arteries, which is called collateral circulation.[167,169] 
(Figure 7) 
Depending on the region affected by the diminution of 
cerebral blood flow (CBF), cerebral ischemic experimental 
models can be classified in global, focal or multifocal 
ischemia,[166] and attending to the duration of the 
ischemic insult, ischemia can be classified in transitory, if the 
artery occlusion is followed by reperfusion, or permanent 
ischemia, without artery reperfusion.[163] In this work we will 
focus on the focal cerebral ischemic model, which normally 
results in an ischemia in the cortex and striatum from 
occlusion or the middle cerebral artery, and it mimics the 
most common site of human stroke. In animal models of 
focal cerebral ischemia, the degree and distribution of CBF, 
and therefore infarction, depend on the duration and the 
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localization of the occlusion, as well on the collateral 
circulation.[170]  
 
Figure 7: Diagrams of cerebrovascular anatomy in rats adapted from 
Longa et.al.[171] 
A wide variety of animal models of focal cerebral ischemia 
have been investigated, and most of them involve 
craniotomy. A non-invasive method to produce permanent 
or transient middle cerebral artery occlusion (MCAO) is the 
intraluminal filament model, described in the late 
1980s[171]. It is a widely used technique to study 
mechanisms of cellular injury and neuroprotection. 
Typically, the occlusion is performed by inserting a 4-0 nylon 
suture into the ICA of rats, advancing the thread cranially to 
block the MCA. In this work, from Longa et. al.,[171] 
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additional extracranial vessels such as vertebral arteries, 
contralateral ICA and ipsilateral ECA, were occluded to 
reduce collateral blood flow to the MCA territory, however 
those occlusions are not indispensable for intraluminal 
filament animal model.   
Animal models of cerebral ischemia are designed to 
generate reproducible infarcts in a high throughput manner 
with a minimum of surgical manipulation, however 
therapeutic approaches have to be also optimized for 
each disease. Thus, optimal conditions for applying stem 
cell therapies for cerebral ischemia are still under discussion, 
fundamental questions related to cell type, 
characterization and dosage, administration route, 
therapeutic timing versus toxicity, or the relationship 
between biodistribution, fate and outcome are still on the 
bench.[172]  
1.3.1. The blood brain barrier 
Brain blood supply is governed by the carotid system, 
vertebrobasilar system and in the last term, by the arterial 
anastomosis of the circle of Willis.[173] Within them, cerebral 
microcirculation is constituted by three entities, endothelial 
cells, pericytes and astrocyte end-feet, which all together 
form the Blood Brain Barrier (BBB). BBB is a diffusion barrier, 
which selective excludes the influx of most compounds from 
blood to most parts of the brain.[174] Endothelial cells from 
BBB, which have been demonstrated by transmission 
electronic microscopic studies being the principal 
anatomic structure of the entity[169], differ from endothelial 
cells of the rest of the body by the absence of fenestrations, 
sparse pinocytic vesicular transport and more extensive 
tight junctions, which block the diffusion through the 
vascular wall. All systemic endothelial cells are 
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interconnected by tight junctions that normally have a low 
resistance (about 5-10 Ω/cm2), however in the BBB this 
resistance is a lot higher (2000 Ω/cm2) impeding the 
transference of small molecules as potassium ions.[169] 
Hydrophilic molecules flow across the BBB is limited but in 
contrast, small lipophilic substances such as O2 or CO2 
diffuse freely depending on their gradient 
concentration.[174] Most of substances that must cross the 
BBB are not lipophilic and enter the brain via transporters. 
But apart from molecules, some cells can also cross the BBB. 
Under normal physiological conditions, lymphocytes entry 
into the central nervous system (CNS) across the BBB is kept 
at a low level. However, during inflammatory diseases, the 
circulating immunocompetent cells readily get access to 
the CNS.[175] In ischemic stroke, the effect of hypoxia-
ischemia on the BBB has been extensively investigated. 
Hypoxia-ischemia sets in motion a series of events, which 
leads to disruption of the tight junctions and increased BBB 
permeability.[174] Several preclinical studies have 
elucidated that while experimental permanent occlusion of 
a cerebral artery is associated with a monophasic leakage 
of BBB, biphasic pattern of BBB leakage is believed to occur 
in a ischemia-reperfusion scenario.[176,177] This leakage 
must be considered not only as a source of disease 
complications like for example brain edema in ischemic 
stroke,[176] as well for treatment approaches, including 
stem cell therapies.  
1.3.2. Mesenchymal Stem Cell therapy in animal 
models of ischemic stroke 
Mesenchymal stem cells are an attractive therapeutic 
agent due to their ease of isolation, established safety and 
also because of their potential to target multiple pathways 
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involved in neuronal regeneration. A large number of 
preclinical and clinical trials have used systemic infusion of 
these cells, however it is still necessary to understand if 
transplanted MSCs can home to and engraft at ischemic 
and injured sites in the brain to exert their therapeutic 
effects.  Several studies have described that MSCs can 
follow a leukocyte-like, multistep homing cascade (rolling, 
adhesion and transmigration) to connect with endothelial 
cells (ECs), however all in vivo and in vitro models have 
found several limitations.[178] Moreover, the in vivo mixed 
results of MSCs therapy efficacy is attributed to an 
incomplete understanding of MSCs biology and their fate 
following transplantation in vivo.  
Functional improvement in animal models of focal cerebral 
ischemia when mesenchymal stem cells were transplanted 
either intravenously or intra-arterial has been demonstrated 
[179-182] however, there is not a preferred route of 
administration. Brain intraparenquimal and intraventricular 
administration routes are invasive, and it would be 
necessary several injection sites to cover the ischemic 
region. On the other hand, several groups have tracked 
labeled cells from different tissues and species donors 
administered i.v., evidencing the high rate of cell 
entrapment in peripheral organs and that reduced number 
of cells reached the brain.[114] Tail, jugular or femoral 
intravenous administrations are less invasive but most of 
cells remain trapped in lungs, liver and spleen.[183] 
Nevertheless, i.a. administration route would be the best 
candidate to direct most of the injected cells to the brain, 
especially on the region of the ischemic injury.[184] 
However, the fate of the injected cells following this route 
remains unknown due to the variable reported results found 
in literature. Thus, some studies have shown that 
approximately 21% of the delivered cells after an intra-
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arterial injection were observed in the ipsilateral 
hemisphere,[103]  however recent studies reported that 24h 
after injection 95% of the delivered cells were found in the 
spleen.[118] At this point, it is important to take into account 
that animal models of focal brain ischemia and the intra-
arterial injection procedure are not the same for all these 
studies, which could explain differences on the cell 
distribution pattern after delivery. Apart from the cell 
distribution, most of them have agreed the main 
inconvenience for intra-arterial cell delivery in cerebral 
ischemia is the high animal mortality compared to other 
routes of administration.[183] 
1.4. Non invasive imaging 
There are many imaging modalities used in clinical and 
preclinical practice and the choice among them is based 
on multiple aspects including the nature of the specific 
diagnostic question, availability and cost-effectiveness. For 
one specific disease, parameters such as specificity, 
sensitivity, spatial resolution and radiation exposure will 
make more suitable one technique among others. 
However, for stem cell therapy the goal is double, not only is 
crucial to determine where the cells are, but to evaluate 
the pathological progress of the target organ as well.  
For the recent development of cell-based therapies, 
imaging plays an important role on the follow-up of cell fate 
after administration and also on the response of the host to 
the treatment.  
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In the field of cell imaging, several techniques for non-
invasive cell imaging in vivo have been developed, 
including Bioluminescence, Intravital Multiphoton 
Microscopy, Positron Emission Tomography (PET) and 
Magnetic Resonance Imaging (MRI) and all these imaging 
modalities are widely used in preclinical studies in stroke.   
X-ray computed tomography (CT) and MRI are used for 
imaging the density and the intensity respectively, of the 
cerebral parenchyma and its anatomic structure in clinical 
procedures. The role of these imaging techniques is to 
identify the presence or absence or hemorrhage, detect 
ischemic tissue and differentiate the ischemic lesion from 
other diseases. However, MRI is considered the gold 
standard not only for the diagnosis in the acute phase of 
the stroke; as well to evaluate the progression of the 
pathology.[185]  
1.4.1. Magnetic resonance imaging (MRI) 
Nowadays, MRI is one of the most powerful medical 
diagnostic tools available due to its high resolution, but also 
because of the non-invasive and no ionizing radiation 
nature of the technique (Figure 8).  
Each pixel of a MR image is the measurement of the 
nucleus spin magnetization, generated by the irradiation of 
the tissue at that position of space with a radiofrequency 
pulse (RF) in presence of an external magnetic field (B0). In 
magnetic resonance imaging we do not measure to what 
extent nuclei (usually protons, represented by 1H) can be 
excited, but how they relax after excitation to return to a 
state of equilibrium. This effect, called free induction decay, 
is detected through the MRI coils and transformed into an 
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electrical signal that can be detected and further 
processed to generate an image.   
 
Figure 8: T2 weighted magnetic resonance image. 
There are two independent and simultaneous physical 
processes responsible for the relaxation of excited proton 
spins, but before, it would be necessary to define what spin 
magnetization vector is.  
To describe MRI from a macroscopic point of view, we can 
suppose that we allocate a tissue into an external magnetic 
field (B0) and that such tissue (Figure 9a.) can be divided in 
different parts, depending on how these parts are affected 
by the magnetic field (Figure 9b.), or in other words, in 
groups of spins that are experiencing the same magnetic 
field strength. Each of the delineated groups of spins can 
be represented by a global magnetization vector (Figure 
9c.), which, at the same time contribute to form the net 
magnetization of the whole tissue (Figure 9d.).  
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Figure 9: Description of spin magnetization vector. 
Under B0 condition, protons have an equilibrium longitudinal 
magnetization vector, parallel to this magnetic field (we 
consider B0 and the net magnetization aligned along the Z 
axis). In this equilibrium, transversal components of the 
magnetization (perpendicular to B0) are not detectable 
because nuclear spins are processing out-of-phase and 
their transversal components cancel each other. However, 
after an excitation of the spins by a RF excitation, the 
system is out of equilibrium in terms of longitudinal and 
transversal magnetization, and in this state, the transversal 
component of this vector can be detected. As we have 
already mentioned, there are two relaxation processes that 
bring the system back to equilibrium, each of them 
described by time constants, the Spin-Lattice relaxation or 
longitudinal relaxation (T1) and the Spin-spin or transversal 
relaxation (T2).  
a. Spin-Lattice Relaxation T1: 
This phenomenon is associated with the recovery of 
the thermodynamic equilibrium magnetization along 
B0 and therefore with transitions between the 
Zeeman energy levels. To get back to equilibrium 
there is needed some energy dissipation into the 
surrounding tissue (lattice), and the emission is 
induced by fluctuations of the magnetic field, as a 
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result of the magnetic dipoles in the neighborhood 
variations (Brownian motion). As a consequence, T1 is 
dependent on the strength of the static field and not 
only on the molecular mobility of the observed 
nucleus, on the surrounding dipoles as well. 
Mathematically, spin-lattice relaxation can be 
expressed as: 
ܯ௭ ൌ ܯ଴ ቈ1 െ eቀ
୲
୘భቁ቉ 
C is a constant dependent on the flip angle of the RF 
pulse.  
 
b. Spin-spin relaxation T2 and effective spin-spin 
relaxation T2*: 
Transversal magnetization is related to the loss of 
phase coherence in the nuclear precession after a 
RF excitation. If the net magnetization is placed in 
“xy” plane, it will rotate following one defined 
frequency called “Larmor frequency”. But, apart 
from rotating, the net magnetization will start 
dephasing and each spin packages would have 
their own Larmor frequency. In this way, the time 
constant which describes the return to equilibrium of 
the transverse magnetization (Mxy) is called the spin-
spin relaxation time (T2).  
ܯ௫௬ ൌ ܯ଴௫௬଴ ቈ݁ቀ
௧
మ்ቁ቉ 
Two factors also contribute to this decay, molecular 
interactions (pure T2 effect) and variations in B0 
(inhomogeneities). The combined time constant is 
called effective spin-spin relaxation and represented 
by T2*. 
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Here, T1 and T2 have been described separately but both 
processes occur simultaneously. The full description of the 
magnetization vector behavior under different conditions is 
implemented in Bloch equations. 
MR images are acquired using a pulse sequence (formed 
for radiofrequency pulses (RF) and gradient pulses). 
Depending on the pathologic condition or the composition 
of the tissue of interest, it will be necessary the use of one or 
another sequence to distinguish between what is called T1 
and T2 weighted images, the two most common modalities 
of MRI in clinical practice. The differences between 
sequences rely on the choice of the acquisition 
parameters, mainly the repetition time (TR) and the echo 
time (TE), but also the contribution of the intrinsic tissue 
values of T1 and T2. However, sometimes for a more specific 
tissue detection or a change in an earlier stage of the 
disease, the combination of intrinsic relaxation times and 
sequence parameters is not enough for being visualized in 
MRI. It is needed an extra tool: MRI contrast agents.  
1.4.2. Contrast agents for magnetic resonance 
imaging. 
MRI contrast agents are mainly used for two purposes, 
enhance the natural contrast and /or obtain dynamic 
information about biological processes.  
There are several options of MRI contrast agents, and 
parameters as pathology under study, target organ, 
therapeutic or diagnosis options, have to make the choice 
among them.  
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Particularly, for stem cell therapy, it would be ideal to 
monitor where and how these cell distribute. For different 
pathologies, also in ischemic stroke, the selected contrast 
agent to label stem cells has to achieve several goals: 
- Specificity of the type of cell 
- Ability to be detected at low concentrations 
- Reasonable clearing period 
- Stability 
- Reduced toxicity 
The most used contrast agent for cell tracking purposes 
verifying all previous conditions are magnetic nanoparticles 
(MNPs).  
1.5. Superparamagnetic iron oxide 
nanoparticles 
Cells are too small to be detectable using MRI, however the 
use of contrast agents to label them leads us to an in vivo 
real-time image of those cells. Superparamagnetic iron 
oxide nanoparticles are an excellent tool for stem cell 
tracking, not only for the high quality of the MR image, for 
the low toxicity and the ease for tagging as well.  
The term nanoparticle is normally referred to particles with a 
size in the nano range, which corresponds to ca. 1-100nm. 
This reduced size gives them extraordinary properties 
compared to their counterparts, bulk materials.  In this way, 
magnetic nanoparticles (MNPS) are nanoparticles made of 
ferro /ferrimagnetic materials, which exhibit 
superparamagnetic properties below certain dimensions 
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and above certain temperatures. To explain these 
properties several preliminary concepts will be introduced.  
1.5.1. Magnetic materials 
All materials are magnetic, but their response under an 
applied external magnetic field depends on their atomic 
structure and the temperature conditions. When a material 
is placed under a magnetic field of strength H, the 
individual atomic moments contribute to the overall 
magnetic response (B), which mathematically is expressed 
 ܤ ൌ ߤ଴ሺܪ ൅ܯሻ     [Eq.1] 
Where is the permeability of free space, and M is the 
magnetization per unit of volume. It is possible to classify the 
materials according to their magnetic response under a 
magnetic field, or what is the same, to the volumetric 
magnetic susceptibility (). Formally, this magnitude is 
defined as the induced magnetization in a material by a 
magnetic field H. 
ܯ ൌ ߯ ൉ ܪ     [Eq.2] 
In this way, depending on the magnetic susceptibility it is 
possible to distinguish between: 
a. Diamagnetism: it is a property common to all 
materials, but normally is very weak. In diamagnetic 
materials there are not unpaired electrons in their 
atoms and consequently, there is not net magnetic 
moment. When these types of materials are placed 
under a magnetic field, the magnetization produced 
is negative, so < 0. As it is shown in Figure 10a, for 
zero field, the magnetization is also null. 
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b. Paramagnetism: The net magnetization of these 
materials is different from zero due to the unpaired 
electrons of their atoms. However, due to the non-
magnetic interaction between the individual 
magnetic moments, the global process is 
randomized, and if the external field is removed, the 
magnetization is also zero. Under the influence of 
applied H, there is a partial alignment of the atomic 
magnetic moments in the direction of the field, 
resulting in a positive magnetization and as a 
consequence, the susceptibility becomes positive as 
well. (Figure 10b) Furthermore, this alignment is 
opposed to the randomizing effect of temperature, 
resulting in a correlation between temperature and 
magnetic susceptibility (Curie Law).  
 
Figure 10: Magnetic responses for a diamagnetic material (a.), 
paramagnetic material (b.) and ferromagnetic material (c.)[186] 
Hence, both diamagnetic and paramagnetic materials, 
exhibit the same behavior; no magnetization when the 
applied field is zero. Nevertheless, some other materials 
remain magnetic even without magnetic field presence. 
Those are ferromagnets, ferrimagnets and 
antiferromagnets.  
a. Ferromagnets: these materials are characterized by 
the parallel alignment (Figure 11a.) of their atomic 
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moments, which results in a large net magnetization 
even when the external magnetic field is zero (Figure 
10b). Two characterizing aspects of ferromagnetic 
materials are their spontaneous magnetization and 
the existence of a magnetic ordering temperature, 
called Curie temperature (Tc). 
b. Ferrimagnets: In these materials the opposing atomic 
moments are unequal so that there is a remaining 
magnetization (see Figure 11c.). This phenomenon 
occurs when there are different ions in the material 
(such as Fe2+ and Fe3+). In this type of materials, the 
spontaneous magnetization is maintained below Tc 
and they behave as paramagnetic materials above 
it.  
c. Antiferromagnets: As in ferromagnetic materials, the 
atomic moments are opposed and equal, so the net 
moment is zero (see Figure 11b.).  In this case, the 
critical temperature is TN (Néel temperature): above 
TN the magnetic susceptibility decreases with higher 
temperature and below it the susceptibility increases 
with temperature.  
The behaviors previously described are also strongly 
dependent on the size of the material, so modifying the 
size it is possible to tune the magnetic response at a 
certain temperature.  
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Figure 11: Alignment of magnetic dipoles for different types of 
magnetism. (a.) Ferromagnetism. (b.) Antiferromagnetism. (c.) 
Ferrimagnetism.  
As presented before, a paramagnetic material is 
characterized by randomly oriented magnetic dipoles, 
which under an external magnetic field are aligned along 
the direction of the field. But when the field is switched off, 
all internal dipoles randomize again and no extra energy is 
needed to demagnetize the material, it goes back to 
equilibrium spontaneously, i.e. this type of material has no 
coercivity and no remanence.  
However, ferromagnetic materials present the individual 
magnetic spins align parallel one to the other exhibiting a 
collective response even in the absence of the external 
applied magnetic field. In this absence of an applied 
magnetic field, a ferri or ferromagnetic material is divided 
into macroscopic magnetic domains. There is a specific 
direction of magnetization within each domain, but 
different from one domain to the other. When a magnetic 
field is applied to a multi-domain material, the domain walls 
move in response to the applied magnetic field, increasing 
the net magnetization of the crystal. As the applied field is 
increased, the magnetization increases until saturation is 
reached, when the crystal consists of a single magnetic 
domain with its magnetization aligned to the field (Figure 
12). In this way, the saturation magnetization (Ms) is a 
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property of the material and can be related to the 
magnetic distribution and ordering. If the applied magnetic 
field is now reduced to zero, the magnetization will 
decrease to MR, which is the remnant magnetization, and in 
order to reduce the magnetization to zero, a reverse field 
has to be applied. The value of this reverse field is called 
coercivity Hc. Increasing the reverse field saturates the 
sample in the reverse direction, and so on, giving a 
hysteresis loop, which describes the relationship between 
the applied field and the magnetization.[187]  
  
Figure 12: The behavior of the domain distribution in a multidomain grain 
during various stages of magnetization. Ms is the saturation magnetization 
where the grain consists of a single domain magnetized in the direction 
of the applied magnetic field. (Adapted from [187]) 
The difference between a magnet and the material to 
which magnets are attracted is the size of the magnetic 
domains. Thus, the shape of the M-H curves is partially 
determined by the size of the material, in this case, the size 
of the particle. In large particles (>m) there is a multi-
domain ground state, which causes a narrow hysteresis 
loop due to the small energy needed to make the domain 
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walls move. On the other hand, smaller particles (100nm - 
m) have wider hysteresis loops. At lower sizes (10-100nm) it 
is possible to observe superparamagnetism, in which the 
magnetic moment of the particle acts as a whole and is 
free to fluctuate in response to thermal energy (Figure 13). 
At the same time, the individual atomic moments maintain 
their ordered state relative to each other, leading to a non-
hysteretic M-H curve, where Hc=MR=0.  
 
Figure 13: Variation of coercivity during transition from multi-domain 
ferromagnetism to single-domain superparamagnetism. (Adapted from 
[188]) 
1.5.2. Superparamagnetism 
Superparamagnetism was firstly and theoretically described 
by Neel (1949), who demonstrated that Hc approaches zero 
when particles become very small, due to thermal 
fluctuations of very small particles, preventing the existence 
of a stable magnetization.  
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As a consequence of the reduced size of the particles, the 
basic mechanism of superparamagnetism is based on the 
relaxation time () of the net magnetization of a magnetic 
particle (Brown 1963): 
߬ ൌ ߬଴ ൉ ݁൤
౴ಶ
ೖಳ೅൨     [Eq.3] 
Where, E is the energy barrier for moment reversal, kBT is 
the thermal energy and the pre-exponential factor is in 
the order or 10 -10 – 10 -12 s, only weakly dependent on 
temperature and is inversely proportional to the jump 
attempt frequency of the particle magnetic moment 
between opposite directions of the magnetization easy-
axis. For non-interacting particles the factor τ0 is in the order 
of 10-10 – 10-12 s, and only weakly dependent on 
temperature. The energy barrier has several origins, 
including both intrinsic and extrinsic effects such as the 
magneto-crystalline and shape anisotropies. The simplest 
case is given by E=KV, where K is the anisotropy energy 
density and V is the particle volume. For small particles E is 
comparable to kBT at room temperature. It should be noted 
that, for a given material, the observation of 
superparamagnetism is dependent not only on 
temperature, but also on the measurement time τm of the 
experimental technique used. As shown in Figure 14 (a.), if 
τ<<τm the flipping is fast relative to the experimental time 
window and the particles appear to be paramagnetic, 
while for τ>>τm (Figure 14 b.) the flipping is slow and such a 
state is called a blocked state. The blocking temperature TB 
can be obtained assuming τ=τm and is associated to the 
energy barrier; hence, TB increases when the size of the 
particle also increases.  
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Figure 14: Illustration of the concept of superparamagnetism, where the 
circles depict three magnetic nanoparticles and the arrows represent 
the net magnetic moment direction in those particles. (a.) the net 
moments are quasi-static and (b.) the moment reversals are so rapid that 
in zero external field the time averaged-net moment on the particles is 
zero. (Adapted from [189]) . 
1.5.3. Superparamagnetic iron oxide nanoparticles 
(SPIOs) 
Nanotechnology refers to the field of science and 
engineering dedicated to materials, having dimensions in 
the range of 100nm or less.[190,191] Although new, the 
starting of nanomaterials dates back to 1959, when Richard 
P. Feynman forecasted the advent of nanomaterials. In one 
of his lectures at California Institute of Technology he said, 
there is plenty of room at the bottom, and suggested that 
scaling down to nanolevel and starting from the bottom 
was the key to future technology and advancement[192]. 
One of these advancements of nanotechnology can be 
found in biological applications, because a variety of 
bioprocesses also occur at the nanoscale level. Fluorescent 
biological labels, drug and gene delivery, bio detection of 
pathogens, detection of proteins, probing of DNA 
structures, tissue engineering, tumor destruction via heating, 
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separation and purification of biological molecules and 
cells, MRI contrast enhancement or phagokinetic studies 
are some of the applications of nanomaterials to biology or 
medicine.[190] Along this way, superparamagnetic iron 
oxide nanoparticles (SPIOs) with appropriate surface 
chemistry have been used for numerous in vitro and in vivo 
applications, such as cell separation, drug delivery, 
hyperthermia, detoxificacion of biological fluids, 
immunoassay, tissue repair and MRI contrast enhancement. 
SPIOs have been the most extensively investigated MNPs for 
biomedical applications due to their excellent 
biocompatibility and ease of synthesis. Normally they are 
composed of a core of nanocrystalline magnetite (Fe3O4) 
or maghemite (Fe2O3) wrapped with a polymeric 
coating[193]. Indeed, magnetite is particularly suitable for 
its use in magnetic resonance (MR), as it has been isolated 
from certain birds, fish and bacteria, in which its interaction 
with the earth magnetic field has been found to play a 
critical role in navigation.[194] 
Maghemite is formed from the oxidation of magnetite and 
is similar to it, possessing cation vacancies. Both, magnetite 
and maghemite have similar magnetic and relaxation 
properties. They have a face/centered cubic packing of 
oxygen that allows fast electron hopping or continuous 
exchange of electrons between irons occupying interstitial 
tetrahedral (surrounded by 4 oxygen atoms) and 
octahedral (surrounded by 8 oxygen atoms) sites. All 
tetrahedral holes are filled by Fe3+ ions, and octahedral sites 
are filled by the remaining Fe3+ and Fe2+ ions (or vacancies). 
The magnetic properties of this material arise from the 
ferrimagnetic alignment of the iron ions. The tetrahedral Fe3+ 
ions are aligned in one direction, and all the octahedral 
ions are aligned in the opposite direction. In magnetite, the 
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octahedral and tetrahedral Fe3+ ions cancel each other 
and the magnetic moment is due to uncompensated 
octahedral Fe2+ ions. In maghemite, the moment arises from 
uncompensated octahedral Fe3+ ions[195].  
Numerous chemical methods can be used to synthesize 
magnetic nanoparticles for medical imaging applications: 
microemulsions, sol-gel synthesis, sonochemical reactions, 
hydrothermal reactions, hydrolysis and thermolysis of 
precursors, flow injection synthesis and electrospray 
synthesis. The synthesis of superparamagnetic nanoparticles 
is a complex process because of their colloidal nature.  The 
main chemical challenge is to define the experimental 
conditions, leading to a monodisperse population of 
magnetic grains of suitable size. The second critical point is 
to select a reproducible process without any complex 
purification procedure, such as ultracentrifugation, size-
exclusion chromatography, magnetic filtration or flow field 
gradient.  However, the most common and the easiest 
method for the production of magnetite nanoparticles is 
the chemical coprecipitation technique of iron salts[196].  
1.5.3.1. Synthesis of SPIONs: Chemical coprecipitation 
method. 
This technique is probably the simplest and the most 
efficient chemical pathway to obtain magnetic 
nanoparticles. Iron oxides (either Fe3O4 or Fe2O3) are 
usually prepared by aging a stoichiometric mixture of 
ferrous and ferric salts in aqueous medium, the chemical 
reaction may be written as 
Fe2+ + 2Fe3+ + 8OH-  Fe3O4 + 4H2O 
According to the thermodynamics of the reaction, 
complete precipitation of Fe3O4 should be expected at a 
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pH between 8-14, with a 2:1 ratio (Fe3+/Fe2+) in non-oxidizing 
oxygen environment. However, magnetite is not very stable 
and it is sensitive to oxidation, transforming into maghemite 
in the presence of oxygen: 
Fe3O4 + 2H+  Fe2O3  + Fe2+ + H2O 
However, oxidation in air is not the only way to transform 
magnetite into maghemite; also the pH of the suspension 
has a big influence.  
The main advantage of the coprecipitation method is that 
a large amount of particles can be synthesized at the same 
time. However, the control of the particle size distribution is 
limited because only kinetic factors are influencing the 
growth of the crystal. The size and shape of the particles 
can be tailored adjusting the pH, ionic strength, 
temperature, nature of salts or the ratio between FeII/FeIII, 
and also the addition of chelating organic anions (oleic 
acid, citric acid,…) or polymer surface complexing agents 
(dextran, polyvinyl alcohol,…).  Other external parameters 
as the mixing rate and the order on adding the reagents 
have also an influence in those parameters.  
1.5.3.2. Surface modifications of MNPS 
Due to the high Brownian mobility of MNPs, they will 
constantly collide and can aggregate if any attractive 
interaction is present. Nanoparticle interactions are 
originated mainly due to 4 different phenomena: Van der 
Waals forces (attractive), electrostatic forces (attractive or 
repulsive), steric hindrance (repulsive) and the hydrophobic 
effect.  
There are two methods to stabilize MNPs, by adding a 
ligand or by exchanging ligands. On one hand, ligand 
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addition is in general performed by using an amphiphilic 
molecule, which hydrophobically interacts with the non-
polar surfactant. On the other hand, ligand exchange 
involves total replacement of the non-polar ligands by a 
polar surfactant.[197] 
There are 3 different approaches to stabilize magnetic 
nanoparticles by adding a ligand: monomeric stabilizers 
(carboxylates, phosphates or sulfates), inorganic materials 
(silica, gold or gadolinium, providing not only stability but 
also helping in binding various biological ligands to the 
surface as well) and polymeric stabilizers. In this approach, it 
is possible to distinguish between in situ coatings, where 
nanoparticles are coated during the synthesis, and post-
synthesis coatings. In the literature, the most common 
coatings are dextran, carboymethylated dextran, 
carboxydextran, arabinogalactan, glycosaminoglycan, 
starch, sulfonated styrene-divinylbencene, PolyEthylene 
Glycol (PEG), PolyVinyl Alcohol (PVA), poloxamers and 
polyoxamines,[196] although the selection of the coating 
will be conditioned by the biological application of the 
coated nanoparticle.   
1.5.3.3. Superparamagnetic nanoparticles for cell labeling 
and cell tracking 
MRI contrast agents for in vivo cell tracking are being widely 
investigated. Transplanted cells not only have the potential 
to replace damaged cells, but also to produce growth and 
trophic factors, or stimulate the release of such factors from 
host brain cells, enhancing endogenous brain repair 
processes.  Many issues for stem cell therapy are still in the 
bench like therapeutic window, cell type, delivery route 
and in vivo monitoring of their migration pattern. The 
possibility to track the transplanted cells could help to 
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clarify all these questions and improve stem cell therapies 
for different pathologies.[198]  
MRI contrast agents for cell tracking require nanoparticles 
with special characteristics as high magnetization values 
and small and narrow size distribution. Thermal 
decomposition and chemical coprecipitation methods are 
the most extended procedures. Coprecipitation technique 
is probably the simplest and most efficient chemical route 
to obtain magnetic nanoparticles. As it was previously 
mentioned, the main advantage is that a large amount of 
particles can be synthesized easily and economically.[199] 
But for biological applications not only the magnetic 
properties are important, a specific surface coating of the 
magnetic particles is also needed, which has to be 
biocompatible.[196]  
Among all the coating possibilities, dextran is one of the 
most widely polymers used as magnetic nanoparticle 
coating due to its biocompatibility. It is a polysaccharide 
polymer composed exclusively of D-glucopyranosyl units 
with varying degrees of chain length and branching. In 
1982, Molday and Mackenzie were the first who reported 
the formation of magnetite in presence of dextran 
40000.[200] The synthesis of dextran coated nanoparticles is 
an in situ procedure, and the effect of reducing the 
terminal glucose of dextran upon the formation and stability 
of dextran-coated superparamagnetic nanoparticles has 
demonstrated to be significant for particle size, coating 
stability and magnetic properties.[199] For cell labeling 
applications, dextran coated nanoparticles normally need 
to be combined with transfection agents or the use of 
electroporation techniques to increase the tagging 
efficiency.[201-204] 
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Other methods to synthesize coated magnetic 
nanoparticles need more than one step. Jain et al. [205]  
developed a novel oleic acid (OA)-Pluronic-stabilized iron 
oxide magnetic nanoparticle formulation, and 
characterized it as a drug carrier system for anticancer 
agents. The hydrophobic drugs would partition into the OA 
shell surrounding the iron oxide nanoparticles, and the 
polymer (Pluronic) would anchor at the interface of the OA 
shell to confer an aqueous dispersity to the formulation. 
[205] Pluronic (Poloxamer) and Tetronic (Poloxamines) are a 
family of amphiphilic nonionic block polymers. More in 
detail, Pluronic block polymer consists of a hydrophobic 
poly(ProPylene Oxide) (PPO) chain flanked on each side 
with hydrophilic Poly(Ethylene Oxide) (PEO) chains, 
meanwhile Tetronic block polymer contain four PPO-PEO 
chains connected together at the PPO subunits to form a 
star shape structure (Figure 15).[206] Because Pluronic and 
Tetronic are a family of polymers, they vary structurally, as 
well as in the ratio of hydrophobic PPO and hydrophilic PEO 
segments in the polymer chain and in molecular weight 
[207]. Moreover, FDA and EMEA have approved the use for 
some of the linear PEO-PPO-PEO triblocks in food, 
pharmaceutical and agricultural industries[208] and also 
Pluronic has been already used as iron oxide nanoparticle 
coating, and their applications on cell labeling experiments 
point out that no transfection agents are needed.[205,209]   
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Figure 15: Schematic of MNPs. Each particle contains an iron-oxide core 
coated with OA and is coated with either Pluronic (single PEO-PPO-PEO 
subunit) or Tetronic (two PEO-PPO-PEO subunits). The PPO subunit from 
the copolymers adsorbs onto the OA rendering the MNPs dispersible in 
aqueous solution. (Pluronic and Tetronic are registered trademarks of 
BASF SE, Ludwigshafen, Germany.) Adapted from [207] 
In addition, when considering MNPs enabled MRI cell 
tracking, there are other parameters with high impact on 
the success of applying this method:[210] the amount of 
nanoparticle uptake,[211,212] reactive oxygen species, 
[213-215]  the specific nanoparticle localization in the cell, 
[210] and the impact of transfection agents (TA).[210,216] 
TAs are macromolecules possessing an electrostatic charge 
and normally are used for non-viral transfection of DNA into 
the nucleus.[216,217] There are different types of TAs 
available, including polyamines (as PoLy-Lysine –PLL-), lipid-
based agents (as lipofectamine) and heat-activated 
dendrimers. Usually, TAs have net positive z-potential, but it 
depends on the type of agent and their molecular 
weight.[218] However, TAs when added to cell medium are 
toxic to the cells, and the toxicity is proportional to the 
concentration in culture medium. Their importance to tag 
non phagocytic cells with dextran coated nanoparticles 
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has already been shown [201,204,219,220] but it is 
necessary to determine the appropriate ratio 
nanoparticles/TAs to efficiently label cells and minimize 
toxic-side effects.[216,221] 
Several studies have demonstrated the migration capacity 
of injected stem cells under normal and pathological 
conditions. Specific cell tracking is a successful application 
of SPIONs in MRI. The ability of load cells with enough MNPs 
in vitro has provided a useful technique to label and track 
cells in vivo by MRI. The detection limit will be conditioned 
by the type or MNPs and the cell load.[222]  
1.5.3.4. Magnetic vectorization 
Recent works have studied the influence of the 
administration route on the efficacy of stem cell therapy, 
suggesting that improved methods for cell delivery to 
targeted areas would lead to better outcomes.[223] 
Several studies have already demonstrated its applicability 
for cell therapy for spinal cord injury [224] and magnetic 
vectorization of labeled endothelial progenitor cells after 
an intra-arterial injection in the common carotid artery in 
mice.[225] In order to increase the amount of injected cells 
close to the ischemic lesion, magnetic vectorization of cells 
tagged with superparamagnetic nanoparticles could be a 
good approach. However, the hypothesis of directing most 
of injected cells to the brain in order to decrease infarct size 
and increase functional recovery after an ischemic event 
was not yet demonstrated.[183] 
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2. Hypothesis 
 
Cell based therapies show great promise in the treatment 
of certain, so far incurable, pathologies like stroke. To 
determine the success of these cell therapies, non-invasive 
monitoring of the cells is required, and MRI is one of the 
most appropriate tools to do it because of its excellent soft 
tissue contrast and high resolution. By tagging cells with MRI 
contrast agents such as superparamagnetic nanoparticles, 
MRI can provide anatomical and pathological information 
and also the possibility of visualize and track cells in vivo.  
In this thesis we hypothesized that it is possible to synthesize 
biocompatible   superparamagnetic nanoparticles for in 
vivo cell tracking. Superparamagnetic nanoparticles-
tagged cells can be monitored in vivo by MRI and guided 
with magnetic fields without harmful effects, providing 
information of the cellular fate after different routes of 
administration. Moreover, the nanoparticle labeling will 
allow us to study therapeutic effects in an animal model of 
ischemic stroke based on the localization of the cells after 
delivery.  
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3. Objectives 
The present work will be structured in 4 sections, and the 
main objectives are: 
1. Superparamagnetic nanoparticles: 
o Synthesis and characterization of 
superparamagnetic nanoparticles as contrast 
agents for MRI. 
 
2. In vitro validation: 
o Biological validation of our synthesized 
superparamagnetic nanoparticles: In vitro 
evaluation of cellular well-being after labeling 
and MRI cell detection.  
o In vitro feasibility of magnetic vectorization of 
labeled cells. 
o Long term evaluation of labeled cells: harmful 
effects in the cells and MR signal after 
proliferation. 
 
3. Cell tracking in animal models of ischemic stroke: 
o Animal models of ischemic stroke and its 
relationship with administration routes for stem 
cell delivery. 
o In vivo feasibility of magnetic vectorization of 
labeled cells. 
o In vivo cell tracking of mesenchymal stem cells 
following intra-arterial and intravenous 
administration. 
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4. Neurorepair mediated by stem cell therapy: 
o Stem cell therapy in ischemic stroke: 
Neuroreparation mediated by intra-arterial and 
intravenous injection of mesenchymal stem cells 
in an animal model of ischemic stroke.  
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Section III 
Synthesis of 
superparamagnetic 
nanoparticles 
for cell labeling 
 
 
 
 
 
 78 
 
  
 79 
 
4. Synthesis of 
superparamagnetic 
nanoparticles coated 
with different polymers 
as contrast agents for 
MRI 
4.1. Hypothesis 
In order to develop an efficient, effective and minimally 
invasive cell tracking system for MRI, this chapter presents 
the synthesis procedure and physicochemical 
characterization of 3 different coated superparamagnetic 
nanoparticles.  Magnetic cores were synthesized following 
the chemical coprecipitation method previously described, 
an in situ procedure was performed for dextran-coated 
superparamagnetic nanoparticles, while Pluronic F127 and 
Tetronic 908- coated magnetic nanoparticles were 
obtained following a two step synthesis method.   
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4.2. Materials and methods 
4.2.1. Reagents 
Iron (III) chloride reagent grade 97% (157740, Sigma-
Aldrich), iron (II) chloride 98% (372870, Sigma-Aldrich), 
ammonia solution 28-30% for analysis (1.05423, Merk), 
dextran from Leuconostoc spp. (31389. Sigma-Aldrich), 
Oleic Acid >99% (O1008. Sigma-Aldrich), Pluronic F-127 
(P2443. Sigma-Aldrich), Tetronic 908 (Basf) and chloroform 
(1.02447. Merk). Deionized water purged with nitrogen gas 
was used in the synthesis and formulation of magnetic 
nanoparticles. 
4.2.2. Synthesis of dextran coated 
superparamagnetic nanoparticles 
Dextran magnetic nanoparticles were prepared following 
the protocol described elsewhere[226] with slight 
modifications. Aqueous solutions of 0.1M Fe(III) and 0.1M 
Fe(II) in a ratio 2:1 were mixed (stirring ratio 400 rpm) under 
N2 atmosphere and T=60°C. After 15 minutes, 100 mg of 
dextran in 5 mL of water were added to the mixture. Next, 5 
mL of 5M ammonia solution was added and mixed for 15 
minutes to form iron oxide nanoparticles. The final solution 
was cooled down to room temperature and finally, the 
suspension was dialyzed (D0530, Sigma-Aldrich) against 
distilled water (DW). 
4.2.3. Synthesis of Pluronic F127 and Tetronic 908 
coated superparamagnetic nanoparticles 
Pluronic F127 (P127) and Tetronic 908 (T908)- coated  
magnetic nanoparticles were prepared through a two step 
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procedure following the protocol described elsewhere 
[205] with several modifications. Briefly, in order to form the 
magnetic core, aqueous solutions of 0.1M Fe(III) and 0.1M 
Fe(II) in volume ratio 2:1 were mixed (stirring ration 400 rpm) 
under N2 atmosphere and room temperature. Ammonium 
hydroxide (5mL 5M) was added drop by drop to produce 
the particles. After 10 minutes, 46 μL of oleic acid (OA) was 
added and the temperature was raised to 80°C and 
maintained for 20 minutes under N2 atmosphere. The 
solution was cooled down to room temperature and the 
suspension was washed with magnetic separation using DW 
(pH=9.5).  
For nanoparticle polymer coating a phase change is 
needed. After removing all the water from the magnetic 
cores prepared in the previous step, 5.5 mg of 
nanoparticles in 4 mL of chloroform were sonicated for 5 
minutes. This solution was mixed with 40 mg of polymer and 
stirred again for 5 minutes.  After cholorform evaporation, 
DW was added and the mixture was placed for 1h 
shacking. Under ambient conditions, the MNPs were 
washed three times with distilled water and separated using 
a rare earth magnet.  
4.2.4. Magnetic nanoparticle characterization 
Dynamic Light Scattering (DLS): For measuring the particle 
size of the OA coated magnetic cores and dextran, 
Pluronic and Tetronic coated nanoparticles, each coated 
sample was dispersed in DW, while for measuring OA-
coated nanoparticles the samples were dispersed in 
chloroform. Dynamic light measurements were performed 
by means of an ALV-5000F (ALV-GmbH, Germany) 
instrument with vertically polarized incident light (θ = 488 
nm) supplied by a diode-pumped Nd:YAG solid-state laser 
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(Coherent Inc., CA, USA) and operated at 2 W, and 
combined with an ALV SP-86 digital correlator with a 
sampling time of 25 ns to 100 ms. Measurements were 
made at an angle θ = 90° to the incident beam, as 
appropriate for particles smaller than the light wavelength. 
The intensity scale was calibrated against scattering from 
toluene.. Each experiment was repeated at least three 
times. Sampling time was 5-10 min for each run in order to 
define an optimal correlation function. The correlation 
functions were analyzed by the CONTIN method to obtain 
the intensity distributions of decay rates (Г).From the decay 
rate distributions the apparent diffusion coefficients 
Dapp=Г/q2, q=(4πns/λ)sin(θ/2) were derived, being ns the 
solvent refractive index. Values of the apparent 
hydrodynamic radius were calculated from the Stokes-
Einstein equation. 
Transmission Electron Microscopy (TEM): For measuring the 
size and determining the shape of the MNPS, TEM samples 
were prepared by evaporating a drop of the nanoparticles 
dispersion of the particles on a carbon-coated cooper grid 
without staining and imaged using a TEM microscope 
model Philips CM-12 operating at 120 kV. The NIH ImageJ 
software was used to calculate the mean particle diameter 
from TEM images. Diameters of ca. 40 particles were 
measured. 
X-Ray Diffraction (XRD): A structural analysis of dextran 
coated and non-coated nanoparticles were performed by 
X-ray diffraction (XRD) data. The samples were measured 
on a Philips powder diffractometer fitted with Philips PW1710 
control unit, vertical Philips PW1820/00 goniometer and 
FR590 Enraf Nonius generator. The instrument was equipped 
with a graphite diffracted beam monochromator and 
copper radiation source ((K)=1.5406Å), operating at 40 
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kV and 30mA. The X-Ray powder diffraction pattern (XRPD) 
was collected by measuring the scintillation response to 
CuK radiation versus the 2 value over a 2 range of 10-
80º, with a step size of 0.02° and counting time of 2 s per 
step. 
Zeta-potential: Polymer-coated MNPs were measured using 
a Zetasizer NanoZS instrument (Malvern) equipped with a 
red laser (633 nm) in backscatter mode. 
Vibrating Sample Magnetometer (VSM): Magnetic 
properties of SPIONs were recorded on a vibrating sample 
magnetometer (VSM) from Quantum Design TM. Hysteresis 
loops (magnetization vs. applied external magnetic field 
plots) of synthesized SPIONs were recorded at 5 and 300 K 
and a maximum applied magnetic field of 50000 Oe. 
Saturation (Ms), and remanent (Mr) magnetizations, and 
coercitive field (Hc) were subsequently derived from 
experimental data. 
Fourier-transform infrared (FTIR): 59.5 mg of potassium 
bromide and 1mg of MNPs were mixed. This mixture was 
dried in a vacuum for 3 days and subsequently pressed to 
form a pellet and mounted in FTIR spectrometer (Varian FTIR 
670). The spectra were obtained at a resolution of 4 cm−1 
and 64 scans were accumulated for each sample.   
Inductive coupled plasma optical emission spectroscopy 
(ICP-OES): The iron concentration was determined by ICP-
OES (Varian Inc., Palo Alto, USA). Hereto, the nanoparticles 
were dissolved in 1mL of 37% HCl after which 4 mL of DW 
were added. The intensity of the emission wavelength for 
iron at 238.204 nm was measured and compared to a 
standard solution. ICP_OES was performed at the Material 
Science Institute (MTM), KU Leuven.   
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Thermal gravimetric analysis (TGA): This analysis was 
performed at imec (Leuven, Belgium) on a Q5000IR (TA 
instruments, New Castle, DE, USA) under nitrogen 
atmosphere to study the organic coating of the MNPs. First, 
100 μL of MNPs were slowly heated to 80ºC to remove all 
solvents. Next, temperature was increased to 850ºC at a 
heating rate of 20ºC/min. Using the software provided by 
the manufacturer (Universal Analysis 2000,  4.5 A), the 
weight difference was analyzed before and after burning 
off the organic coating.  
Magnetic Resonance Imaging (MRI): Samples were 
prepared using an agar phantom holder following the 
protocol described elsewhere [227]. Triplicates of dextran, 
Pluronic F127 and Tetronic 908 coated nanoparticles, 4 
concentrations for each type of nanoparticle were 
measured. MRI studies were conducted on a 9.4 T MR 
system (Bruker Biospin, Ettlingen, Germany) with 440 mT/m 
gradients, using a combination of a linearly polarized  
birdcage resonator of 7 cm of diameter for signal 
transmission and a 2x2 arrayed pick-up surface coil for 
signal detection. T2-weighted images were typically 
acquired using a Multi-Slice Multi-Echo (MSME) sequence (3 
averages with a train of 16 echoes of 7.32 ms Echo time 
and a repetition time of 5.4 s. The whole agar phantom was 
covered with 14 consecutive axial slices of 1 mm thickness 
with a field-of-view (FOV) of 75x75 mm (with saturation 
bands to suppress the signal outside the FOV) and an in-
plane resolution 0.75mm/pixel. Post-processing of all images 
was performed using ImageJ software (Rasband, W. NIH). 
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4.3. Results 
4.3.1. Dextran coated magnetic nanoparticles. 
4.3.1.1. Iron oxide core 
Magnetic nanoparticles were synthesized in the presence 
of dextran through the chemical coprecipitation method. 
TEM micrographs (Figure 16) confirmed the spherical shape 
of the dextran-coated magnetic nanoparticles. The mean 
particle size using this technique was 3.70.8 nm. 
The crystal structure (Figure 17) of MNPs determined by XRD 
showed peaks at 2θ positions of ca. 30.2º; 35.6º; 43.2º; 57.1º; 
62.7º, corresponding to the  (220), (311), (400), (511) and 
(440) planes of magnetite respectively with a lattice 
parameter of 8.330.02 Å. It was also possible to determine 
the core size of the dextran coated nanoparticles from XRD 
data. The calculated cristallite size (Figure 17) was 4.80.5 
nm. 
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Figure 16: TEM image of dextran Coated Nanoparticles. 
 
Figure 17: XRD spectrum of dextran coated nanoparticles 
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4.3.1.2. Dextran coated nanoparticles. 
The hydrodynamic size measured by DLS was 943 nm. Z-
potential of these coated particles dispersed in DW was 
negative, with values of ca. -113 mV. The presence of the 
polymeric coating on the nanoparticles was further 
confirmed by TGA and FITR. The TGA data showed two 
peaks corresponding to mass losses  at approximately 
280ºC and 322ºC, close to polymer loss temperature of 
dextran (289ºC), demonstrating that about 66 wt % of 
dextran can be found in the nanoparticles (Figure 18). The 
FTIR spectrum exhibits several polysaccharide characteristic 
absorption bands, at 3351 cm-1 due to the O-H stretching. 
Vibrational modes (C-H) and (C-H) correspond to 2906 
cm-1, 1420 cm-1 and 1380 cm-1. Water molecular bending is 
assigned to 1620 cm-1; 1145 cm-1 and 1010 cm-1 peaks due 
to C-O vibrations and the small peaks at 908 cm-1, 877 cm-1 
and 746 cm-1 corresponding to -glucopyranose ring 
deformation modes (Figure 19). There are also two 
absorption bands at 578-1 and 430 cm-1 corresponding to 
Fe-O vibration modes. 
 
Figure 18: TGA spectrum of dextran polymer and dextran coated NPs.  
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Figure 19: FTIR spectrum of Dextran coated nanoparticles. 
VSM data showed that Dextran coated nanoparticles 
exhibited superparamagnetic behavior (Figure 20).  
MRI contrast in T2* weighted images of 4 different 
concentrations of dextran coated nanoparticles were 
measured: 0.19mM; 0.09mM; 0.05mM and 0.02mM (Figure 
21). The relaxation rate (R2) was plotted versus the 
concentration of iron. A linear relationship was found 
between R2 and the MNPs concentration, enabling the 
calculation of the transverse relaxivity (r2) (the slope). The r2 
for dextran coated magnetic nanoparticles resulted in 
699±4 mM-1s-1. 
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Figure 20: VSM results of dextran coated magnetic iron oxide 
nanoparticles. 
 
Figure 21: MRI T2 weighted of dextran-coated nanoparticles for each 
concentration. 
4.3.2. Polymer coated magnetic nanoparticles: 
Pluronic F127 and Tetronic 908. 
4.3.2.1. Core 
Pluronic and Tetronic-coated MNPs were prepared 
following a two step procedure. First, magnetic cores were 
synthesized and next the polymer coating was added. 
Magnetic cores coated with oleic acid were obtained 
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through the chemical coprecipitation method, obtaining 
spherical MNPs (Figure 22). The core size was 8.61.4 nm 
determined through TEM. The core size was also determined 
by XRD spectrum data and by DLS, being 7.70.8 nm and 
7.30.8 nm respectively.  
 
Figure 22: TEM picture of superparamagnetic nanoparticle cores. 
The core crystal structure determination using XRD (Figure 
23) showed peaks at 2 positions of approximately 30.2º; 
35.6º; 43.2º; 57.1º; 62.7º, corresponding to the  (220), (311), 
(400), (511) and (440) planes of magnetite respectively with 
a lattice parameter of 8.3610.004 Å. Data obtained 
through VSM measurements showed that the cores 
exhibited superparamagnetic behavior at room 
temperature (Figure 24). 
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Figure 23: XRD spectrum of magnetic nanoparticle cores synthesized 
through chemical coprecipitation method. 
 
Figure 24: Magnetization versus magnetic field plots for magnetic cores 
of superparamagnetic nanoparticles.  
The presence of oleic acid attached to the surface of the 
nanoparticle was evaluated through TGA. In Figure 25A two 
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peaks can be observed at 179ºC and 213ºC, which is near 
to the boiling or decomposition point of the oleic acid 
chains (239ºC) (figure not shown). This corresponded to a 
mass loss percentage of 17,14%. The main peak was 
observed at ca. 356.51ºC with a 25.49 wt% of mass loss 
percentage. 
4.3.2.2. Pluronic F127 and Tetronic 908 coated magnetic 
nanoparticles. 
After coating the magnetic cores with Block copolymers, 
the hydrodynamic size measured by DLS was 1546 nm for 
Pluronic-coated nanoparticles, and 1806 nm for Tetronic-
coated nanoparticle. Z-potential of these coated particles 
dispersed in DW was negative for both, being -183 mV and 
-243 mV respectively. 
TGA of Pluronic coated iron oxide nanoparticles indicated 
the presence of the polymer and the oleic acid. TGA 
showed two peaks approximately 262ºC (19.1 wt%) and 
313ºC (35.5 wt%), close to oleic acid and pure Pluronic F127 
boling points respectively. For Tetronic 908 coated 
nanoparticles the behavior is similar. TGA data also showed 
two peaks, first one at about 260ºC (26.3%) corresponding 
to oleic acid and second one at 311ºC (42 wt%) 
corresponding to pure Tetronic 908. (Figure 25 B and C) 
FTIR spectrum (Figure 26) exhibited similar peaks for Pluronic 
and Tetronic coated superparamagnetic nanoparticles 
and oleic acid coated cores.  Two broad peaks at 
approximately 440 cm-1 and 610 cm-1 corresponded to Fe-O 
vibration modes, and ca. 1430 cm-1 and 1600 cm-1 specific 
for symmetric and asymmetric stretching vibrations of COO- 
respectively. Additionally, the peaks at 1700 cm-1 and 3400 
cm-1 can be attributed to the stretching vibration of the 
hydroxyl groups on the surface of the magnetite 
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nanoparticles. It was also possible to identify the 
asymmetric CH2 and the symmetric CH2 stretching bands at 
2850 cm-1 and 2920 cm-1 respectively. The difference 
between the polymer coated and uncoated nanoparticles 
in FTIR data was the peak at 1100 cm-1, typical for 
symmetric stretching vibrations of C-O-C bonds. 
MRI contrast in T2 weighted images of 4 different 
concentrations of nanoparticles coated with Pluronic F127 
(0.36mM; 0.18mM; 0.09mM; 0.04mM) and Tetronic 908 
(0.45mM; 0.22mM; 0.11mM; 0.06mM) copolymers are shown 
in Figure 27.  The relaxation rate (R2) was plotted versus the 
concentration of iron, and a linear relationship was found 
between R2 and the MNPs concentration, enabling the 
calculation of the transverse relaxivity (r2) for each coated 
MNPs. The r2 For Pluronic F-127 coated magnetic 
nanoparticles resulted in 398±12 mM-1s-1 and for Tetronic 908 
coated MNP 330±20 mM-1s-1. 
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Figure 25: TGA of Oleic acid-coated MNPs (A), Pluronic F127-coated 
nanoparticles (B) and TGA of Tetronic 908-coated nanoparticles (C).  
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Figure 26: Oleic acid-coated cores (A), Pluronic F127-coated 
nanoparticles (B) and Tetronic 908-coated nanoparticles (C). 
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Figure 27: MRI T2 weighted of (A) Pluronic F127- and (B) Tetronic 908- 
coated nanoparticles for each concentration. 
4.4. Discussion 
The chemical coprecipitation method used for the 
magnetic nanoparticle synthesis was chosen because it is 
considered the easiest method to produce 
superparamagnetic nanoparticles. The main lack of this 
method is the big influence in the final particle size of 
several parameters such as temperature, pH, presence of 
oxygen in the reaction, stirring speed or Fe3+/Fe2+ molar 
ratio. Special care must be taken for a robust and 
reproducible NP synthesis, because the particle formation 
takes place when the ammonium hydroxide is added drop 
by drop, which is a tricky process to control. 
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4.4.1. Dextran coated superparamagnetic 
nanoparticles.  
Since non coated nanoparticles have a large surface area 
to volume ratio, they tend to aggregate in order to reduce 
their surface energy.[199] However these nanoparticles can 
be stabilized with high molecular weight polymers such 
dextran. TEM image of dextran coated nanoparticles 
showed a regular distribution of sizes and shape of the 
synthesized particles. It wass possible to identify the core 
(spherical dark spots) but the polymer chains of dextran 
have too low density for contributing to contrast in the 
image and therefore cannot be observed. It has to be 
mentioned that it was not possible to take a micrograph of 
single dextran coated nanoparticles due to the 
aggregative nature of this polymer already previously 
reported[226].  
Because dextran coated nanoparticles synthesis is a single 
step method, it was not possible to measure exclusively 
magnetic cores and dextran coated particles separated 
and all determinations were performed on dextran coated 
nanoparticles. However, several techniques as TEM and 
XRD are appropriate to measure the core size in presence 
of the coating material. Using TEM, the mean experimental 
size was 3.70.8 nm, a close value to core sizes already 
published following similar synthesis methods (4.110.85 
nm).[226] Moreover, the crystallite size value from XRD 
spectrum using the Scherrer equation was 4.80.5 nm, in 
agreement with TEM results. Indeed, grain size should be 
smaller than TEM (multiple crystals, defects in crystals, 
amorphous shell). Normally, the grain size obtained from the 
XRD data should be smaller than the sizes measured from 
the TEM micrographs, due to several reasons: First, the outer 
layer of the MNPs tend to be amorphous due to the 
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curvature of the particles. This amorphous layer is detected 
by TEM, but does not contribute to the XRD diffractograms. 
Secondly, crystal defects can form within the MNPs crystal 
structure distorting the XRD data.  Additionally, a MNP can 
be made up of several crystals, all of course being smaller 
than the size measured through TEM. A possible reason for 
the unexpected larger grain size can be attributed to the 
both methods, where size analysis based on TEM has a 
limited sample size, whereas the XRD data is taken from 
larger samples. Overall, both experimental values are in 
concert with each other. It is also important to mention that 
the standard deviation derived from the TEM measurement 
and therefore the size distribution is adequate considering 
that they were synthesized following the chemical 
coprecipitation method.  
The crystalline structure from XRD data reflects a magnetite 
and/or maghemite crystal with a cubic spinel structure. 
Magnetite can be easily oxidized in air to form  
maghemite,[228]  making it difficult to distinguish between 
them. This even can occur during sample preparation.  The 
maghemite phase is known to exhibit few extra peaks at 
23.77º (210) and 26.10º (211), and these peaks may be used 
to distinguish it from magnetite phase, however the intensity 
of these peaks are very weak (5%) for the positive 
identification of the maghemite phase.[229] Our XRD 
experimental spectrum of synthesized MNPs did not exhibit 
those diffraction peaks, but this fact does not guarantee 
that the sample is a single-phase maghemite, considering 
the previous point made. With regard to the calculated 
lattice parameter from XRD spectrum, the value 8.330.02 A 
is closer to maghemite (8.3515 A –JCPDS 39 1346-) than to 
magnetite (8.396 A –JCPDS 19 629-), what suggests that the 
obtained cores through chemical coprecipitation method 
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in presence of dextran are mostly composed of 
maghemite.  
Moreover, the size of the dextran-coated nanoparticles was 
measured by DLS with a mean size 943 nm is in agreement 
with previous works.[230] Apart from the size, the surface 
charge is an important factor to take into account in terms 
of nanoparticle stability. The synthesized dextran-coated 
nanoparticles are stable in distilled water and negatively 
charged (-113 mV), a remarkable aspect to take into 
account for further in vitro and in vivo experiments in terms 
of not only cell labeling, but also of protein binding as 
well.[231,232]  
To study the nature of the nanoparticle coating, FTIR and 
TGA were performed. FTIR spectrum demonstrated the 
presence of dextran and magnetite. The peak at 3351cm-1 
is attributed to the stretching vibrations of –OH, which is 
assigned to OH- absorbed by iron oxide nanoparticles or 
leftover water from KBr preparation.  Also vibrational modes 
(C-H) and (C-H) at 2906 cm-1, 1420 cm-1 and 1380 cm-1, 
water molecular bending due to C-O vibrations at 1620 cm-
1, 1145 cm-1 and 1010 cm-1 and small peaks at 908 cm-1, 877 
cm-1 and 746 cm-1 corresponding to -glucopyranose ring 
deformation modes (Figure 18) demonstrated the presence 
of dextran in the sample. The two absorption bands at 578 
cm-1 and 430 cm-1 corresponding to Fe-O vibration modes 
verify the presence of the iron oxide core. However, it is 
necessary to look of TGA data for a better understanding of 
the dextran coated magnetic nanoparticles. TGA data 
indicates the presence of two close peaks (280ºC and 
322ºC), demonstrating that the 66% of total weight of the 
sample was dextran, which points towards a thick and 
dense coating of the MNPs, this result agrees with other 
published works.[199,233] However, those two peaks also 
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show that the high stability of the sample is also conditioned 
for the presence of free dextran, which would be more 
easily detached (therefore 280ºC) and nanoparticle-
attached dextran (more difficult to unbound, 322ºC). In this 
sense, 32.44 wt % would correspond to free dextran and 
33.57 wt% to nanoparticle bonded one. Together, the 
results of FTIR and TGA, confirm the presence of dextran 
coating on the magnetic nanoparticles and also free 
polymer increasing the stability of the suspension.  
Magnetic characterization of the MNPs showed the relative 
magnetization curve as a function of magnetic field at 5K 
and 300K. The absence of hysteresis loop at 300K indicated 
the characteristic superparamagnetic behavior of the 
particles. This means that these particles have non-
interacting domains, so no magnetic clustering and high 
magnetization saturation, an important aspect for MRI 
contrast enhancement.[199] To assess the transverse 
relaxivity measured by MRI and therefore that those 
particles are suitable as MRI contrast agents, T2-weighted 
images were acquired. Four different concentrations of 
dextran coated nanoparticles were measured and all 
parameters, such as echo time, repetition time and 
resolution were adjusted to obtain a well-defined 
exponential decay. The higher concentration (0.19mM) of 
particles could not be adjusted to an exponential decay 
because there were not enough data points to perform the 
adjustment. The relaxivity r2 of dextran-coated particles 
from this data was 6994 mM-1s-1. 
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4.4.2. Pluronic F127 and Tetronic 908 coated 
superparamagnetic nanoparticles.  
The iron oxide nanoparticles formation through chemical 
coprecipitation method is a fast reaction, and happens 
when the ammonium hydroxide is added to iron salts 
mixture. After the formation of iron oxide nanoparticles, 
oleic acid is added in order to create an OA shell 
surrounding the iron oxide nanoparticle, which will be used 
as an anchor for further polymer functionalization. However, 
due to the excess of OA for the coating process, a 
multilayer of OA on the surface of the nanoparticles is 
formed, making them hydrophilic like. This multilayer is not 
stable, so a deep DW wash process will turn them into their 
natural hydrophobic state, and easily dispersible in organic 
solvents. This full procedure, including chemical 
coprecipitation, OA coating and nanoparticle washing 
results in OA-coated iron oxide nanoparticles nicely 
dispersed in chloroform.[205]  
The oleic acid coated nanoparticles were found to be 
spherical in TEM micrographs, and it was also possible to 
measure their size, being this one about 8.61.4 nm. DLS and 
XRD nanoparticle sizes were 7.70.8 nm and 7.30.8 nm 
respectively. It is expectable that standard deviation (SD) of 
TEM size determination is higher than XRD and DLS due to 
the number of total counts taken into account to calculate 
the mean. However, OA-coated nanoparticles size 
determination was similar for all techniques, and also 
consistent with previous studies.[205,234]  
In accordance with dextran-coated MNPs XRD spectrum, 
the position and intensities of OA-coated nanoparticles 
peaks matched well with magnetite and/or maghemite 
crystals with a cubic spinel structure. Apart from the fact 
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that the peaks at 23.77º (210) and 26.10º (211) are not 
observed, it is not possible to reassure that the sample is 
pure magnetite. The calculated lattice parameter from XRD 
spectrum is about 8.3610,004 Å, which is in between 
maghemite (8,3515 A –JCPDS 39 1346-) and magnetite 
(8,396 A –JCPDS 19 629-), exhibiting, as a consequence, the 
presence of both phases. 
The magnetization curve of these OA-coated nanoparticles 
at room temperature showed not coercivity and 
remanence, indicating that the sample is 
superparamagnetic at room temperature.  
With regard to the functionalization with Pluronic F127 and 
Tetronic 908 of OA-coated nanoparticles, DLS size 
determination were performed, as it was not possible to 
measure through TEM pictures the size of the polymer 
coated nanoparticles. Tetronic coated MNPs are slightly 
bigger compare to Pluronic, 1206 nm and 1546 nm 
respectively and these values are in consonance with other 
block copolymers coated nanoparticles.[207] Z-potential 
was negative for both, Pluronic F127 coated MNPs were -
183 mV and -243 mV for Tetronic 908 coated MNPs, which 
confirms the stability of the nanoparticles and prevents  
aggregation for storage[235]. 
TGA of OA-, Pluronic F127- and Tetronic 908- coated 
nanoparticles was performed to quantify OA and polymer 
contents. For all formulations the percentage of oleic acid 
present in the MNPs went from 19% to 26%, and the amount 
of polymer was 35.5% for Pluronic F127 and 42% for Tetronic 
908. Because these preparations were washed through 
magnetic separation, these percentages correspond just to 
attached polymer. Nevertheless, FTIR spectrums showed 
that OA-, Pluronic F127- and Tetronic 908-coated MNPs 
 103 
 
have all peaks at same wave numbers except for 1100 cm-
1, which is not present in OA-coated nanoparticles. It has 
been published that broad bands around 1250-1000 cm-1 
are due to the CH2 rocking and C-O-C stretch vibrations of 
Pluronic. The well-defined band at 1100 cm-1 is typical for a 
block copolymer in the optimal formulation in which OA 
completely covers the iron oxide nanoparticle surface.[205] 
MRI T2* weighted images were acquired to calculate the 
transverse relaxivity and evaluate if these particles are 
suitable as MRI contrast agents for cell tracking. Four 
different concentrations of each polymer coated 
nanoparticles were measured and all parameters, such 
echo time, repetition time and resolution were adjusted to 
obtain a well-defined exponential decay. As happened 
before for dextran coated MNPs, the higher concentrations 
(0.36 mM for Pluronic F127- and 0.45 mM for Tetronic 908-
coated MNPs) of particles cannot be adjusted to an 
exponential decay because there were not enough data 
points to perform the adjustment. On the other hand lower 
concentration data points described a nice adjustment. 
With this data it was also possible to determine the relaxivity 
r2 of Pluronic F-127 and Tetronic 908- coated particles, being 
398±12 mM-1s-1 and 33020 mM-1s-1 respectively. It was 
expected that both values are similar because they have 
common magnetic cores, similar coatings and almost 
equal DLS sizes. 
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4.5. Conclusions 
In conclusion, 3 types of superparamagnetic nanoparticles 
coated with different polymers have been developed. 
After a careful chemical coprecipitation synthesis 
processes, spherical-shaped maghetite/maghemite 
nanoparticles exhibiting superparamagnetic behavior at 
room temperature were obtained. Two methods were 
described for core synthesis and polymer coating; in situ 
dextran coated MNPs and two step procedure for Pluronic 
F127 and Tetronic 908 coating. Both processes resulted in 
clustered, well-coated and nicely dispersed nanoparticle 
suspensions in aqueous solutions, being biocompatible and 
suitable as a MRI contrast agent.  Overall, this has resulted in 
an easy method to produce water-stable 
superparamagnetic nanoparticles with different size and 
coatings, which will be essential for next biological and 
biomedical applications. 
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In this section we present the in vitro validation of the 
superparamagnetic nanoparticles synthesized in the 
previous chapter. In vitro studies are divided in three 
chapters, where different aspects of the cell labeling 
process will be detailed.  
As we have mentioned in the introduction section, several 
studies have demonstrated the need of transfect agents for 
an efficient labeling process. In previous test (data not 
shown) we have observed that Pluronic F127- and Tetronic 
908-coated MNPs do not need Transfect Agents (TAs), while 
TAs are indispensable for dextran-coated labeling. Thus, in 
the first chapter of this section (Chapter 4) we have 
evaluated the use of TAs for dextran-coated MNPs 
previously synthesized and its influence in mesenchymal 
stem cells.  
Considering these transfection agent results, in Chapter 5 
we have studied the MNPs influence in the well-being of 
two types of cells. Rat mesenchymal stem cells and the 
multi-potent neural progenitor cell line C17.2. were used for 
the in vitro evaluation due to their therapeutic potential. 
Here, different concentrations and incubation times were 
evaluated to elucidate which of our synthesized MNP is the 
most suitable for further in vivo cell tracking experiments.  
However, prior to in vivo studies, in the last chapter of this 
section we have studied the long-term evolution of the MRI 
signal of labeled mesenchymal stem cells. We have 
evaluated in vitro how the proliferation rate affects the MRI 
detection limit and if the labeling has a long-term harmful 
effect in the cells.  In addition, we have also evaluated the 
magnetic vectorization in vitro with MSCs labeled with our 
MNPs.  
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5. Mesenchymal stem 
cells labeled with 
Dextran coated 
MNPs: Transfection 
agents evaluation 
5.1. Hypothesis 
The purpose of this chapter is to evaluate the use of 
Transfect Agents (TAs) for labeling mesenchymal stem cells 
with dextran-coated magnetic nanoparticles (D-MNPs) and 
to study the bio-influence of the TA and MNPs in the cells. 
5.2. Materials & Methods  
Seven different conditions were studied: Control, 3 
concentrations of Poly-L-Lysine hydrobromide (PLL) (0 
g/mL; 0.75 g/mL and 1.5 g/mL) and 2 concentrations of 
D-MNPs (200 g/mL and 100 g/mL) for each PLL condition 
(n=3 for each condition). To evaluate the viability, two 
control groups were included, 1) 1.5g/mL of PLL in cell 
medium (No D-MNPs) and 2) lysed cells.  
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5.2.1. Cell lines 
All experiments were performed using Mesenchymal Stem 
Cells (MSCs) purchased from Cultrex, Trevigen and were 
cultured in IMDM (78%), Fetal bovine serum (10%), Horse 
serum (10%), Penicillin-Streptomycin (1%) all from Gibco 
Invitrogen, and Amphotericin-B (1%) from Sigma-Aldrich. 
Cell passage numbers between 7 and 18 were used in 
these experiments.  
5.2.2. Dextran-coated superparamagnetic 
nanoparticles 
Dextran coated MNPs (D-MNPs) were synthesized in the 
Clinical Neuroscience Research Laboratory following the in 
situ protocol described in Chapter 3.  
5.2.3. Preparation of Poly-L-lysine hydrobromide-
coated D-MNPs 
Two concentrations of Poly-L-lysine hydrobromide (PLL) 
(Sigma-Aldrich) were studied: 0.75 g/mL and 1.5g/mL. 
One hour prior to cell incubation, the D-MNPs were mixed 
with MSCs medium and with 0.75 or 1.5 g/mL PLL and 
vigorously shaken.  
5.2.4. Cell labeling with PLL-coated D-MNPs 
Cells were labeled following the protocol described 
elsewhere [227] with slight modifications. MSCs were 
incubated with different concentrations of PLL (0; 0.75 and 
1.5g/mL) and D-MNPs (200 and 100 g of Fe/mL) for 24h. 
The D-MNP containing medium was removed and the cells 
were 3 times washed with 1.5 mL of Phosphate Buffered 
Saline (PBS without Mg2+ and Ca2+, Gibco Invitrogen) to 
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remove non-attached MNPs. After washing, the cells were 
left overnight (12h) in 1mL of fresh medium. The following 
day the medium was removed, cells were washed once 
with 1.5mL of PBS, and 0.5mL of EDTA-trypsin (Gibco 
Invitrogen) was added to detach the cells from the well. 
The trypsin was neutralized with fresh medium and the 
detached cells were collected in a Falcon tube. After a 
mild centrifugation, the supernatant was discarded and the 
cells were resuspended in fresh medium.  
5.2.5. Proliferation 
To determine the proliferation rate, total cell count was 
performed with Trypan Blue staining and a Neubauer 
chamber. Samples were diluted 1:5 with PBS and 1:2 with 
Trypan Blue. 
5.2.6. Cell viability assay: Lactate Dehydrogenase 
Assay (LDH) 
For assessing the viability of the cells after labeling 
compared to control, supernatants from last 12h (fresh 
medium incubation) were collected in eppendorf tubes. A 
negative control of lysed cells was also included (death) 
following manufacturer protocol for lysis. After a mild 
centrifugation of the supernatants, 75 L were mixed in a 96 
well plate with 150 L LDH reagents following the 
manufacturer protocol (Lactate Dehydrogenase Assay Kit. 
Sigma-Aldrich). After 20 minutes incubation, the plate was 
read in Synergy2 (Biotek) at 490 nm. To calculate the 
viability rate respect to control, next equation was applied.  
ܸܾ݈݅ܽ݅݅ݐݕ	ሾ%	ܿ݋݊ݐݎ݋݈ሿ ൌ ܮܦܪ௟௬௦௘ௗ െ ܮܦܪ௘௫௣௢௦௘ௗܮܦܪ௟௬௦௘ௗ െ ܮܦܪ௖௢௡௧௥௢௟ ൉ 100 
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5.2.7. Intracellular iron determination 
An amount of 100.000 cells per condition were dissolved in 
1mL of 37% HCl (Hydrochloric acid fuming 37% extra pure, 
Merk) and then 4 mL of DIW was added to reach total 
volume of 5mL. Iron concentration was determined by 
inductive coupled plasma optical emission spectroscopy 
(ICP-OES) (Varian Inc). The intensity of the emission line at 
238.204 nm was measured for iron and compared to a 
standard solution. ICP-OES was performed at the Material 
Science Institute (MTM), KU Leuven.  
5.2.8. Prussian Blue staining 
Prussian Blue staining was performed to demonstrate the 
uptake of the D-MNPs by the cells. Labeled cells were 
planted and after 8h, were washed with PBS and incubated 
for 20 minutes with a mix of equal parts of aqueous solution 
of 20% HCl (Hydrochloric acid fuming 37% extra pure, Merk) 
and aqueous solution of 10% Potassium ferrocyanide 
Trihydrate (KFe(CN)6.3H2O, FW 422.2, Sigma-Aldrich). After 
incubation, cells were washed 3 times with PBS and 
photographs were taken using an inverted microscope 
(Olympus IX51). 
5.2.9. Transmission electron microscopy (TEM) 
To assess the localization of the D-MNPs in the cell, TEM 
images of cells were taken. Fixation and postfixation of 
500.000 cells were carried out in 2% glutaraldehyde in 
sodium cacodylate buffer and in 1% OsO4 in the same 
buffer. Inclusion was done in Spurr’s epoxy resin. Semithin 
sections (0.5 μm) were stained with Toluidine blue and 
ultrathin sections (100 nm) were stained with uranyl acetate 
and lead citrate. 
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5.2.10. Magnetic resonance imaging of labeled 
cells 
Agar phantom were made following the procedure 
described elsewhere.[227] 100.000 cells per condition were 
scanned in a Bruker Biospec 9.4 T small animal MR scanner 
(Bruker, Biospin) equipped with actively shielded gradients 
(400 mT/m). A quadrature radio-frequency transmit-recive 
resonator was used for data acquisition. T2-weighted 
images were acquired using a MSME sequence of 10.26 ms 
echo time, 3 s repetition time, 16 echoes, 14 slices, 1 
average, FOV of 7.5 cm x 7.5cm and matrix size of 256 x 
256. T2*-weighted images were acquired using a MGE 
sequence of 4.44 ms echo time, 6.75 ms echo spacing, 1.8 s 
repetition time, 16 echoes, 14 slices, 2 averages, FOV of 
7.5cm x 7.5cm and a matrix size of 256 x 256. Post-
processing was performed using ImageJ software 
(Rasband, W. NIH). 
5.2.11. Flow cytometry of MSCs 
The characterization of MSCs after labeling was performed 
by flow cytometry analysis. MSCs (0.25x106 cells) were 
washed with 50 L of PBS and stained by incubation (15 
minutes) with 5 L CD90-FITC and 5 L CD45-PE (BD 
Pharmigen) antibodies. Firstly, MSCs were separated by 
their forward and side scattering signal characteristics. 
MSCs were characterized as CD90+/CD45- cells. For analysis 
20.000 cell events were acquired in a BD FACS Aria I (BD 
Bioscience), and data were analyzed with the use of 
FACSDiva software (BD Biosciences). 
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5.2.12. Statistical analysis 
The statistical analyses of the data were performed using 
GraphPad Prism 5.01(GraphPad Software, Inc) and mean 
and standard deviation are presented.  
5.3. Results  
5.3.1. Cellular internalization of the MNPs 
The amount of internalized iron oxide nanoparticles was 
determined by ICP and results are plotted in (Figure 28). PLL 
alone does not increase the Fe signal measured by ICP, 
which can be observed in control (2.32±0.04 pg/cell) and 
control+PLL (2.34±0.02 pg/cell). D-MNPs internalization is PLL 
dose dependent; no PLL labeling group showed similar 
values than controls, 2.75±0.02 pg/cell for 200 g/mL D-
MNPs and 2.57±0.05 pg/cell for 100 g/mL D-MNPs. 
Increasing the PLL concentration in cell medium enhances 
the uptake, being for 0.75 g/mL of PLL about 6.1±0.2 
pg/cell for 200 g/mL D-MNPs and 5.27±0.14 pg/cell for 100 
g/mL D-MNPs. For the highest PLL concentration studied 
(1.5 g/mL), experimental values were 10.4±0.5 pg/cell for 
200 g/mL D-MNPs and 9.9±0.3 pg/cell for 100 g/mL D-
MNPs. 
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Figure 28: Iron content of D-MNPs labeled and non-labeled MSCs. 
5.3.2. Magnetic resonance imaging of labeled 
cells 
To assess the D-MNPs internalized contrast, MRI of labeled 
and control cells was performed. T2 and T2* maps were 
calculated from T2 and T2* weighted images respectively 
and R2 and R2* relaxivities were obtained for each 
concentration using ImageJ software. 
Hence, R2 were similar for Control, No PLL 200 g/mL D-MNPs 
and No PLL 100g/mL D-MNPs, being 5.00.2 s-1, 4.91.1 s-1 
and 5.21.2 s-1 respectively. For 200 g/mL D-MNPs, R2 = 
7.11.4 s-1 for 0.75g/mL and R2 = 8.60.8 s-1 for 1.5g/mL. 
And for 100 g/mL D-MNPs, R2 = 7.20.8 s-1 for 0.75g/mL 
and R2 = 7.11.9 s-1 for 1.5g/mL. Experimental values are 
plotted in Figure 29, and MSCs T2-weighted images are 
shown in Figure 30.  
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Figure 29: R2 values [s-1] of D-MNPs labeled and non-labeled MSCs. 
 
 
Figure 30: T2-weigthed images of MSCs. (A) Control; (B) 200 g/mL of D-
MNPs and No PLL, (C) 200 g/mL of D-MNPs and 0.75 g/mL of PLL, (D) 
200 g/mL of D-MNPs and 1.5 g/mL of PLL, (E) 100 g/mL of D-MNPs and 
No PLL, (F) 100 g/mL of D-MNPs and 0.75 g/mL of PLL, (G) 100 g/mL of 
D-MNPs and 1.5 g/mL of PLL.  
Accordingly to T2* maps, R2* for Control cells was 154 s-1. 
For 200 g/mL D-MNPs was: 245 s-1for No PLL, 385 s-1 for 
0.75 g/mL of PLL and 64.8 0.6 s-1 for 1.5 g/mL of PLL. For 
100 g/mL D-MNPs, R2 values were: 205 s-1 for No PLL, 356 
s-1 for 0.75g/mL of PLL and 519 s-1 for 1.5g/mL of PLL. 
Experimental values are plotted in Figure 31 and MSCs T2-
weighted images are shown in Figure 32.  
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Figure 31: R2* values [s-1] of D-MNPs labeled and non-labeled MSCs. 
 
 
Figure 32: T2*-weigthed images of MSCs. (A) Control; (B) 200 g/mL of D-
MNPs and No PLL, (C) 200 g/mL of D-MNPs and 0.75 g/mL of PLL, (D) 
200 g/mL of D-MNPs and 1.5 g/mL of PLL, (E) 100 g/mL of D-MNPs and 
No PLL, (F) 100 g/mL of D-MNPs and 0.75 g/mL of PLL, (G) 100 g/mL of 
D-MNPs and 1.5 g/mL of PLL.  
5.3.3. Optical microscopy and TEM 
Two microscopic techniques were used to assess the 
cellular labeling. The most common is Prussian Blue staining, 
which shows the MNPs in a blue color in bright field 
microscopy imaging. Control and No PLL conditions 
showed no Prussian Blue Figure 33((A), (B), (C), (D)), 
therefore no cell labeling. Under PLL presence, Prussian Blue 
staining can be observed, revealing also a dependence 
between amount of PLL and blue staining as can be seen in 
Figure 33 (E, F, G, H). For 100 g/mL of D-MNPs results were 
similar (Data not shown). 
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Apart from optical microscopy, transmission electron 
microscopy was performed. There were no particles in the 
cells for the No PLL group (Figure 34 (A)).  For the rest of the 
groups, D-MNPs were engulfed in cellular compartments 
and distributed along the cell. MSCs labeled with 1.5 g/mL 
of PLL and 200 g/mL of D-MNPs are shown in Figure 34 (B), 
where black circular dots can be observed within the cell 
cytoplasm.  It was also possible to zoom into one labeled 
cell (see Figure 35 (A), (B), (C)), and the particle pattern 
inside the endosomes can be observed in Figure 35(C). One 
important result is that all particles observed were fully 
internalized and not attached to the cell membrane. 
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Figure 33: Prussian Blue staining of MSCs. (A) Control cells in phase 
contrast, (B) Bright field of Control cells, (C) Phase contrast 200 g/mL D-
MNPs and NO PLL, (D) 200 g/mL D-MNPs and NO PLL in Bright field, (E) 
Phase contrast 200 g/mL D-MNPs and 0.75 g/mL, (F) 200 g/mL D-MNPs 
and 0.75 g/mL in bright field, (G) Phase contrast 200 g/mL D-MNPs and 
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1.5 g/mL PLL and (H) 200 g/mL D-MNPs and 1.5 g/mL PLL in bright 
field. 
 
Figure 34: TEM micrographs of (A) No PLL 200 μg/mL D-MNPs, (B) 1.5 
μg/mL PLL and 200 μg/mL of D-MNPs. 
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Figure 35: TEM micrographs of 1.5 g/mL of PLL and 200 g/mL of D-MNPs 
(A) one labeled cell, (B) 200x zoom of A, (C) 400x zoom of A. 
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5.3.4. Effect of the MNPs internalization on the cells 
Proliferation rate experimental data is referred to control 
group (100%). There are no significant differences between 
all groups in terms of proliferation 12h after full D-MNPs 
internalization, see Figure 36. 
 
Figure 36: Proliferation rate for D-MNPs labeled and non-labeled MSCs.  
Moreover, LDH viability assay performed at same timepoint 
showed that there are not significant differences between 
control group and the rest of the conditions. As it is shown in 
Figure 37, experimental values of control are slightly 
increased for the presence of PLL and/or D-MNPs but there 
is not a statistical difference between conditions.  
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Figure 37: Viability rate [% respect control] for D-MNPs labeled and non-
labeled MSCs. 
To evaluate phenotypic changes in MSCs after cell tagging, 
CD45 and CD90 markers for flow cytometry were used to 
characterize labeled and non-labeled MSC. Figure 38 
shows the results for the control and for highest 
concentration of D-MNPs, 200 g/mL. There were no 
differences between all labeling conditions; all groups were 
negative for CD45 and positive for CD90, as can be 
observed in Figure 38 (blue). Conditions of 100 g/mL 
showed the same behavior (data not shown). It can also be 
noted that the shape of side scattering (SSC), in Figure 38 is 
different depending on the condition, and this can be 
correlated with the amount of PLL and therefore with 
internalized MNPs. Control and No PLL are more similar 
between them than 0.75 g/mL PLL, and 1.5 g/mL PLL is 
the most different one. SSC is influenced by the complexity 
of the sample, pointing out the amount of internal 
organelles. The more PLL combined with D-MNPs, the more 
cellular uptake and as a consequence, the higher will be 
the SSC in flow cytometry.   
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Figure 38: Flow cytometry for CD45 and CD90 markers in MSCs (A) control 
group, (B) 1.5 g/mL of PLL for 200 g/mL of D-MNPs, (C) 0.75 g/mL of 
PLL for 200 g/mL of D-MNPs and (D) No PLL for 200 g/mL of D-MNPs. 
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5.4. Discussion  
In this chapter we have assessed the use of D-MNPs 
synthesized in the previous chapter as contrast agents for 
MRI. After D-MNPs characterization, all data suggested their 
potential for cell tagging; however it was necessary to 
demonstrate their use, not only because of the magnetic 
properties, but also to the biocompatibility after labeling as 
well.   
It is known that dextran coated superparamagnetic 
nanoparticles should be combined with transfect agents for 
an efficient cell labeling, but the use and concentration of 
these TAs is limited due to their toxicity[215,236]. In order to 
assess the labeling capacities of D-MNPs alone or 
combined with Poly-L-lysine (PLL), different labeling 
conditions were studied in vitro.  
PLL is a polycationic amine. The combination of excessive 
amounts of polycations with cells results in pore formation in 
the membrane and an intracellular ionic embalance that 
can ultimately lead to cell death.[216] However, PLL use is 
widely extended and accepted for nanoparticle cell 
labeling based upon the toxicity profile and iron content 
per cell for certain concentrations.[216,227,237-239] To 
evaluate the optimal cell tagging, 3 concentrations of PLL 
(No PLL; 0.75 g/mL and 1.5 g/mL) combined with 200 and 
100 g/mL of D-MNPs were studied in MSCs culture. The 
selection of MSCs for in vitro labeling validation was made 
based on their inherent therapeutic capacities and on the 
promising preclinical results in ischemic stroke. 
Our results show that cellular uptake is mainly governed by 
PLL concentration. The uptake profile is the same for 200 
and 100 g/mL D-MNPs concentrations, and is the amount 
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of PLL that makes the difference between groups. No PLL 
conditions showed similar values to the control, meaning no 
labeling occurs without transfection agents. On the other 
hand, the highest cell uptake is reached for the highest PLL 
concentration. For the two D-MNPs concentration studied 
(200 and 100 g/mL), double amount of PLL is reflected in 
almost double amount of internalized iron; For 200 g/mL of 
D-MNPs, 6.1±0.2 pg/cell and 10.4±0.5 pg/cell for 0.75 g/mL 
and 1.5 g/mL respectively, and in the other case, for 100 
g/mL of D-MNPs, 5.27±0.14 pg/cell and 9.9±0.3 pg/cell for 
0.75 g/mL and 1.5 g/mL respectively. But this numerical 
data must be supported by other technique that shows 
where those MNPs are, in essence to demonstrate that the 
measured iron is internalized.  
Prussian Blue staining is designed for qualitative detection of 
MNPs in labeled cells, but using this technique is not possible 
to discriminate if they are in the cell or attached to the 
surface. TEM and confocal microscopy are the gold-
standard techniques for this task, but because of the non-
fluorescent nature of our D-MNPs confocal microscopy will 
not determine whether D-MNPs are fully internalized. For 
taking TEM micrographs of labeled and non-labeled cells 
no staining was needed. A black circular dot distribution 
along the cytoplasm can easily be observed in labeled cell 
slices Figure 34 (B) and Figure 35, and going more in detail, 
D-MNPs can be observed encapsulated in small cellular 
vesicles. Moreover, no particles are attached to the cell 
membrane or new endosome-shapes are being formed, 
what means that the labeling protocol is highly efficient; 
uptake process has finished and all particles are inside the 
cell. At this point, it is important to keep in mind that the 
ultimate goal of cell labeling is to inject and track these 
cells in vivo. Surface associated MNPs of injected cells 
could result in uncontrolled label transfer to cells of the host, 
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leading to unspecific contrast and possible 
misinterpretation of MRI. However, TEM micrographs confirm 
that labeled cells are Trojan-horse-like; the host will not 
distinguish between labeled and non-labeled cells, 
because all D-MNPs are fully internalized. 
The efficient cellular uptake and the dependence with the 
amount of PLL were also seen in MRI. 5000 cells/L loaded 
with 5-10 pg/cell can be properly detected in T2 and T2* 
weighted images in MRI. This is in consonance with other 
studies that suggested that the minimum concentration for 
in vivo cell visualization is 2-5 pg/cell. [212,239,240]  
Regarding the MNPs biocompatibility, optical and 
transmission electron microscopy also showed that cells 
exhibit normal external morphology and internal organelle 
distribution, as was reported in previous studies.[215,239,241] 
It is also important to mention at this point that labeled cells 
were replanted to perform Prussian Blue staining, assessing 
their further viability. Additionally, cell proliferation after PLL 
and/or D-MNPs incubation was not affected compared to 
control group as can be noted in Figure 36. It is well known 
that high concentrations of PLL are toxic, and can lead to 
cell death,[215,236] but in our experiments we have seen 
that under 0.75 g/mL and 1.5 g/mL of PLL incubation, the 
proliferation rate is not diminished after cell labeling.  
Furthermore it is also crucial to study the toxicity-viability 
induced by PLL and/or D-MNPs. LDH viability assay is a 
widely used procedure which, measuring the amount of 
cytoplasmic LDH released into the medium, evaluates cell 
viability as well as a function of membrane integrity. 
However, it has been described that MNPs presence in 
medium induces artifacts in several viability assays, also in 
LDH, mainly due to the interactions between the particles 
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and the reagents from the assay.[242,243] Nevertheless, our 
labeling protocol is compatible with LDH assay; cell viability 
can be evaluated once the labeling medium is removed 
and fresh medium is added and incubated for 12h. As it has 
been already mentioned, after the labeling process, MNPs 
are fully internalized so no free particles can be found in cell 
medium, and therefore no interaction can occur with the 
LDH assay. At this point, in regard to LDH viability results, 
there are no significant differences between groups. This 
result is in concert with the proliferation data and the TEM 
pictures, assessing that the incubation with these amounts 
of PLL and/or D-MNPs does not have a harmful effect on 
the cells.  
Addressing to the phenotype characterization, labeled and 
non-labeled cells exhibited a similar surface markers profile 
in flow cytometry analysis, negative for the hematopoietic 
marker CD45 and positive for the mesenchymal progenitor 
marker CD90. So no adverse effect was detected in MSCs 
after PLL and/or D-MNPs incubations with regard to CD45 
and CD90, which is in agreement with previous published 
studies using D-MNPs.[236,244] 
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5.5. Conclusions 
This chapter has demonstrated that our synthesized 
dextran-coated superparamagnetic nanoparticles in 
combination with a transfection agent as Poly-L-lysine can 
be sufficiently taken up by potential therapeutic cells as 
mesenchymal stem cells. The labeling protocol ensured a 
full internalization of the PLL coated D-MNPs without 
affecting the wellbeing of the cells. The relatively high 
uptake rate depends on the PLL concentration, and cells 
can be properly detected in MRI, providing promising results 
for further in vivo applications. In conclusion, the results of 
this study showed that our synthesized dextran coated 
superparamagnetic nanoparticles combined with 1.5 
μg/mL of PLL are an efficient and biocompatible MRI 
contrast agent for cell tracking. 
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6. Dextran-, Pluronic 
F127- and Tetronic 908- 
coated 
superparamagnetic 
nanoparticles: In vitro 
validation 
6.1. Hypothesis 
The aim of the present chapter is to evaluate the 
biocompatibility of our synthesized dextran-, pluronic F127- 
and tetronic 908-coated MNPs in 2 different cell types, 
MSCs and C17.2., combining D-MNPs with PLL for an 
efficient cellular uptake. Moreover, we will study the 
influence of the incubation time and MNPs concentration in 
the well-being, in the uptake, and therefore in the MRI 
signal produced by these labeled cells. 
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6.2. Materials & Methods 
6.2.1. Cell lines 
Mesenchymal Stem Cells (MSCs) were purchased from 
Cultrex, Trevigen and cultured in IMDM (78%), Fetal bovine 
serum (10%), Horse serum (10%), Penicillin-Streptomycin (1%) 
all from Gibco Invitrogen, and Amphotericin-B (1%) from 
Sigma-Aldrich. Cell passage numbers between 7 and 18 
were used in these experiments.  
Multi-potent neural progenitor cell line C17.2 were 
characterized by Markus Auswendt and kindly donated by 
Prof. Mathias Hoehn (Max-Planck Institute, Cologne, 
Germany) and cultured in DMEM (78%), Fetal bovine serum 
(10%), Horse serum (5%), Penicillin-Streptomycin (1%) all from 
Gibco Invitrogen, and Amphotericin-B (1%) from Sigma-
Aldrich.  
6.2.2. Dextran-, Pluronic F127- Tetronic 908-coated 
superparamagnetic nanoparticles 
Dextran coated MNPs (D-MNPs), Pluronic F127 coated 
MNPS (P-MNPs) and Tetronic 908 coated MNPS (T-MNPs) 
were synthesized in the Clinical Neuroscience Research 
Laboratory following the protocols described in chapter 3.  
5.2.3. Preparation of Poly-L-lysine hydrobromide-
coated D-MNPs 
One hour prior to cell incubation, different concentrations 
of D-MNPs (500 and 250 g/mL) were mixed with MSCs or 
C17.2 mediums and with 1.5 g/mL PLL (Sigma-Aldrich) and 
vigorously shaken.  
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6.2.3. Cell labeling with MNPs 
Cells were labeled with 3 different types of MNPs, as it has 
been mentioned before. Two concentrations (500 and 250 
g/mL for D-MNPs and 35 and 15 g/mL for P-MNPs and T-
MNPs) respectively; and two incubations times (24h and 6h) 
were studied in this chapter (n=6 for each condition). 
Labeling protocol was the same for all groups.  
Cells were labeled following the protocol described 
elsewhere [227] with slight modifications, already used in 
the previous chapter. Cells were incubated with different 
concentrations of MNPs for 6h or 24h. The MNP containing 
medium was removed and the cells were 3 times washed 
with 1.5 mL of Phosphate Buffered Saline (PBS without Mg2+ 
and Ca2+, Gibco Invitrogen) to remove non-attached 
MNPs. After washing, the cells were left overnight (12h) in 1 
mL of fresh medium. The following day the medium was 
removed, cells were washed once with 1.5mL of PBS and 
0.5mL of EDTA-trypsin (Gibco Invitrogen) was added to 
detach the cells from the well. The trypsin was neutralized 
with fresh medium and the detached cells were collected 
in a Falcon tube. After a mild centrifugation, the 
supernatant was discarded and the cells were resuspended 
in fresh medium.  
6.2.4. Proliferation 
To determine the proliferation rate, total cell count was 
performed with Trypan Blue staining and a Neubauer 
chamber. Samples were diluted 1:5 with PBS and 1:2 with 
Trypan Blue. 
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6.2.5. Cell viability assay: Lactate Dehydrogenase 
Assay (LDH) 
For assessing the viability of the cells after labeling 
compared to control, supernatants from last 12h (fresh 
medium incubation) were collected in eppendorf tubes. A 
negative control of lysed cells was also included. After a 
mild centrifugation of the supernatants, 75L were mixed in 
a 96 well plate with 150L LDH reagents following the 
manufacturer protocol (Lactate Dehydrogenase Assay Kit. 
Sigma-Aldrich). After 20 minutes incubation, the plate was 
read in Synergy2 (Biotek) at 490nm. To calculate the viability 
rate respect to control, next equation was applied.  
ܸܾ݈݅ܽ݅݅ݐݕ	ሾ%	ܿ݋݊ݐݎ݋݈ሿ ൌ ܮܦܪ௟௬௦௘ௗ െ ܮܦܪ௘௫௣௢௦௘ௗܮܦܪ௟௬௦௘ௗ െ ܮܦܪ௖௢௡௧௥௢௟ ൉ 100 
6.2.6. Intracellular iron determination 
An amount of 100.000 cells per condition was dissolved in 1 
mL of 37% HCl (Hydrochloric acid fuming 37% extra pure, 
Merk) and then 4 mL of DIW was added to reach total 
volume of 5 mL. Iron concentration was determined by 
inductive coupled plasma optical emission spectroscopy 
(ICP-OES) (Varian Inc). The intensity of the emission line at 
238.204 nm was measured for iron and compared to a 
standard solution. ICP-OES was performed at CACTUS-Lugo 
(University of Santiago de Compostela).  
6.2.7. Prussian Blue staining 
Prussian Blue staining was performed to demonstrate the 
uptake of the MNPs by the cells. Labeled cells were planted 
and after 8h, were washed with PBS and incubated for 20 
minutes with a mix of equal parts of aqueous solution of 20% 
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HCl and aqueous solution of 10% Potassium ferrocyanide 
Trihydrate (KFe(CN)6.3H2O, FW 422.2, Sigma-Aldrich). After 
incubation, cells were washed 3 times with PBS and 
photographs were taken using an inverted microscope 
(Olympus IX51). 
6.2.8. Transmission electron microscopy (TEM) 
To assess the localization of the D-MNPs in the cell, TEM 
images of cells were taken. Fixation and postfixation of 
500.000 cells were carried out in 2% glutaraldehyde in 
sodium cacodylate buffer and in 1% OsO4 in the same 
buffer. Inclusion was done in Spurr’s epoxy resin. Semithin 
sections (0.5 μm) were stained with Toluidine blue and 
ultrathin sections (100 nm) were stained with uranyl acetate 
and lead citrate. 
6.2.9. Magnetic resonance imaging of labeled 
cells 
Agar phantom was made following the procedure 
described elsewhere.[227] 100.000 cells per condition were 
scanned in a Bruker Biospec 9.4 T small animal MR scanner 
(Bruker, Biospin, Ettlingen, Germany) equipped with actively 
shielded gradients (400 mT/m). A quadrature radio-
frequency transmit-receive resonator was used for data 
acquisition. T2-weighted images were acquired using a 
MSME sequence of 10.26 ms echo time, 3 s repetition time, 
16 echoes, 14 slices, 1 average, FOV of 7.5 cm x 7.5cm and 
matrix size of 256 x 256. T2*-weighted images were acquired 
using a MGE sequence of 4.44 ms echo time, 6.75 ms echo 
spacing, 1.8 s repetition time, 16 echoes, 14 slices, 2 
averages, FOV of 7.5cm x 7.5cm and a matrix size of 256 x 
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256. Post-processing was performed using ImageJ software 
(Rasband, W. NIH). 
6.2.10. Statistical analysis 
The statistical analysis of the data was performed using 
GraphPad Prism 5.01 (GraphPad Software, Inc). For 
descriptive analyses, means and standard deviations were 
calculated for the normally distributed continuous variables. 
For confirmatory analyses one-way ANOVA was performed 
to calculate overall p-values for the comparison of the 
different groups for each variable. The global significance 
level for all statistical test procedures was chosen as =0.05.  
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6.3. Results 
Thirteen conditions were studied for each type of cell. Every 
group and the nomenclature assigned are presented 
below: 
<Polymer>-MNPs <Concentration> <Incubation time> 
o Control 
o D-MNPs 500 24h: Cells labeled with 500 g/mL D-
MNPs with1.5 g/mL of PLL incubated for 24 h. 
o D-MNPs 500 6 h: Cells labeled with 500 g/mL D-MNPs 
with1.5 g/mL of PLL incubated for 6 h. 
o D-MNPs 250 24 h: Cells labeled with 250 g/mL D-
MNPs with1.5 g/mL of PLL incubated for 24 h. 
o D-MNPs 250 6h: Cells labeled with 250 g/mL D-MNPs 
with1.5 g/mL of PLL incubated for 6 h. 
o P-MNPs 35 24h: Cells labeled with 35 g/mL P-MNPs 
incubated for 24 h. 
o P-MNPs 35 6h: Cells labeled with 35 g/mL P-MNPs 
incubated for 6 h.  
o P-MNPs 15 24h: Cells labeled with 15 g/mL P-MNPs 
incubated for 24 h.  
o P-MNPs 15 6h: Cells labeled with 15 g/mL P-MNPs 
incubated for 6 h.  
o T-MNPs 35 24h: Cells labeled with 35 g/mL P-MNPs 
incubated for 24 h. 
o T-MNPs 35 6h: Cells labeled with 35 g/mL P-MNPs 
incubated for 6 h. 
o T-MNPs 15 24h: Cells labeled with 15 g/mL P-MNPs 
incubated for 24 h. 
o T-MNPs 15 6h: 15 g/mL P-MNPs incubated for 6 h.  
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6.3.1. Cellular internalization of the MNPs 
The amount of internalized iron oxide nanoparticles was 
determined by ICP and results are shown in Table 1 and 
Figure 39. All labeling conditions showed variable amount 
of iron internalization depending on MNPs concentration in 
the medium and also on the incubation time. 
 MSCs C17.2 
 Mean [pg] SD Mean [pg] SD 
Control 0.4 0.1 0.4 0.0 
D-MNPs 500 24h 15 2 9.3 1.6 
D-MNPs 250 24h 8.7 0.9 8.4 0.1 
D-MNPs 500 6h 7.7 0.9 4.8 0.7 
D-MNPs 250 6h 5.9 0.9 5.1 0.3 
P-MNPs 35 24h 36.8 1.4 28 7 
P-MNPs 15 24h 16.2 0.4 9.7 0.8 
P-MNPs 35 6h 39 3 33 3 
P-MNPs 15 6h 8.9 0.5 12.7 0.8 
T-MNPs 35 24h 37 3 39 1 
T-MNPs 15 24h 9.9 1.5 14 2 
T-MNPs 35 6h 36 4 16.7 1.5 
T-MNPs 15 6h 12.4 1.4 8 3 
 
Table 1: Iron content per cell [pg] 
 
Figure 39: Iron internalization [pg/cell] for all labeling conditions.  
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6.3.2. Magnetic resonance imaging of labeled 
cells 
To assess the contrast generated by MNPs internalization, 
MRI of all labeling conditions was performed. T2 and T2* 
maps were calculated from T2 and T2* weighted images 
respectively, and R2 and R2* relaxivities were obtained for 
each condition using ImageJ. R2* values are shown in Table 
2 and plotted in Figure 40. Moreover, the contrast 
generated by the labeled and non-labeled cells can be 
observed in the first echo of T2* weighted images in Figure 
41 and Figure 42 for MSCs and C17.2 respectively.  
 MSCs C17.2 
 Mean [s-1] SD Mean [s-1] SD 
Control 32 5 31 5 
D-MNPs 500 24h 69 23 60 3 
D-MNPs 250 24h 57 17 59 5 
D-MNPs 500 6h 62 21 41 7 
D-MNPs 250 6h 47 14 40 12 
P-MNPs 35 24h 69 24 63 24 
P-MNPs 15 24h 60 21 66 5 
P-MNPs 35 6h 71 32 53 14 
P-MNPs 15 6h 78 29 58 12 
T-MNPs 35 24h 53 26 57 31 
T-MNPs 15 24h 69 10 67 11 
T-MNPs 35 6h 72 16 62 8 
T-MNPs 15 6h 72 22 48 8 
 
Table 2: R2* of different label conditions determined by MRI in an agar 
phantom with concentrations of 500 cell/L. 
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Figure 40: R2* of different label conditions. determined by MRI in an agar 
phantom with concentrations of 500 cell/L. 
 
Figure 41: First echo of T2* weighted images of MSCs for all conditions: (A) 
Control, (B) D-MNPs 500 24h, (C) D-MNPs 500 6h, (D) D-MNPs 250 24h, (E) 
D-MNPs 250 6h, (F) P-MNPs 35 24h, (G) P-MNPs 35 6h, (H) P-MNPs 15 24h, 
(I) P-MNPs 15 6h, (J) T-MNPs 35 24h, (K) T-MNPs 35 6h, (L) T-MNPs 15 24h 
and (M) T-MNPs 15 6h. 
 
Figure 42: First echo of T2* of C17.2 for all conditions: (A) Control, (B) D-
MNPs 500 24h, (C) D-MNPs 500 6h, (D) D-MNPs 250 24h, (E) D-MNPs 250 6h, 
(F) P-MNPs 35 24h, (G) P-MNPs 35 6h, (H) P-MNPs 15 24h, (I) P-MNPs 15 6h, 
(J) T-MNPs 35 24h, (K) T-MNPs 35 6h, (L) T-MNPs 15 24h and (M) T-MNPs 15 
6h. 
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In the same way, R2 values are shown in Table 3 and 
plotted in Figure 43. Moreover, the contrast generated by 
the labeled and non-labeled cells can be observed the first 
echo of T2 weighted images in Figure 44 and Figure 45 for 
MSCs and C17.2 respectively. 
 MSCs C17.2 
 Mean [s-1] SD Mean [s-1] SD 
Control 8,3 2,1 5,6 2,3 
D-MNPs 500 24h 10,2 1,2 9,1 0,3 
D-MNPs 250 24h 11,0 0,8 9,4 0,5 
D-MNPs 500 6h 11,2 2,7 9,2 0,8 
D-MNPs 250 6h 10,6 2,5 8,3 2,3 
P-MNPs 35 24h 16,0 2,3 12,1 0,4 
P-MNPs 15 24h 12,4 0,1 8,9 0,5 
P-MNPs 35 6h 13,3 1,0 11,4 2,5 
P-MNPs 15 6h 10,8 3,1 8,0 4,4 
T-MNPs 35 24h 13,4 0,8 15,3 0,9 
T-MNPs 15 24h 11,7 2,0 10,4 0,4 
T-MNPs 35 6h 10,1 1,8 11,6 1,7 
T-MNPs 15 6h 12,1 1,8 8,6 0,5 
 
Table 3: R2 of different label conditions determined by MRI in an agar 
phantom with concentrations of 500 cell/L. 
 
 
Figure 43: R2 of different label conditions determined by MRI in an agar 
phantom with concentrations of 500 cell/L. 
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Figure 44: First echo of T2 of MSCs for all conditions: (A) Control, (B) D-
MNPs 500 24h, (C) D-MNPs 500 6h, (D) D-MNPs 250 24h, (E) D-MNPs 250 6h, 
(F) P-MNPs 35 24h, (G) P-MNPs 35 6h, (H) P-MNPs 15 24h, (I) P-MNPs 15 6h, 
(J) T-MNPs 35 24h, (K) T-MNPs 35 6h, (L) T-MNPs 15 24h and (M) T-MNPs 15 
6h. 
 
Figure 45: First echo of T2 of C17.2 for all conditions: ((A) Control, (B) D-
MNPs 500 24h, (C) D-MNPs 500 6h, (D) D-MNPs 250 24h, (E) D-MNPs 250 6h, 
(F) P-MNPs 35 24h, (G) P-MNPs 35 6h, (H) P-MNPs 15 24h, (I) P-MNPs 15 6h, 
(J) T-MNPs 35 24h, (K) T-MNPs 35 6h, (L) T-MNPs 15 24h and (M) T-MNPs 15 
6h. 
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6.3.3. Optical microscopy and TEM 
In order to assess and visualize the MNPs uptake, Prussian 
Blue staining and TEM micrographs were taken. All labeling 
conditions and cell types showed Prussian Blue staining, 
supporting ICP and MRI quantitative data Figure 46 and 
Figure 47. 
These results were further confirmed by TEM. All incubation 
conditions for MSCs and C17.2 resulted in cell labeling with 
all different MNPs. In addition, TEM pictures showed a 
nucleus free of MNPs and a variable number of MNPs in the 
cytoplasm (Figure 48). Cellular vesicles containing D-MNPs 
exhibit a circular shape in where MNPs are condensed 
(Figure 49(A)), meanwhile vesicles morphology for P-MNPs 
and T-MNPs is not well defined, as it can be observed Figure 
49 for P-MNPs.  
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Figure 46: Prussian Blue staining of MSCs. (A) Phase contrast microscopy 
of control cells, (B) Bright field microscopy of control cells, (C) Phase 
contrast microscopy of D-MNPs 500 24h, (D) Bright field microscopy of D-
MNPs 500 24h, (E) Phase contrast microscopy of P-MNPs 35 24h, (F) bright 
field microscopy of P-MNPs 35 24h, (G) Phase contrast microscopy of T-
MNPs 35 24h, (H) Bright field microscopy of T-MNPs 35 24h. (Scale bar 
100m) 
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Figure 47: Prussian Blue staining of C17.2. (A) Phase contrast microscopy 
of control cells, (B) bright field microscopy of control cells, (C) Phase 
contrast microscopy of D-MNPs 500 24h, (D) Bright field microscopy of D-
MNPs 500 24h, (E) Phase contrast microscopy of P-MNPs 35 24h, (F) Bright 
field microscopy of P-MNPs 35 24h, (G) Phase contrast microscopy of T-
MNPs 35 24h, (H) Bright field microscopy of T-MNPs 35 24h. (Scale bar 
100m) 
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Figure 48: (A) MSC labeled with D-MNPs 500 24h, (B) MSCs labeled with P-
MNPs 35 24h, (C) MSCs labeled with T-MNPs 35 24h, (D) C17.2 labeled 
with D-MNPs 500 24h, (E) C17.2 labeled with P-MNPs 35 24h, (F) C17.2 
labeled with T-MNPs 35 24h 
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Figure 49: MNPs internalized. (A) PLL coated D-MNPs internalized in an 
endosome in the cellular cytoplasm (1.5 μg/mL PLL and 500 μg/mL D-
MNPs incubated for 24h), (B) P-MNPs internalized in an endosome in the 
cellular cytoplasm (35 μg/mL of P-MNPs incubated for 24h). (Scale bar 
500 nm) 
6.3.4. Effect of the MNPs internalization in the cells 
Proliferation rate experimental data is referred to control 
group (%). Experimental values are shown in Table 4 and 
plotted in Figure 50 (A) and (B). For the highest 
concentrations of MNPs there is a reduction in proliferation 
rate respect to control for both cell types.  
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 MSCs C17.2 
 Mean [%] SD Mean [%] SD 
Control 100 18 100 4 
D-MNPs 500 24 h 67 19 80 15 
D-MNPs 250 24h 84 22 66 20 
D-MNPs 500 6h 86 10 84 22 
D-MNPs 250 6h 102 9 76 10 
P-MNPs 35 24h 46 9 62 4 
P-MNPs 15 24h 51 11 91 26 
P-MNPs 35 6h 61 16 66 9 
P-MNPs 15 6h 87 2 67 16 
T-MNPs 35 24h 44 4 50 19 
T-MNPs 15 24h 73 5 55 10 
T-MNPs 35 6h 75 6 65 7 
T-MNPs 15 6h 62 17 79 3 
 
Table 4: Proliferation rate [%] respect to control. 
Moreover, LDH viability assay showed that there are not 
significant differences between control group and any 
labeling condition for MSCs and well as for C17.2 (Table 5 
and Figure 50 (C) and (D)).  
 MSCs C17.2 
 Mean [%] SD Mean [%] SD 
Control 100 2 100 4 
D-MNPs 500 24 h 96 2 102 4 
D-MNPs 250 24h 95 2 102 3 
D-MNPs 500 6h 97 3 100 3 
D-MNPs 250 6h 98 1 98 5 
P-MNPs 35 24h 97 1 97 4 
P-MNPs 15 24h 95 1 100 3 
P-MNPs 35 6h 98 2 98 3 
P-MNPs 15 6h 100 2 98 3 
T-MNPs 35 24h 96 2 100 3 
T-MNPs 15 24h 97 2 100 3 
T-MNPs 35 6h 100 2 98 3 
T-MNPs 15 6h 99 2 100 3 
 
Table 5: Viability [%] respect to control. 
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Figure 50: (A) Proliferation rate (respect to control %) for MSCs after 
labeling, (B) Proliferation rate (respect to control %) for C17.2 after 
labeling, (C) Viability rate (respect to control %) for MSCs after labeling 
and (D) Viability rate (respect to control %) for MSCs after labeling. (* 
p<0.05; ** p<0.01) 
6.4. Discussion 
In this chapter we have successfully validated the use of our 
synthesized dextran-, pluronic F127- and tetronic 908- 
coated superparamagnetic nanoparticles for in vitro 
applications. Previously we had reported the dependence 
on transfect agents as PLL for D-MNPs cellular 
internalization, and here we have proven that no 
transfection agent is needed for P-MNPs and T-MNPs cell 
labeling. However, besides transfect agent influence 
findings, other parameters such as incubation time, MNPs 
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concentration or cell type were also studied in order to find 
out the best labeling conditions. But, the best scenario 
requires not only the best MRI signal, which actually is the 
main goal as MRI contrast agents; but must also maintain 
the well-being of the cells, as they will be used as treatment 
agents in a  potential therapy for stroke.  
One of the most direct parameters that can be influenced 
by the presence of MNPs is cell proliferation. With regard to 
the proliferation rate of labeled cells, PLL coated D-MNPs 
do not significantly affect their proliferative capacity 
compared to control for both types studied, MSCs and 
C17.2. Viability is slightly reduced for these conditions, but it 
only has statistic significance for D-MNPs 250 24h in MSCs 
(p<0.05). On the other hand, P-MNPs and T-MNPs have a 
similar behavior between them. For both cell types, the 
highest concentration (35 g/mL) and the longest 
incubation time (24h), reduce the proliferation up to 45-
60%, for P-MNPs (p<0.05) and also for T-MNPs (p<0.01). In 
addition, the lowest concentration (15 g/mL) of P-MNPs 
reduces the proliferation of MSCs to 51% (p<0.05) and also 
T-MNPs for C17.2 to 55% (p<0.01). Twelve hours after 
labeling, LDH viability assay shows a reduction in all 
conditions being statistic significant just for MSCs labeled 
with P-MNPs 250g/mL for 24h. As it has been mentioned 
before we can attribute this fact to an artifact (higher 
concentration does not show a significant effect) and not 
as a viability reduction. In general, the proliferation after 
labeling is reduced and depends on the incubation time as 
well as in the concentration of MNPs in medium. For MSCs it 
is possible to observe a trend, proliferation rate decreases 
with the increase of incubation time and MNPs 
concentration for all coated MNPs. In the case of C17.2, 
same trend can be observed for T-MNPs, meanwhile 
standard deviations of D-MNPs and P-MNPs are too high to 
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show this effect. In regard to viability 12h after labeling, 
there are no significant differences between groups in terms 
of LDH release.  
In order to perform Prussian Blue staining, harvested cells 
were replanted again. With this staining it is possible to 
observe that all studied conditions showed MNPs, which 
can be observed through optical microscopy in blue color 
Furthermore, the fact of replant the cells also indicates that 
the behavior of labeled cells is the same as controls, they 
get attached to the well and enabling Prussian Blue 
staining. 
Other way to evaluate the wellbeing of labeled cells and 
also demonstrate the MNPS presence is based on their 
morphology in TEM micrographs. There were no differences 
in morphology observed by TEM and all coated MNPs are 
encapsulated in vesicles along the cytoplasm. As it was 
demonstrated in the previous chapter, we can assess that 
the labeling protocol used is highly efficient to tag cells with 
MNPS, and no MNPS were observed attached to the 
cellular membrane.  Particularly, the endosomes of cells 
labeled with P-MNPs and T-MNPs showed big clustering of 
MNPs where individual particles (cores) cannot be easily 
observed. On the other hand, endosomes containing D-
MNPs are more regular in shape and present a uniform 
dotted pattern, where MNPs cores can be observed.  
The MNP internalization is variable depending on the MNPs 
type. We have already reported the dependency on PLL 
for D-MNPs internalization, however for this study the 
concentration has been kept constant (1.5g/mL). 
However, it is possible to observe the dependency on 
concentration and incubation time for both types of cells 
labeled with PLL coated D-MNPs.  
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The dependency on concentration is more remarkable for 
P-MNPs and T-MNPs, where the amount of MNPs during the 
incubation process is decisive. The more concentration, the 
more internalization value with one exception, T-MNPs 
35g/mL 6h, which showed similar values to 15 g/mL. 
Nevertheless, it is important to remark that MNP 
internalization of P-MNPs and T-MNPs (for 35 g/mL) are 2, 3 
or even 4 times higher than D-MNPs (for 500 g/mL). This 
could be explained based on two factors, on one hand the 
nature of the coating and, on the other hand on terms of 
MNPs stability in cell medium. Considering the small size of 
all these MNPs, it is not possible to observe clustering or 
aggregation after MNPs dispersion in cell medium by 
optical microscopy, but P-MNPs and T-MNPs could be 
precipitating onto the cells facilitating the uptake. TEM 
images indicate that Pluronic and Tetronic coated MNPs 
could be micro-aggregated due to the irregular 
morphology of the endosomes observed. This idea would 
be also supported by ICP data, which revealed a strong 
dependence on the MNPs concentration in medium for this 
kind of particles, suggesting that higher uptake would occur 
because more particles precipitate onto the cell. Clusters of 
P-MNPs and T-MNPs would be big enough to lay onto the 
cells and facilitate the uptake, and small enough to be 
washed after labeling and grant full MNPs internalization, as 
it was observed in TEM micrographs.  
Iron internalization can be related to MRI relaxation values. 
Relaxation rates R2* of labeled cells did not reflect the 
differences in terms of MNPs internalization. This fact can be 
explained due to the high concentration of labeled cells 
(500 cells/L) for the phantom. In T2* weighted images, the 
signal decays so fast that the adjustment to an exponential 
decay is based on 2-4 experimental points (others are zero). 
In order to perform a better exponential decay adjustment 
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it would be necessary to reduce the cell concentration 
(therefore the iron concentration in the phantom) or the 
echo time of the MRI sequence (MGE).  
Overall, in this chapter we have evaluated our synthesized 
MNPs, which enable efficient and non-invasive imaging of 
cells in MRI. D-MNPs, P-MNPs and T-MNPs demonstrated 
their use for cell labeling at different concentrations and 
incubation times without a short-term harmful effect for the 
most of the studied conditions. However, a long-term 
cellular wellbeing evaluation would be necessary to assess 
their further use for in vivo cell tracking studies.  
In this way, as mesenchymal stem cells have demonstrated 
their potential use in cerebrovascular diseases, also in 
stroke, we will consider MSC for further in vivo studies of cell 
tracking. Moreover, in this chapter we had validated our 3 
synthesized coated MNPs as suitable MRI contrast agents 
for these cells. However, among all possibilities, PLL- coated 
D-MNPs offer several advantages in terms of cell labeling 
compared to P-MNPs and T-MNPs for further in vivo studies. 
MNP uptake for D-MNPs is concentration/incubation time 
dependent and stable in terms of internalization, as it has 
been shown here and in the previous chapter. It is possible 
to detect cells labeled with this kind of particles in MRI with 
relatively low amount of internalized nanoparticles (about 
10pg/cell) and from 100g/mL to 500g/mL D-MNPs 
concentrations, there is not significant influence on 
proliferation and toxicity. The cytoplasmic distribution in 
endosomes of regular shape is also crucial because after 
proliferation, cells will split the internalized MNPs, being 
daughter cells also detectable by MRI. Another important 
point to take into account is the ease on the in situ synthesis 
of D-MNPs, because further in vivo studies will require a high 
amount of them.  
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6.5. Conclusions 
In the present chapter, we have evaluated the in vitro 
short-term biocompatibility of D-MNPs, P-MNPs and T-MNPs 
by labeling MSCs and C17.2 cells.  In general terms, the 
internalization behavior was the same for both types of 
cells. Cellular uptake is conditioned by concentration and 
incubation time for PLL coated D-MNPs meanwhile P-MNPs 
and T-MNPs internalization depends mostly on the MNPs 
concentration in cell medium. MNPs influence on the 
cellular wellbeing is dependent on the internalized iron, 
reducing proliferation and viability for cells with more than 
28 pg/cell and once again, we have demonstrated that 
the labeling protocol used is highly efficient for full MNPs 
internalization, providing reliable MRI values for labeled 
cells.  
Based on these results, for further in vitro and in vivo studies 
we will choose dextran-coated MNPs due to its ease for 
synthesis, stable cell labeling, reduced cellular toxicity, high 
MRI signal of cells labeled and nanoparticle endosomal 
distribution observed by TEM in the cellular cytoplasm. 
However, we have studied short-term biocompatibility, a 
long-term in vitro study of proliferation, viability and MRI 
signal evolution is needed for further in vivo studies.    
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7. Long-term study of 
mesenchymal stem cells 
labeled with PLL- 
Dextran coated 
superparamagnetic 
nanoparticles 
7.1. Hypothesis 
So far, we have developed 3 different coated 
superparamagnetic nanoparticles, and we have already 
demonstrated their short-term biocompatibility for cell 
tracking. However, a long-term evaluation of labeled cells 
and how the proliferation rate influences the MRI signal are 
needed prior to in vivo cell tracking studies. Additionally, 
the study of magnetic field influence on the cells after 
magnetic vectorization is needed. In this way and 
considering previous results, the main goal of this chapter is 
the long-term biocompatibility study and the evaluation of 
the MRI signal clearance with the proliferation of rat 
mesenchymal stem cells labeled with PLL-Dextran coated 
superparamagnetic nanoparticles for further cell tracking 
and magnetic vectorization in vivo.  
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7.2. Materials & methods 
7.2.1. Cell lines 
All experiments were performed using Mesenchymal Stem 
Cells (MSCs) purchased from Cultrex, Trevigen and were 
cultured in IMDM (78%), Fetal bovine serum (10%), Horse 
serum (10%), Penicillin-Streptomycin (1%) all from Gibco 
Invitrogen, and Amphotericin-B (1%) from Sigma-Aldrich. 
Cell passage numbers between 7 and 18 were used in 
these experiments (n=3 for each condition). 
7.2.2. Dextran-coated superparamagnetic 
nanoparticles 
Dextran coated MNPs (D-MNPs) were synthesized in the 
Clinical Neuroscience Research Laboratory following the in 
situ protocol described in chapter 3.  
7.2.3. Preparation of Poly-L-lysine hydrobromide-
coated D-MNPs 
One concentration of PLL (Sigma-Aldrich) was used: 
1.5g/mL. One hour prior to cell incubation, D-MNPs were 
mixed with MSCs medium and 1.5 g/mL PLL and vigorously 
shaken.  
7.2.4. Cell labeling with PLL-coated D-MNPs 
Cells were labeled following the protocol described 
elsewhere [227] with slight modifications. MSCs were 
incubated with 1.5 g/mL of PLL combined with D-MNPs 
(100 g/mL) for 24h. The D-MNP containing medium was 
removed and the cells were 3 times washed with 1.5 mL of 
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Phosphate Buffered Saline (PBS without Mg2+ and Ca2+, 
Gibco, Invitrogen) to remove non-attached MNPs. After 
washing, the cells were left overnight (12h) in 1 mL of fresh 
medium. The following day the medium was removed, cells 
were washed once with 1.5 mL of PBS and 0.5 mL of EDTA-
trypsin (Gibco Invitrogen) was added to detach the cells 
from the well. The trypsin was neutralized with fresh medium 
and the detached cells were collected in a Falcon tube. 
After a mild centrifugation, the supernatant was discarded 
and the cells were resuspended in fresh medium. These 
cells, control and labeled, were named as “Plant 0”.  
To evaluate the effect of the D-MNPs dilution, control and 
labeled cells from “Plant 0” were replanted in fresh 
medium. After 48h, the cells were washed once with 1.5 mL 
of PBS and 0.5 mL of EDTA-trypsin (Gibco Invitrogen) was 
added to detach the cells from the well. The trypsin was 
neutralized with fresh medium and the detached cells were 
collected in a Falcon tube. After a mild centrifugation, the 
supernatant was discarded and the cells were resuspended 
in fresh medium. These control and labeled cells were 
named as “Plant 1”.  
Control and labeled cells from “Plant 1” were replanted in 
fresh medium. After 48h, the cells were washed once with 
1.5mL of PBS and 0.5mL of EDTA-trypsin (Gibco Invitrogen) 
was added to detach the cells from the well. The trypsin 
was neutralized with fresh medium and the detached cells 
were collected in a Falcon tube. After a mild centrifugation, 
the supernatant was discarded and the cells were 
resuspended in fresh medium. These control and labeled 
cells were named as “Plant 2”. Timeline scheme of these 
Plants 0, 1 and 2 can be observed in Figure 51.  
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Figure 51: Timeline of Plant 0, Plant 1 and Plant 2 for in vivo experiments. 
7.2.5. Proliferation 
To determine the proliferation rate of Plant 0, Plant 1 and 
Plant 2, total cell count was performed with Trypan Blue 
staining and a Neubauer chamber. Samples were diluted 
1:5 with PBS and 1:2 with Trypan Blue. 
7.2.6. Cell viability assay: Lactate Dehydrogenase 
Assay (LDH) 
For assessing the viability of the cells after labeling 
compared to control, supernatantswere collected in 
eppendorf tubes. LDH ciability assay was performed for 
Plant 0 (12h after labeling), Plant 1 (3 days after labeling) 
and Plant 2 (5 days after labeling). A negative control of 
lysed cells was also included. After a mild centrigufation of 
the supernatants, 75L were mixed in a 96 well plate with 
150L LDH reagents following the manufacturer protocol 
(Lactate Dehydrogenase Assay Kit. Sigma-Aldrich). After 20 
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minutes incubation, the plate was read in Synergy2 (Biotek) 
at 490nm. To calculate the viability rate respect to control, 
next equation was applied.  
ܸܾ݈݅ܽ݅݅ݐݕ	ሾ%	ܿ݋݊ݐݎ݋݈ሿ ൌ ܮܦܪ௟௬௦௘ௗ െ ܮܦܪ௘௫௣௢௦௘ௗܮܦܪ௟௬௦௘ௗ െ ܮܦܪ௖௢௡௧௥௢௟ ൉ 100 
7.2.7. Intracellular iron determination 
An amount of 200.000 cells per condition and Plants were 
dissolved in 1mL of 37% HCl (ref) and 4mL of DW was added 
to reach total volume of 5mL. Iron concentration was 
determined by inductive coupled plasma optical emission 
spectroscopy (ICP-OES) (Varian Inc). The intensity of the 
emission line at 238.204 nm was measured for iron and 
compared to a standard solution. ICP-OES was performed 
at the Material Science Institute (MTM), KU Leuven.  
7.2.8. Prussian Blue staining 
Prussian Blue staining was performed to demonstrate the 
uptake of the D-MNPs by the cells in all time points (Plant 0, 
Plant 1, Plant 2). Cells were washed with PBS and incubated 
for 20 minutes with a mix of equal parts of aqueous solution 
of 20% HCl (Hydrochloric acid fuming 37% extra pure, Merk) 
and aqueous solution of 10% Potassium ferrocyanide 
Trihydrate (KFe(CN)6.3H2O, FW 422.2, Sigma-Aldrich). After 
incubation, cells were washed 3 times with PBS and 
photographs were taken using an inverted microscope 
(Olympus IX51). 
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7.2.9. Magnetic resonance imaging of labeled 
cells 
Agar phantom was made following the procedure 
described elsewhere.[227] 100.000 cells per group were 
scanned in a Bruker Biospec 9.4 T small animal MR scanner 
(Bruker, Biospin, Ettlingen, Germany) equipped with actively 
shielded gradients (400 mT/m). A quadrature radio-
frequency transmit-recive resonator was used for data 
acquisition. T2*-weighted images were acquired using a 
MGE sequence of 4.44 ms echo time, 6.75 ms echo 
spacing, 1.8 s repetition time, 16 echoes, 14 slices, 2 
averages, FOV of 7.5 cm x 7.5 cm and a matrix size of 256 x 
256. Post-processing was performed using ImageJ software 
(Rasband, W. NIH). 
7.2.10. Flow cytometry of MSCs 
The characterization of MSCs after labeling was performed 
by flow cytometry analysis in timepoint Plant 0 and Plant 2. 
MSCs (250.000 cells) were washed with 50 L of PBS and 
stained by incubation (15 minutes) with 5 L CD90-PerCP, 
2.5 L CD45-PE (BD Pharmigen) and 1 L of CD73-APC 
(Inmunostep) antibodies. Firstly, MSCs were separated by 
their forward and side scattering signal characteristics. 
MSCs were characterized as CD90+CD73+/CD45- cells. For 
analysis 20.000 cell events were acquired in a BD FACS Aria I 
(BD Biosciences) and data were analyzed with the use of 
FACSDiva software (BD Biosciences). 
7.2.11. Angiogenic assay: Matrigel.  
Tube formation was assayed by using Matrigel (BD 
Pharmigen). Angiogenic assay medium was prepared with 
95% IMDM (Gibco. Invitrogen) and 5% FBS (Gibco. 
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Invitrogen). 300 L of Matrigel (4ºC) per well was added in a 
24-well plate and it was further incubated for 30 min till full 
solidification. 80.000 labeled and non-labeled MSCs 
dispersed in angiogenic assay medium were placed and 
well distributed in each well. After 6h incubation, pictures of 
tubular structures were taken by using and inverted 
microscope (Olympus IX51). 
7.2.12. Cellular protein determination: Bradford 
assay. 
Total protein quantification was determined by Bradford 
techniques.[245] 400 L of 0.2% NaOH (Sodium Hydroxide 
pellets PA-ACS-ISO. Panreac) was added to each well and 
plate was placed under shaking for 4h at room 
temperature. Standard curve was generated from different 
concentrations of Bovine Serum Albumin (BSA) (Cell Culture 
Grade, pH 7.0, Lyophilized Powder, GE Healthcare Life 
Sciences). 10 L of each sample was mixed with 190 L of 
distilled water and 50 L of Protein Assay Dye Reagent 
Concentrate (Bio-Rad) and plate was read in Synergy2 
(Biotek) at 595 nm.   
7.2.13. Vascular endothelial growth factor (VEGF) 
determination: ELISA kit assay. 
VEGF concentrations of MSC control and labeled mediums 
were measured with a Quantikine VEGF ELISA kit (R&D 
Systems) following the manufacturer’s protocol. VEGF 
values are corrected for the amount of total cell protein 
calculated by Bradford techniques.  
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7.2.14. In vitro magnetic vectorization 
To investigate the effects of a magnetic field in vitro, two 
experiments were performed: 2D and 3D vectorization 
assays.   
For 2D vectorization experiments, several neodymium 
magnets (0.3T) were placed and stuck below a culture dish 
(diameter 100mm) as is shown in Figure 52. After placing the 
magnets, 150.000 cells were added to each well and 4 
conditions were studied, non-labeled cells with and without 
magnet, and D-MNPs labeled cells with and without 
magnet. Dishes were placed under intense shaking for 30 
min and after that moved into the incubator for 4 h. 
Afterwards, magnets were removed, cells were washed 
once with PBS and Prussian Blue staining was performed.  
For 3D vectorization experiments, 100 L of Matrigel (4ºC) 
was added to small eppendorfs and incubated for 1 h till 
full solidification. One neodymium magnet (1T) was placed 
below the tip of the eppendorf (Figure 53), 50.000 cells in 
cell medium were added onto the solidified Matrigel, and 
samples were taken to incubator for 4h. Two groups were 
studied, non-labeled and labeled cells. After 4h incubation, 
MRI of eppendorf was performed to evaluate the cell 
migration through the Matrigel. MRI setup was the same as 
the mentioned in 7.2.9, T2 weighted images were acquired 
using a RARE sequence of rare factor 4, echo time 22.5ms, 
repetition time of 5133 ms, 1 average, and 1 echo image. 
FOV of 28.8 mm x 28.8 mm and a matrix size of 192x192. Post 
processing was performed using ImageJ software (NIH).  
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Figure 52: Neodiymium magnets (0.3T) distributed for 2D vectorization 
studies.  
 
Figure 53: Neodymium magnet (1T) for 3D vectorization experiments.  
7.3. Results 
Biocompatibility of MSCs labeled with D-MNPs was 
evaluated for further in vivo applications. Since the main 
goal of the use of MRI contrast agents for cell tracking is to 
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monitor the cells after injection, the long-term evaluation of 
the biocompatibility of these MNPs is determined by their 
rapid clearance. Thus, considering rate proliferation of 
MSCs and internalized iron, the endpoint of our study was 5 
days after cell labeling.  
7.3.1. Cellular internalization and MNPs clearance 
The amount of internalized iron nanoparticles was 
determined by ICP. Three times 150.000 labeled and non-
labeled cells from “Plant 0” were replanted and harvested 
48 h later, corresponding to “Plant 1”. Three times 150.000 
labeled and non-labeled cells from “Plant 1” were 
replanted and harvested 48 h later, corresponding to “Plant 
2”.  In this way, the amount of internalized iron was 
0.250.13 pg/cell for control and for MSCs labeled with D-
MNPs was 7.70.7 pg/cell for “Plant 0”, 2.40.2 pg/cell for 
“Plant 1” and 0.900.09 pg/cell for “Plant 2”. (Figure 54 (A))
 
Figure 54: (A) Iron content of labeled and non-labeled MSCs for different 
timepoints (Plant 0, Plant 1 and Plant 2).  (B) R2* of labeled and non 
labeled MSCs for different timepoints ((Plant 0, Plant 1 and Plant 2). 
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7.3.2. Magnetic resonance imaging of labeled 
cells and MNPs clearance 
In order to assess the contrast generated by MNPs 
internalization and to study the clearance of the signal, MRI 
of labeled cells and non-labeled cells at different 
timepoints was performed. T2* maps were calculated from 
T2* weighted images and R2* relaxivities were obtained for 
each condition. Experimental results are plotted in Figure 
54(B). Thus, for “Plant 0” R2* was 36.01.2 s-1 for control and 
68.00.9 s-1 for D-MNPs. For “Plant 1” R2* was 214 s-1 for 
control and 31.81.1 s-1 for D-MNPs, and for “Plant 2” R2* was 
192 s-1 for control and 19.60.8 s-1 for D-MNPs. Clearance 
effect can also be observed in Figure 55.  
 
Figure 55: First echo of T2* weighted images of (A) control, (B) “Plant 0” of 
labeled MSCs with D-MNPs, (C) “Plant 1” of labeled MSCs with D-MNPs 
and (D) “Plant 2” of labeled MSCs with D-MNPs. 
7.3.3. Internalization and clearance assessed by 
Prussian Blue staining  
Cell labeling was assessed by Prussian Blue staining. Same 
trend as ICP and MRI results was observed. “Plant 0” 
exhibited a great amount of MNPs internalization and this 
staining was reduced for “Plant 1”, as can be noted in 
Figure 56 (C), (D), (E) and (F). In “Plant 2” Prussian Blue 
staining was similar to control, whereas almost no MNPs 
were in the cells (Figure 56 (A) and (B) for control and (G) 
and (H) for “Plant 2”).  
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Figure 56: Prussian Blue staining (A) Phase contrast Control, (B) Bright field 
Control, (C) Phase contrast Plant 0 D-MNPs, (D) Brightfield Plant 0 D-MNPs, 
(E) Phase Contrast Plant 1 D-MNPs, (F) Bright field Plant 1 D-MNPs, (G) 
Phase contrast Plant 2 D-MNPs and (H) Bright field Plant 2 D-MNPs.  
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7.3.4. Long-term effect of D-MNPs internalization in 
MSCs in proliferation rate and viability 
Proliferation rate experimental data is referred to control 
group (100%) for each timepoint (Figure 57 (A)). There were 
no significant differences between control and D-MNPs for 
each plant in terms of proliferation.  
Moreover, as it can be observed in Figure 57 (B) there were 
not significant differences between control and D-MNPs in 
terms of viability (referred to control %) measured by LDH 
assay.  
 
Figure 57: (A) Proliferation rate and (B) Viability for control and D-MNPs. 
7.3.5. Long-term effect of D-MNPs internalization in 
MSCs in cell phenotype and angiogenic 
capacity 
In order to evaluate phenotypic long-term changes after 
labeling, CD45, CD90 and CD73 markers for flow cytometry 
were studied for “Plant 0” and “Plant 2”. There were no 
differences between groups for all conditions studied, 
meaning that after 5 days all conditions of MSCs were 
CD90+/CD73+ and CD45-.   
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Figure 58: Flow cytometer graphs for Plant 0 and Plant 2 of non-labeled 
MSCs (control) and D-MNPs labeled MSCs for CD90+/CD73+ and CD45- 
analysis. 
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The angiogenic capacity of labeled MSCs was also studied. 
There were no differences observed between control and 
D-MNPs labeled cells after labeling (Plant 0) and after 5 
days labeled (Plant 2) (Figure 59).   
 
Figure 59: Matrigel angiogenic assay. (A) Control “Plant 0”, (B) D-MNPs 
“Plant 0”, (C) Control “Plant 2”, (D) D-MNPs “Plant 2”.  
7.3.6. Long-term effect of D-MNPs internalization in 
MSCs in VEGF release 
To determine the amount of VEGF release per microgram of 
protein, Bradford assay and VEGF ELISA assay were 
performed for each timepoint. For “Plant 0” 0.330.04 pg/g 
protein for control and 0.400.05 pg/g protein for D-MNPs 
was found. For “Plant 1” 0.270.04 pg/g protein for control 
and 0.370.07 pg/g protein for D-MNPs was obtained, and 
for “Plant 2” it was 0.520.07 pg/g protein for control and 
0.530.07 pg/g protein for D-MNPs was measured. There 
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were no differences between control and D-MNPs for each 
timepoint as it can be seen in Figure 60.  
 
Figure 60: VEGF release pg/g of protein for different timepoints (Plant 0, 
Plant 1 and Plant 2) 
7.3.7. Magnetic vectorization of MSCs labeled with 
D-MNPs 
2D magnetic vectorization experiment demonstrated the 
cellular magnetic guidance towards the magnet. Figure 61 
(A) and (B) showed control MSCs evenly dispersed along 
the dish, which was also de case with MSCs labeled with D-
MNPs but without the presence of the magnet (Figure 61 
(C) and (D)). A similar pattern distribution occurred under 
neodymium magnet presence for control, being non-
labeled MSCs (Figure 62 (A)). The distribution of labeled cells 
under the presence of a magnet was totally different; cells 
were attached to the well only at the regions where the 
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magnet was placed. This phenomenon is clearly visible in 
Figure 62(B), (C) and (D).  
 
Figure 61: Optical microscopy of 2D magnetic vectorization. (A) Control 
through phase contrast microscopy without magnet, (B) Control through 
bright field without magnet, (C) D-MNPs through phase contrast 
microscopy without magnet, (D) D-MNPs through bright field without 
magnet. 
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Figure 62: Bright field optical microscopy of 2D magnetic vectorization. 
(A) Control (scale bar 500 m), (B) D-MNPS with magnet (scale bar 1 
mm), (C) D-MNPS with magnet (scale bar 100 m), (D) D-MNPS with 
magnet (scale bar 50 m).  
In spite of 2D magnetic vectorization, in a 3D environment 
our results showed that labeled MSCs are not able to 
migrate through Matrigel even under the presence of a 1T 
magnet. In Figure 63 (B) it is possible to observe the 
brownish color in the interface between cell medium and 
Matrigel (black arrows) corresponding to labeled cells. 
Meanwhile in Figure 63 (A) non-labeled cells have a pale 
color. To evaluate the migration through Matrigel, MR 
images of control and D-MNPs were acquired (Figure 64). A 
difference between labeled and non-labeled cells was 
determined by the hypointense signal for D-MNPs in Figure 
64 (A) and (C) compared to control groups Figure 64 (B) 
and (D). However, when evaluating the migratory 
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capacities through Matrigel, no differences between D-
MNPs with and without magnet presence were observed.  
 
Figure 63: 3D magnetic vectorization. (A) (i) Control without magnet, (A) 
(ii) Control with magnet, (B) (i) D-MNPs without magnet, (B) (ii) Control 
with magnet.  
 
Figure 64: T2-weighted images of 3D magnetic vectorization for (A) D-
MNPs cells without magnet, (B) Control cells without magnet, (C) PLL-
MNPs cells after placing 1T magnet, and (D) Control cells after placing 1T 
magnet.  
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7.4. Discussion 
The aim of MRI cell tracking is to follow injected cells in vivo 
and, in order to achieve this goal, contrast agents as 
superparamagnetic nanoparticles must be used. However, 
parameters such as number of injected cells and amount of 
MNPs per cell are critical for cell tracking. Moreover, it is 
important to take into account that cells are active systems, 
i.e. they proliferate, which means that initial MRI signal can 
be cleared after cellular proliferation.  In this chapter we 
have studied the clearance of MRI signal induced by the 
proliferation of MSCs labeled with D-MNPs and PLL.  
Cells were labeled with 1.5g/mL of PLL combined with 
100g/mL of D-MNPs based on our previous results from 
Chapter 4 and Chapter 5. Internalization values for “Plant 0” 
were similar to previous ones, and it was possible to observe 
in Figure 54 (A) how iron concentration per cell was 
reduced after replants and therefore, proliferation. This 
trend could also be noted in Figure 54 (B) and Figure 55 for 
T2* MRI signal. D-MNPs cells could be detected in “Plant 0” 
and “Plant 1” meanwhile MRI signal from “Plant 2” was too 
close to control to be detected. As we have mentioned 
before, the lower detectability limit for labeled cells is 
between 2-5 pg Fe/cell,[212,239] and, in “Plant 1” our 
labeled cells are loaded with 2.40.2 pg/cell and still can 
be detected in MRI. For “Plant 2” internalized iron was 
higher than control however it was not possible to 
distinguish between control and labeled cells in MRI T2*. This 
dilution effect is also showed in Prussian Blue staining for 
different replants, Figure 56. 
Signal clearance is not only important to track injected 
cells, but also crucial for the cell wellbeing in an effective 
therapy. Prussian Blue staining requires replant control and 
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labeled cells, and as could be observed, morphology of 
labeled cells was similar to control for all replants. With 
regard to proliferation and viability data there are not 
significant differences between control and D-MNPs, what 
points out that long-term labeling did not show any harmful 
effect on the cells.  
Furthermore, phenotypically, MSCs express a number of 
markers, none of which unfortunately, are specific for 
MSCs.[132,133,246] However, in order to evaluate 
phenotypic changes after labeling, CD45, CD90 and CD73 
markers were studied. All cells for all time points studied 
were CD45-, CD90+ and CD73+. No phenotypic influence 
after labeling on a 5 days following was found. Angiogenic 
capacity was evaluated using Matrigel, and tubular 
formations were observed for short-term labeled cells with a 
high amount of D-MNPs and also for long-term labeled cells 
with almost no internalized MNPs. 
Additionally, vascular endothelial growth factor release was 
determined. It is known that once MSCs have entered the 
microenviroment of injured tissues, many factors, including 
cytokines, toxins of infectious agents and hypoxia can 
stimulate the release of many growth factors by MSCs. This 
includes VEGF, which could promote the development of 
fibroblasts, endothelial cells and tissue progenitor cells, and 
carried out tissue regeneration and repair.[247] That is why 
the study of the influence of cell labeling with D-MNPs on 
VEGF release is very important. In our experiments, we have 
observed that labeled cells and non-labeled cells secrete 
same levels of VEGF for all time points of evaluation, as can 
be observed in Figure 60. Therefore, D-MNPs labeled cells 
would potentially have the same benefits than non-labeled 
cells in terms of VEGF production.  
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During the last years, the use of superparamagnetic 
nanoparticles combined with magnetic fields for 
enhancing targeted delivery of stem cells has been widely 
investigated. Several in vivo studies have shown that this 
method could improve migration of intravenously injected 
stem cells. [223,248,249] However, prior to an in vivo study it 
is necessary to evaluate the wellbeing of the labeled cells 
after being under magnetic forces. First approach explored 
was a 2D setup where the influence of the magnet can be 
easily observed. In normal cell culture conditions, it takes 
about 4h for MSCs to get attached to the culture dish. For 
our 2D experiments, we added labeled and non-labeled 
cells to each culture dish and placed it under vigorously 
shaken for 30 minutes. Without magnet presence, this 
agitation produced a homogeneous cell distribution along 
the well for labeled and non-labeled cells (Figure 61), 
meanwhile under magnetic fields presence the distribution 
is governed by the location of the neodymium magnets for 
D-MNPs labeled cells. Further incubation for 4h indicated no 
harmful effect after magnetic guidance because all cells 
are attached to the well in the proximal regions of the 
magnet (Figure 62 (B), (C) and (D)). However, for further in 
vivo applications, cellular magnetic vectorization will occur 
in a 3D environment, different from liquid conditions. For this 
purpose, Matrigel granted us the tridimensional 
background where cells can survive and migrate under a 
magnet action, and a higher magnetic field produced by 
a 1T neodymium magnet. Considering this setup, it was not 
possible to observe any migration through Matrigel for 
labeled cells by MRI, which would point out the safety of 3D 
magnetic vectorization for a non-liquid environment. The 
effective use of Matrigel for migration and invasion studies 
has been performed previously where labeled human 
dermal lymphatic microvascular endothelial cells migrate 
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through in response to metastatic MDA-MB-231 breast 
cancer cells under hypoxic conditions.[250]  
7.5. Conclusions 
In this chapter, we have validated the in vitro long-term 
biocompatibility of D-MNPs by following labeled MSCs over 
time till full MNPs clearance. Our results showed that labeled 
cells did not differ from control cells in terms of proliferation 
rate and viability after 5 days, as well as the maintenance 
of CD45-, CD90+ and CD73+ cellular phenotype. 
Angiogenesis capacity in Matrigel was not altered by the 
presence of internalized D-MNPs, as well as VEGF release 
measurements did not exhibit differences between control 
and labeled cells. Under the labeling conditions studied 
and for cell tracking applications, MRI can easily detect 
labeled cells 3 days after being tagged. From then, MRI 
signal is affected by the clearance of the internalized D-
MNPs due to proliferation, being only possible to detect 
MNPs loaded cells by ICP. Moreover, we have proven the 
efficacy of cellular magnetic vectorization in a liquid 
environment without harmful effects for future targeted 
delivery of stem cells. Overall, our results suggest that MSCs 
loaded with D-MNPs are a promising tool for cell tracking 
and cellular magnetic vectorization in vivo without cellular 
harmful effects.  
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Section V 
In vivo animal models of 
ischemic stroke  
and cell tracking 
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This in vivo section is divided in two chapters. On one hand, 
in Chapter 7 we have optimized the experimental 
conditions and procedures for stem cell administration in an 
animal model of ischemic stroke. On the other hand, in 
Chapter 8, ischemic and non-ischemic animals were 
injected following different administration routes to 
evaluate if the pathologic condition has an influence in the 
fate of the delivered cells, assessed by magnetic resonance 
imaging and histological techniques.  
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8. Animal models of 
focal cerebral ischemia 
and their influence on 
the intra-arterial 
administration route for 
stem cell therapy 
8.1. Hypothesis 
One of the main goals of this chapter is to find the least 
invasive and most reproducible animal model of focal 
ischemia in rats. We will explore the different variations of 
tMCAO model in order to find out the most efficient and the 
safest protocol for intra-arterial delivery of mesenchymal 
stem cells. In this chapter we will study the in vivo distribution 
of labeled stem cells after an intra-arterial injection and 
how cerebral blood flow can affect the brain distribution of 
administered cells.  
Furthermore, we have also demonstrated that tagged cells 
can migrate in vitro under presence of magnetic fields, so in 
this chapter we will explore the influence of magnetic fields 
after intra-arterial injection of labeled stem cells in order to 
increase their presence in the brain.  
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8.2. Materials & Methods 
8.2.1. Cell labeling preparation 
8.2.1.1. Cell lines 
All experiments were performed using Mesenchymal Stem 
Cells (MSCs) purchased from Cultrex, Trevigen and were  
cultured in IMDM (78%), Fetal bovine serum (10%), Horse 
serum (10%), Penicillin-Streptomycin (1%) all from Gibco 
Invitrogen, and Amphotericin-B (1%) from Sigma-Aldrich. 
Cell passage numbers between 7 and 18 were used in 
these experiments.  
8.2.1.2. Dextran-coated superparamagnetic nanoparticles 
Dextran coated MNPs (D-MNPs) were synthesized in the 
Clinical Neuroscience Research Laboratory following the in 
situ protocol described in chapter 3.  
8.2.1.3. Preparation of Poly-L-lysine hydrobromide-coated 
D-MNPs 
1.5μg/mL of Poly-L-lysine hydrobromide (PLL) (Sigma-
Aldrich) was used. One hour prior to cell incubation, D-
MNPs were mixed with cell medium and with 1.5 μg/mL PLL 
and vigorously shaken.  
8.2.1.4. Cell labeling with PLL-coated D-MNPs 
MSCs were labeled following the protocol previously 
described [227] with slight modifications. Cells were 
incubated with 1.5 g/mL PLL and 100 μg/mL of D-MNPs for 
24h. The MNP containing medium was removed and the 
cells were 3 times washed with 1.5 mL of Phosphate 
Buffered Saline (PBS without Mg2+ and Ca2+, Gibco 
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Invitrogen) to remove non-attached MNPs. After washing, 
the cells were left overnight (12h) in 1mL of fresh medium. 
The following day the medium was removed, cells were 
washed once with 1.5mL of PBS and 0.5mL of EDTA-trypsin 
(Gibco Invitrogen) was added to detach the cells from the 
well. The trypsin was neutralized with fresh medium and the 
detached cells were collected in a Falcon tube. After a 
mild centrifugation, the supernatant was discarded and the 
cells were resuspended in PBS 1X. Cell count was performed 
with Trypan Blue staining and a Neubauer chamber. 
Samples were diluted 1:5 with PBS and 1:2 with Trypan Blue. 
8.2.1.5. Cell preparation for intra-arterial injection 
Labeled cells were harvested and counted just before 
being injected. Different amount of cells were injected in 
order to study the cell tracking and the safety of the 
procedure. Cell numbers vary from 2.5x105 to 1x106 MSCs.  
8.2.2. Animal management 
In this study we have used 113 Wistar rats (Harlan) with a 
weight of 288±9 g. Animals were kept at controlled 
conditions of temperature (22±1°C) and humidity (60±5%), 
with a 12/12 hours light/dark cycle, and granting free 
access to food (commercial chow pellets) and tap water. 
For surgery and MRI, rats were anesthetized with sevoflurane 
(3% in 70% N2O and 30% O2). Rectal temperature was 
monitored and maintained at 37±0.5°C with a feedback 
controlled heating system (1025 system, SA Instruments). At 
the end of the procedures animals were sacrificed under 
deep anesthesia (8% sevoflurane). Experimental protocols 
were approved by the local Animal Care Committee 
according to the Spanish and European Union (EU) rules 
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(86/609/CEE, 2003/65/CE, 2010/63/EU, RD 1201/2005 and 
RD53/2013). 
8.2.3. Model of focal transient ischemia in the rat 
Transient focal ischemia was induced in rats by intraluminal 
occlusion of the middle cerebral artery (tMCAO), 
performed as previously described[171] with several 
modifications. In order to monitor the relative cerebral 
blood flow (CBF) during the surgery, a laser-Doppler flow 
probe (tip diameter 1 mm) attached to a flow meter 
(PeriFlux 5000; Perimed AB) was located over the thinned 
skull, over the middle cerebral artery territory 
(approximately 4 mm lateral to bregma).  
Under a surgical microscope, common carotid, external 
carotid, and the internal carotid arteries of the left side 
were dissected from connective tissue through a midline 
neck incision. Left external carotid and pterygopalatine 
arteries were separated and tied with 6-0 silk sutures, 
showing a CBF reduction of 20% measured by laser 
Doppler. A silicon rubber-coated monofilament 
(403512PK5Re; Doccol Corporation) was inserted through 
the external carotid into the left common carotid artery 
and advanced into the internal carotid 17-20 mm from the 
bifurcation to occlude the origin of the MCA. The 
intraluminal filament was removed after 45 minutes of 
occlusion. Only animals with a CBF reduction higher than 
60% and with reperfusion after occlusion were included in 
the studies. To perform tMCAO, both vertebral arteries 
remained intact all surgical procedures.  
To study the influence of the collateral blood flow on 
labeled cells distribution after i.a. injection ipsilateral and 
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contralateral common carotids will remain open and/or 
closed during different stages of tMCAO.  
8.2.4. Intra-arterial administration of stem cells 
Cells were administrated 4h after the reperfusion of the 
ACM. Several arterial cerebral blood flow configurations 
based on ipsilateral common carotid (Ip-CC) and 
contralateral common carotid (Con-CC) arteries were 
evaluated after tMCAO for intra-arterial delivery of stem 
cells (Figure 65): 
a. Con-CC is ligated during tMCAO. Ip-CC remains 
closed after MCA reperfusion. Intra-arterial stem 
cell delivery is performed with Ip-CC closed. 
b. Con-CC is ligated during tMCAO. Ip-CC remains 
closed after tMCAO. At the moment of the 
injection Ip-CC is opened and remains opened 
after the stem cell delivery.  
c. Con-CC is ligated during tMCAO. Ip-CC is 
reperfunded at the same time than middle 
cerebral artery. Ip-CC is opened before, during 
and after the injection. 
d. Con-CC is intact during tMCAO. Ip-CC is 
reperfunded at the same time than middle 
cerebral artery. Ip-CC is opened before, during 
and after the injection. 
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Figure 65: Diagram of cerebrovascular anatomy of rats. 
All these different conditions for the common carotid artery 
will be further explained in Results and Discussion section; 
however Table 6 summarizes the main aspects of each 
protocol: 
Conditions 
Con-CC 
closed 
during 
tMCAO 
Ip-CC is opened 
from MCA 
reperfusion till 
the injection 
Ip-CC is 
opened 
during the 
injection 
Ip-CC 
remains 
opened 
after the 
injection 
a Yes No No No 
b Yes No Yes Yes 
c Yes Yes Yes Yes 
d No Yes Yes Yes 
 
Table 6: Common carotid configurations for animal models of tMCAO 
and intra-arterial delivery of labeled stem cells.  
Intra-arterial injections of MSCs were performed following 
identical protocol for all surgery combinations. Briefly, a 0.28 
mm ID & 0.61 mm OD catheter (Smiths) connected to a 
30G needle and a 1 mL syringe was inserted into the stump 
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of ECA through an incision on the vessel under the 
operation microscope, and was tightened to ECA by a 6-0 
silk suture. The catheter went forward into ICA till reach the 
branch of common and internal carotid. This tube was filled 
with heparinized physiological saline to prevent air bubble 
and blood coagulation. (At this point it was possible to 
observe a small blood reflux in the catheter if the common 
carotid would be opened). The syringe was filled with 
labeled cells in PBS and using slow hand injection over 15 
minutes, 300 μL of cells in PBS were delivered into the 
internal carotid. 
8.2.5. Animals and drug administration 
8.2.5.1. Antiplatelets administration 
The influence of antiplatelets on cell distribution was studied 
following the specifications described elsewhere.[251] Adiro 
tablets (Bayer) were dissolved in potable water and 
administrated at 100 mg/kg· day for 4 days, previous to 
intra-arterial stem cell delivery.  
8.2.5.2. Anticoagulant administration 
Similar to antiplatelets, anticoagulant effect was also 
studied in combination with MSCs administration. For such 
purpose, animals after tMCAO were injected with 
mesenchymal stem cells dispersed in a mixture of 450 μL of 
PBS 1X and 50 μL of Heparin 5000 unit/5mL (Mayne Pharma) 
prior to be injected. Doses were calculated following these 
studies.[252,253]  
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8.2.6. Laser Doppler flow monitoring of cerebral 
blood flow 
Transcranial laser Doppler flow (TLDF) was used to monitor 
the cerebral blood flow during the surgery procedure of 
intra-arterial stem cell administration. Three optic fiber 
probes were placed onto the squamosal part of the 
temporal bone of the rat skull. In order to facilitate the 
positioning of the fiber, this bone was slightly smooth over 
and fibers were attached to the bone using conventional 
glue. Optical probes were distributed along the squamosal 
bone to cover different branches of ACM. Cerebral blood 
flow was monitored prior the injection, during it and for 1h 
after stem cell delivery.  
8.2.7. In vivo magnetic vectorization 
All different conditions for intra-arterial delivery specified in 
section 8.2.4 were assessed for magnetic vectorization. In 
order to study the magnetic guidance of labeled stem 
cells, a rare magnet (Supermagnete. Webcraft GmbH) of 
about 1T and dimensions of 50.8 cm x 50.8 cm x 25.4 cm 
was used. Rats were anesthetized with sevoflurane (3% in 
70% N2O and 30% O2) and rectal temperature was 
monitored and maintained at 37±0.5 °C during all 
procedure. Prior to injection, rat neck and head were 
placed onto the magnet in supine position, so that parietal 
part of rat head was in contact with the magnet. Surgery 
and stem cell delivery was performed under magnetic field 
presence and maintained for 4 hours after injection.  
8.2.8. Magnetic resonance imaging 
Infarct size, angiography and cell tracking were assessed by 
magnetic resonance imaging. Magnetic resonance 
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imaging studies were conducted on a 9.4 T horizontal bore 
magnet (Bruker BioSpin, Ettligen, Germany) with 20 cm wide 
actively shielded gradient coils (440 mT/m). Radio-
frequency transmission was achieved with a birdcage 
volume resonator; signal was detected using a four-
element surface coil, positioned over the head of the 
animal, which was fixed with a teeth bar, earplugs, and 
adhesive tape. Transmission and reception coils were 
actively decoupled from each other. Gradient-echo pilot 
scans were performed at the beginning of each imaging 
session for accurate positioning of the animal inside the 
magnet bore.  
Apparent diffusion coefficient maps were acquired using a 
spin-echo echo-planar imaging sequences with the 
following acquisition parameters: FOV 24 x 16 mm2, image 
matrix 96 x 64 (isotropic in plane resolution of 200mm/pixel), 
14 consecutive slices of 1mm thickness, repetition time 4 s, 4 
averages, echo time 26.91 ms, spectral bandwidth 200 KHz 
and 7 b-values: 0; 300; 600; 900; 1200; 1600 and 2000 s/mm2. 
Diffusion-weighted images were acquired during the ACM 
occlusion.  
To evaluate the status of the ACM occlusion in a 
noninvasive manner, the TOF-MRA was performed.  The 
MRA scan was performed with a 3D Flash sequence with 
the following acquisition parameters: FOV 30.72 x 30.72 x 14 
mm3, image matrix 256 x 256 x 58 (in plane resolution 120 
mm/pixel x 120 mm/pixel x 241 mm/pixel), repetition time 15 
ms, 2 averages, echo time 2.5 ms and excitation pulse 
angle of 20º. MRA was performed during ACM occlusion 
and 4h after stem cell injection.  
T2-weighted images were acquired using a multislice 
multiecho spin-echo sequence with the following 
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acquisition parameters: FOV 19.2 x 19.2 mm2, image matrix 
192 x 192 (isotropic in-plane resolution of 100 μm/pixel x 100 
μm/pixel), 14 consecutive slices of 1mm thickness, repetition 
time of 3 s, and 16 echoes with 9 ms of echo time. T2-
weighted images were acquired 24h after the onset of the 
ischemia. 
T2*-weighted axial images were acquired using a multi 
gradient echo sequence with the following acquisition 
parameters: FOV 19.2 x 19.2 mm2, image matrix 192 x 192 
(isotropic in-plane resolution of 100 μm/pixel ), 14 
consecutive slices of 1mm thickness, repetition time of 1.5 s, 
and 16 echoes with 2.9 ms for the first echo time and 3.28 
ms of echo spacing. T2*-weighted coronal images were 
acquired using previous parameters with different in plane 
geometry: FOV 25.6 x 19.2 mm2 and image matrix 128 x 96 
(isotropic in-plane resolution of 200 μm/pixel). T2*-weighted 
images were acquired 4h after the stem cell delivery. 
Post-processing of all images was performed using ImageJ 
software (Rasband, W. NIH). 
8.2.9. In vitro evaluation of cell aggregation with 
different serums 
5mL of blood was extracted from tail vein in a Wistar rat 
prior being sacrificed under sevofluorane overdose (8%). 1h 
after being extracted, blood is centrifuged for 7 minutes at 
3000 rpm to obtain the blood serum.  
Two different serums were tested: Wistar serum and fetal 
bovine serum (Invitrogen, Gibco); 2 types of cells: MSCs and 
C17.2 and 4 different conditions for each one were studied. 
For C17.2/MSCs:  Normal cell medium (See Chapter 5), PBS 
1x, DMEM/IMDM respectively (Invitrogen. Gibco) + 20% 
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Wistar serum and DMEM/IMDM respectively + 20% fetal 
bovine serum (FBS). 1x105 cells per well were planted under 
each previous condition in a 6 well plate and pictures with 
an inverted optical microscope were taken. (Olympus IX51) 
8.3. Results and discussion 
8.3.1. Animal models of focal ischemia and intra-
arterial delivery route for stem cell therapy 
Animal models of stroke and their treatment are 
indispensable prior clinical trials. However, several therapies 
for acute stroke have proven effective in reducing lesion 
size in animal models while being clinically ineffective in 
humans.[162,254] So far, animal models in rodents satisfy all 
basic requirements needed to induce, manipulate and 
treat diseases like stroke. Nevertheless, it is obvious that 
there can never be one model that mimics all types of 
strokes because the pathogenesis of stroke is multifaceted 
with overlapping and interacting mechanisms.[255] For this 
study we have selected focal stroke model, mimicking 
clinical situations of stroke with atherosclerosis, thrombus 
and embolus. 
Transient intraluminal occlusion of the middle cerebral 
artery is one of the most wide extended protocols to induce 
cerebral ischemia in rats. Craniotomy is not needed, and as 
a consequence, intraluminal occlusion of MCA is a good 
model to also study cerebral edema induced by the 
ischemia. Normally, infarcts affect to cortex and striatum 
and it is highly reproducible. Variability in infarct size or 
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distribution is due to the slightly differences on the filament 
position during the tMCAO. However, several parameters as 
ligature of common carotids (one or both) or their 
reperfusion after the tMCAO can be modified in order to 
minimize collateral circulation and therefore, variability.  
Before discussing different tMCAO protocols and their 
implications in intra-arterial administration of labeled stem 
cells, it would be useful to identify the circle of Willis and 
their integrants in the images obtained from magnetic 
resonance angiography (MRA). Axial MRA images of rat 
brain are a stack of 58 slices where all brain is mapped. In 
Figure 66 it is shown different slices from a MRA of a healthy 
rat. Internal carotids are pointed with orange arrows in 
Figure 66(A) meanwhile in (B), (C) and (D) it is possible to 
observe their branches: middle (green) and anterior 
(magenta) cerebral arteries in different slices.  
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Figure 66: MR angiography of a healthy Wistar rat. (A) Orange arrows 
correspond to internal carotids of both sides, (B) (C) and (D) Green and 
magenta arrows correspond to middle cerebral arteries (MCA) and 
anterior cerebral arteries (ACA) respectively of both hemispheres in 
different slices.    
Normally, MRA is shown as a z-projection, i.e. a coronal 
image, and from this point of view it is possible to observe 
the circle of Willis of the rat. This representation is useful to 
assess the occlusion of the MCA during tMCAO; however 
we may not forget that this is a projection and because of it 
several arteries would be overlapped in some parts of their 
way (Figure 67).  
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Figure 67: Coronal projection of a MR angiography of a healthy Wistar 
rat. Orange arrows correspond to internal carotids. Green arrows 
correspond to middle cerebral arteries. Magenta arrows correspond to 
anterior cerebral arteries. Cyan arrows correspond to external carotid 
arteries. Blue arrows correspond to pterygopalatin arteries. White arrow 
corresponds to basilar artery.  
As it has been mentioned before, one of the most 
extraordinary characteristics of Willis circle is the blood flow 
compensations if an occlusion event happens. Under 
normal conditions, blood flow in the posterior 
communicating arteries, which connect carotid system with 
vertebrobasilar system, is negligible. However, if a subject 
has an incomplete circle of Willis, or if is under an occlusion 
of one or two of the cerebral or carotid vessels, the flow 
can be redirected to perfuse deprived areas.[256] This 
arterial system plasticity could also have an influence on 
the intra-arterial route of administration, because the 
directions of the flows in each artery could vary if one of the 
arteries is maintained closed. 
Thus, to perform an occlusion of the middle cerebral artery 
using an intraluminal filament it is necessary to tie the 
ipsilateral common carotid artery. External carotid will be 
closed with a permanent suture, the filament will be 
inserted through it and will advance into the internal carotid 
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artery. In order to avoid that the filament can go through 
pterygopalatin (PPA) artery, instead through middle 
cerebral artery; PPA will be also tied with a permanent 
suture. Cerebral blood flow is monitored during all surgery 
procedure; when CC is tied, about a 20% reduction of CBF 
is registered and when MCA is occluded, the CBF drops 60% 
more. The Doppler probe position onto the skull of the rat to 
acquire these measurements is deeply critical. Coyle and 
Jokelainen[257] published a study where they 
demonstrated that MCA and ACA of Wistar rats are not 
independent arteries, i.e. their branches are anastomosed, 
as it can be observed in Figure 68.  
 
Figure 68: Patterns of rat cerebral arterial collaterals made visible with 
Vultex. (A) and (C) demonstrate collateral units composed of end-to-end 
rami. Inter- and intra-arterial anastomoses indicated by circles and stars 
respectively Stars outside the unit's boundary in A and C indicate intra-
arterial anastomoses are not confined within a unit. R is a view of a 
vascular complex with end-to-side branches. Vein(V). x 15. Adapted 
from [257]. 
So, because of this arterial anastomoses and for an 
accurate measurement of CBF reduction on MCA, Doppler 
probe should be placed onto the main branch of the MCA, 
or the measurement will be mainly conditioned by 
collateral flow. In our experiments, and in order to 
discriminate where the intraluminal filament is and which 
brain regions are affected by the reduced blood flow, we 
have performed MR angiography and diffusion weighted 
images (DWI) meanwhile the filament was inserted. In that 
way, Figure 69 and Figure 70 shows MRA images for a 
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typical intraluminal filament occlusion. Figure 69 (A) assess 
the presence of IC for contralateral hemisphere (Orange 
arrow) meanwhile no signal is observed for ipsilateral IC, 
due to the ligature of CC. In Figure 69(B) it is possible to note 
that no MRA signal for MCA of ipsilateral hemisphere can 
be detected due to the occlusion, meanwhile ACA of the 
same side can be noted. Moreover, in coronal projection of 
MRA (Figure 70), it is possible to observe where the filament 
is. In this experiment, intraluminal filament is well-positioned 
occluding the MCA.  
 
Figure 69: MRA slices during tMCAO. (A) Orange arrow points 
contralateral IC, meanwhile ipsilateral IC cannot be visualized because 
of ipsilateral CC ligature.  (B) Blue arrow points out contralateral PPA 
artery, Green arrow points contralateral IC artery and Magenta arrows 
point ACAs from both sides.  
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Figure 70: Coronal projection of MRA during tMCAO.  
Besides, in order to evaluate the extent and localization of 
the hypoperfunded brain region, MR DWI was performed. It 
is important to note that in clinical practice MR DWI infarct 
region are displayed as hyperintense signal in MRI[258] 
while preclinical displays are normally hypoinense. This is 
because clinical MR images normally present the image for 
the higher “b” value of the sequence (DWI) while 
preclinical images are normally maps (Apparent diffusion 
coefficient, ADC), resulted from the adjustment of all “b” 
values to an exponential decay. So, for the previous animal, 
ADC maps are shown in grayscale in Figure 71 and color 
scale in Figure 72.  In regard to these maps, tMCAO is 
affecting to MCA territory where a reduction of the 
cerebral blood flow (CBF) can be noted in cortex and 
striatum (dark in grayscale, black-purple-blue in color 
scale).  
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Figure 71: ADC of a Wistar rat during tMCAO. Coefficient diffusion values: 
grayscale (0.3-2.0)·10-3 mm2/s.  
 
Figure 72: ADC maps of a Wistar rat during tMCAO. Coefficient diffusion 
values: color scale (0.3-2.0)·10-3 mm2/s. 
Our occlusion of the MCA lasts 45 minutes, and after that 
time this artery is perfused. So far, all procedures of tMCAO 
are identical for all variations we are going to go through in 
next section, and as we have mentioned before, 
mentioned variations involve exclusively the contralateral 
and ipsilateral common carotid arteries. We may not forget 
that the main goal of this part is to find out the most 
efficient and the safest route for intra-arterial delivery of 
stem cells in an animal model of ischemic stroke. So, in 
order to assess the efficiency and safety of the procedure, 
animas will be scanned following T2 and T2* sequences in 
MRI to evaluate the presence, the absence and the 
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distribution of injected cells labeled with dextran coated 
superparamagnetic nanoparticles (Figure 73).  
 
Figure 73: Pellet color differences between labeled cells and no labeled 
cells. 
8.3.2. Analysis of different conditions for i.a. 
delivery in an animal model of cerebral 
ischemia 
a. Contralateral common carotid is ligated during 
tMCAO. Ipsilateral common carotid remains closed 
after middle cerebral artery reperfusion. Intra-arterial 
stem cell delivery is performed with ipsilateral 
common carotid closed.  
This is condition “a” from Table 6. During tMCAO, 
contralateral common carotid is closed in order to reduce 
the collateral flow and in this way, the brain will receive 
blood through vertebrobasilar system. Thus, after 45 minutes 
of occlusion, the intraluminal filament is pulled out 
perfunding the MCA, sutures of ipsilateral external carotid 
and common carotid are tightened while contralateral CC 
is reperfunded too.  
Cannulation of EC is performed and the artery is flushed 
with heparinized saline to prevent blood clots formation. 
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The syringe is filled for the intra-arterial delivery of 1x106 
labeled mesenchymal stem cells dispersed in PBS. After the 
injection, the catheter is removed and EC is tied with a 
suture. (Figure 74) 
 
Figure 74: Scheme of animal procedures of tMCAO and intra-arterial 
cannulation for stem cell delivery following condition ”a”.  
Results showed a high variability in this protocol for intra-
arterial delivery: 9 rats did not show labeled cells in the 
brain (Figure 75), while following the same procedure it was 
possible to detect labeled cells in other 6 animals (Figure 
76).  
As we have seen in previous chapters, in phantoms for MRI, 
labeled cells can be observed as hypointensity signal in T2* 
weighted images. A dark dotted pattern along the left 
brain hemisphere in Figure 76 denotes labeled cells 
presence.  
The high variability on cell detection following this 
procedure could be explained by the circle of Willis 
compensation flows. Ipsilateral common carotid has been 
maintained closed since the tMCAO started, and arterial 
system (contralateral common carotid artery and 
vertebrovasilar system) had compensated the cerebral 
blood flow reduction. Because Willis circle might not be the 
same for all subjects and the direction of the blood flow 
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after an ischemic event is not well-defined, the most 
plausible explanation is that the cerebral blood flow is 
blocking the entrance of the labeled cells in those cases 
where cells were not detected by T2* weighted images in 
MRI.  
On the other hand, the safety of this injection model is high 
because both groups of animals, with and without labeled 
cells in brain after the injection, survived after all 
procedures.  
Consequently, this animal model of cerebral ischemia and 
intra-arterial injection is not a valid model due to its high 
variability and low efficiency for brain cell delivery. Our 
results suggest that an extra blood pumping is needed to 
push the cells after intra-arterial delivery. Thus, in next 
section we will study condition “b” from Table 7:Table 6 
Conditions 
Con-CC 
closed 
during 
tMCAO 
Ip-CC is 
opened 
from MCA 
reperfusion 
till the 
injection 
Ip-CC is 
opened 
during 
the 
injection 
Ip-CC 
remains 
opened 
after the 
injection 
Evaluation 
a Yes No No No No 
b Yes No Yes Yes ? 
 
Table 7: Evaluation of Ip-CC configuration “a” for animal models of 
tMCAO and intra-arterial delivery of labeled stem cells. 
 
 204 
 
 
Figure 75: MR T2*-weighted image 4h after intra-arterial injection of 
labeled MSCs following delivered route condition “a”. No labeled cells 
were observed after the injection. 
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Figure 76: MR T2*-weighted image 4h after intra-arterial injection of 
labeled MSCs following delivered route condition “a”. Labeled cells can 
be observed along right hemisphere (dotted pattern).  
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b. Contralateral common carotid is ligated during 
tMCAO. Ipsilateral common carotid remains closed 
after tMCAO. At the moment of the injection 
Ipsilateral common carotid is opened and remains 
opened after the stem cell delivery. 
Here, we will study condition “b” from Table 6. During 
tMCAO, contralateral common carotid artery is closed in 
order to reduce the collateral flow and in this way, the 
circle of Willis will receive blood flow through vertebrobasilar 
system. Thus, after 45 minutes of occlusion, the intraluminal 
filament is pulled out perfunding the MCA, sutures of 
ipsilateral external carotid and common carotid are 
tightened while contralateral CC is reperfunded too.  
Cannulation of EC is performed and suture of Ip-CC is 
opened, perfunding this artery and all its branches. After it, 
it is possible to observe blood reflux coming from this vessel 
entering the EC. As it has been done before, EC artery is 
flushed with heparinized saline to prevent blood clots 
formation at the end of the catheter. The syringe is filled 
with 1x106 labeled mesenchymal stem cells dispersed in PBS 
for intra-arterial delivery. After the injection, the Ip-CC is 
temporally ligated to remove the catheter, then EC is tied 
with a suture and Ip-CC is opened again. (Figure 77)  
 
Figure 77: Scheme of animal procedures of tMCAO and intra-arterial 
cannulation for stem cell delivery following condition “b”. 
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We have found labeled cells in T2* weighted MRI after this 
procedure for intra-arterial administration in all cases (Figure 
78), however, 6 over a total of 8 animals died within 7 days; 
4 of them the night after the injection and 2 animals the 4th 
and 7th day after the injection respectively.  Most of the 
animas died during the night so was not possible to scan 
them; however, our hypothesis to explain this high mortality 
was that animals suffered from intracerebral hemorrhage. 
Ip-CC was closed for 4 hours prior the injection, which could 
induce damage on the vessel. During and after the 
injection, the artery and therefore all its branches are 
opened and carrying blood again. The blood pressure on 
damage vessels could induce their rupture and 
consequently, blood extravasations to the parenchyma. It 
was possible to scan one animal before it was dead and, 
for this particular case, our hypothesis was confirmed. 7 
days after cerebral ischemia and intra-arterial stem cell 
delivery several hemorrhages were found scattered along 
the brain in MRI (Figure 79 and Figure 80 (C) and (D)).  
These hypointensities could be a misinterpretation of 
labeled stem cells that migrate into the brain after 7 days 
instead an hemorrhage, however, by using T2 and T2* MRI 
sequences it is possible to distinguish between hemorrhages 
and our labeled cells. Labeled cells can be barely 
detected in T2 weighted images, as it was already showed 
in MRI phantoms in Chapters 5 and 6, meanwhile 
hemorrhages can be easily reported using both sequences. 
For a better understanding of this fact, Figure 80 shows it. 
Figure 80 (A) corresponds to T2 weighted images 24h after 
the injection and Figure 80 (B) corresponds to T2* at the 
same timepoint, where labeled cells can be observed in T2* 
sequence while not in T2. On the other hand, after 7 days 
several hypointensities can be observed in both, T2 and T2* 
(Figure 80 (C) and (D)) with a higher blooming effect than 
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in Figure 80(B), denoting the hemorrhage nature of the MR 
signal. 
In general, this procedure for intra-arterial delivery is 
efficient in terms of directing labeled cells to brain however 
it presents a high mortality rate, which makes this protocol 
not valid for intra-arterial administration route. Overall, our 
results suggest the need of blood which pumps the injected 
cells to the brain; however ipsilateral common carotid 
artery perfusion must be performed sooner to prevent vessel 
damage. Thus, in next section we will study condition “c” 
from Table 8 to overcome these pitfalls.  
Conditions 
Con-CC 
closed 
during 
tMCAO 
Ip-CC is 
opened 
from MCA 
reperfusion 
till the 
injection 
Ip-CC is 
opened 
during 
the 
injection 
Ip-CC 
remains 
opened 
after the 
injection 
Evaluation 
a Yes No No No No 
b Yes No Yes Yes No 
c Yes Yes Yes Yes ? 
 
Table 8: Evaluation of Ip-CC configuration “a” and “b” for animal models 
of tMCAO and intra-arterial delivery of labeled stem cells. 
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Figure 78: 3rd echo of MGE sequence 24h after intra-arterial injection of 
labeled MSCs following delivered route condition “b”.  
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Figure 79: T2 weighted MRI 7 days after the onset of cerebral ischemia 
and MSCs injection. 
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Figure 80: (A) T2 weighted images of Wistar rat brain 24h after cerebral 
ischemia and MSCs injection, (B) T2* weighted images of Wistar rat brain 
24h after cerebral ischemia and MSCs injection, (C) T2 weighted images 
of Wistar rat brain 7 days after cerebral ischemia and MSCs injection and 
(D) T2* weighted images of Wistar rat brain 7 days after cerebral ischemia 
and MSCs injection. 
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c. Contralateral common carotid is ligated during 
tMCAO. Ipsilateral common carotid is reperfunded 
at the same time than middle cerebral artery. 
Ipsilateral common carotid is opened before, during 
and after the injection. 
Considering results from previous sections, here we will 
consider condition “c” of Table 8, where contralateral CC 
will be closed exclusively during tMCAO while ipsilateral CC 
will be reperfunded after tMCAO and it will remain open 
during all further procedures.  
Once animal was cannulated, EC artery was flushed with 
heparinized saline to prevent blood clots formation at the 
end of the catheter. The syringe was filled with 1x106 
labeled mesenchymal stem cells dispersed in PBS. In order 
to perform the intra-arterial injection, Ip-CC will be open 
helping the cells migrate into the brain. After the injection 
EC is tied with a suture. (Figure 81) 
 
Figure 81: Scheme of animal procedures of tMCAO and intra-arterial 
cannulation for stem cell delivery following condition “c”. 
This procedure for intra-arterial administration is efficient in 
terms of cell administration because all animals (12) 
showed hypointense dotted signal in T2*-weighted images. 
However, all of them had difficulties for breathing when 
woke up from anesthesia, and several (6) died few hours 
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after being injected. For a better understanding of this 
procedure results, we are going to focus on one animal 
which was being scanned when died. MRI showed 
dispersed cells along the brain as it was reported in previous 
sections, but performing a coronal T2*-weighted scan, cells 
did also appear in the cerebellum (Figure 82 (A), (B)). To 
discard hemorrhagic events, T2 weighted images were 
acquired and a hyperintense signal was observed, not only 
in the territory of MCA, as well in the cerebellum, which 
could be related to ischemias in this region. 
Our hypothesis of why cells migrate not only to the brain, 
along the cerebellum as well is based on the posterior 
communicating artery flows.  Vertebrobasilar system is 
connected to carotid system through these arteries. When 
an occlusion of both common carotids is performed (for 
tMCAO model), posterior communicating arteries provide 
the blood to the brain from vertebrobasilar system. These 
arteries must adapt to new situation increasing their caliber 
for this blood supply. However, when the cell injection is 
performed, the distribution along the brain and cerebellum 
is going to depend on the CBF distribution in the circle of 
Willis, and in this particular case, cells migrated towards 
cerebellum.  In order to avoid this distribution, it is necessary 
to have an extra blood supply apart from the provided by 
vertebrobasilar system. For tMCAO surgery is necessary that 
the ipsilateral common carotid remains closed, because 
the intraluminal filament will pass through the external 
carotid and advance through the internal carotid to reach 
the middle cerebral artery. But there is still a possibility for 
reducing the vertebrobasilar incoming flow: the 
contralateral common carotid artery. Normally, we close 
this artery to avoid collateral flow during tMCAO and 
therefore more stable ischemic lesions after tMCAO. 
However, due to the nature of the intra-arterial injection we 
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will study the influence of the contralateral common 
carotid incoming flow for labeled stem cell delivery in the 
next section.  
On the other hand and apart from cell distribution, one 
million cells for intra-arterial delivery could be inducing 
ischemia, as it can be early detected in Figure 82(C) and 
(D). We have chosen 1 million cells for intra-arterial delivery 
based on recent studies, which have been injecting from 1 
million to 30 million cells[117-120,182,184,259-261]; however, 
not all of these studies have tracked the cells after being 
injected assessing the efficiency and safety of the route.  
So, considering MRI of the last injected animals and before 
assessing the influence of the contralateral common 
carotid artery flows, we will inject different amount of 
labeled cells (1x106 cells, 0.5x106 cells and 0.25x106 cells), in 
order to evaluate the well-being of the animal and the cell 
distribution in MRI.   
 
Figure 82: (A) and (B) same slice of the 5th echo of MGE sequence 4h 
after intra-arterial injection of 1x106 labeled MSCs following delivered 
route condition “c”. In (B) hypointense signal produced by labeled cells is 
delimitated in green.  (C) and (D) are T2 weighted MR images of same 
slice 4h after intra-arterial injection of 1x106 labeled MSCs following 
delivered route condition “c”. Yellow line and Pink line in (D) would 
correspond to ischemic lesion produced by tMCAO and region where 
labeled cells were found respectively.   
In Figure 83 intra-arterial injections of 1x106 cells (A), 0.5x106 
cells (B) and 0.25x106 cells (C) were performed. It was not 
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observed cerebellar ischemia for less than one million cells 
injection, and 0.25x106 labeled cells can still be observed 
after intra-arterial injection. With regard to the safety of the 
injection, in next sections we will further study the influence 
of the injections into the CBF for these amounts of cells.  
Thus, considering all these findings, in next section we will 
study the distribution of 0.25x106 labeled cells after an intra-
arterial injection without contralateral common carotid 
artery occlusion. We will also evaluate the localization and 
the possibility of ischemic injuries induced by the injection. 
Hence, in next section we will study condition “d” from 
Table 9; Ip-CC is reperfunded after perfunding the MCA, 
during the injection and remains open after it in order to 
push the cells to the brain, but maintaining contralateral 
CC intact during all procedures. 
Conditions 
Con-CC 
closed 
during 
tMCAO 
Ip-CC is 
opened 
from MCA 
reperfusion 
till the 
injection 
Ip-CC is 
opened 
during 
the 
injection 
Ip-CC 
remains 
opened 
after the 
injection 
Evaluation 
a Yes No No No No 
b Yes No Yes Yes No 
c Yes Yes Yes Yes No 
d No Yes Yes Yes ? 
 
Table 9: Evaluation of Ip-CC configuration “a”, “b” and “c” for animal 
models of tMCAO and intra-arterial delivery of labeled stem cells. 
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Figure 83: T2* weighted images of different slices of a Wistar rat with 
cerebral ischemia 4h after the injection of (A) 1x106 labeled MSCs, (B) 
0.5x106 labeled MSCs and (C) 0.25x106 labeled MSCs. 
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d.  Contralateral common carotid is intact during 
tMCAO. Ipsilateral common carotid is reperfunded 
at the same time than middle cerebral artery. 
Ipsilateral common carotid is opened before, during 
and after the injection. 
Surgery for tMCAO and further cannulation for intra-arterial 
delivery of labeled MSCs is only performed in the left side. 
Ipsilateral common carotid is occluded during tMCAO 
procedure, and furthermore is temporally ligated to insert 
and pull out the cannula for the MSCs intra-arterial delivery. 
0.25x106 labeled cells were dispersed in 300 μL of PBS and 
injected through EC as previously described. Ipsilateral 
common carotid is open before, during and after the 
procedure. 3 animals were included for these experiments 
and all of them survived.   
Figure 84 shows one of the animals 4h after being injected 
following this route. As we had expected, hypointense 
dotted pattern signal is more reduced than in previous 
procedures due to the lower amount of injected cells 
(0.25x106 now versus 1x106 before), however all slices do 
display labeled cells. We have also performed coronal 
scans (T2* and T2) in order to evaluate the cell distribution in 
the cerebellum and possible ischemic regions (Figure 85). 
No labeled cells were found in cerebellum in T2*(Figure 85 
(A)) and also no hyperintensity signal in T2 was detected 
(Figure 85 (B)), i.e. no ischemia in the cerebellum was 
observed.   
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Figure 84: T2* weighted images 24h after intra-arterial injection of labeled 
MSCs following delivered route condition “d”. 
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Figure 85: (A) T2* weighted image of a coronal slice 4h after labeled 
MSCs injection; labeled cells are spread in the right brain hemisphere 
and no cells are observed in the cerebellum. (A) T2 weighted image of 
same coronal slice 4h after labeled MSCs injection; it can be observed a 
shadow in the right ventricle which could be ischemic lesion after 
tMCAO.  
Eventually, surgery of tMCAO performed exclusively on the 
left side allowed a uniform cell distribution along the brain 
after intra-arterial delivery. With contralateral common 
carotid artery opened during tMCAO, posterior 
communicating arteries contribute to the cerebral blood 
flow; however vertebrobasilar system is not the unique 
source of blood supply for deprived areas. When tMCAO is 
over and intraluminal filament is pulled out from middle 
cerebral artery, ipsilateral common carotid is perfunded to 
prevent vessel necrosis and therefore hemorrhagic 
transformation.[262] As we had observed in previous 
sections, it is necessary an extra blood flow to push the 
injected cells to brain, so during the injection common 
carotid flow will further transport them. Labeled cells were 
not observed in cerebellum and multifocal ischemias 
produced by them either.  
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In regard to the safety of the procedure, all animals 
survived after injection and their behavior after waking up 
from anesthesia was normal; they did not present difficulties 
for breathing or exploring the cage. Hence, gathering all 
these data, this is the safest and most efficient model of 
ischemic stroke and intra-arterial administration of 
mesenchymal stem cells in Wistar rat.  
However, after these results two questions are still on the 
bench. On one hand it is necessary to evaluate if the 
magnetic vectorization of labeled cells could increase the 
amount of cells in the animal brain following intra-arterial 
delivery without compromise the safety, and on the other 
hand, if cells after an intra-arterial injection with or without 
magnetic vectorization could provoke occlusions that can 
lead to multifocal ischemias.  
8.3.3. Magnetic vectorization in vivo 
In chapter 7, we have already demonstrated that 
mesenchymal stem cells labeled with dextran coated 
nanoparticles can be magnetic vectorizated in a 2D 
environment without harmful effects on the cells. 
In this section we will discuss if 1T magnet can guarantee or 
increase the amount of labeled cells in the brain after an 
intra-arterial injection. Previous studies have used 0.3 T 
magnets[223] however, considering that the adhesive force 
follows an exponential decay with the distance, as it can 
be noted in Figure 86 (1T Magnet data sheet, article Q-51-
51-25-N, Supermagnete) we have selected the rare 
magnet with the highest magnetization available to cover 
most of the brain with the highest adhesive possible force.   
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Figure 86: Adhesive force in ration to the air gap between magnet and a 
steel plate. (1T Magnet data sheet, article Q-51-51-25-N, Supermagnete) 
Under sevofluorane anesthesia, the head and the neck of 
the animal were placed on to the magnet as it is shown in 
Figure 87 prior to be injected. After cell administration, 
animals stayed in contact with the magnet for 4 extra hours, 
and then magnetic vectorization was evaluated in MR T2* 
weighted images, as it was done before for cell tracking in 
animal models of stroke. In vivo conditions are quite 
different from in vitro, however timing for magnetic 
vectorization was chosen based on in vitro experiments; 
where MSCs in culture get attached to the flask or well after 
4h.  
We have studied the influence of the magnet for all 
previous tMCAO-injection conditions and no differences 
with and without magnet were observed, however we went 
through the different possibilities.   
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Figure 87: Wistar rat positioning for magnetic vectorization experiments.  
For the first condition “a” without the magnet, where 
common carotid is not pumping the cells and therefore, the 
cells not always reach the brain, magnetic vectorization did 
not contribute to attract labeled cells to brain region. No 
differences were found after an intra-arterial injection of 
one million cells with and without the magnet. So, all seem 
to point out that applied magnetic forces were not enough 
to attract injected cells to the brain, but maybe they could 
hold the cells if eventually they enter into the magnetic 
field.  
In order to prove last hypothesis, conditions “b” and “c” 
were evaluated. The major inconvenience of these 
conditions is the high mortality associated to the procedure 
as it was previously reported. For these cases, the magnet 
effect on the cells did not reduce the mortality and no 
differences on labeled cell distribution along the brain were 
observed either (data not shown). 
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Then, 4h after cerebral ischemia, 0.5x106 labeled MSCs were 
injected following “d” condition. No differences were 
observed 4h after injection in MRI as it can be observed in 
Figure 88 with and without magnet. Cell brain distribution is 
not exactly the same with and without magnet considering 
the hypointense signal in T2* weighted images, but these 
pattern asymmetries could be more influenced by the 
differences on the brain vessel ramifications than by the 
magnet presence because no cell pattern associated to 
magnetic field lines was observed. If magnetic field would 
have a macroscopic influence on the cell retention, it 
would be expectable that as closer to the magnet as 
higher would be the hypointensities in T2* weighted images, 
however no differences in cell distribution were observed 
for both groups.  
To elucidate the mechanism that holds the cells in the brain 
of the animal and allow us to detect labeled cells at least 
4h after being injected, several experiments were 
performed following condition “d”. Next table summarizes 
all approaches performed: 
Hypothesis Approach 
Cellular aggregation 
prior to injection 
Reduce cell concentration 
Controlled delivery rate  
Manual-Infusion pump 
Increase catheter length 
Cell passage number 
Cellular aggregation  
after injection 
Antiaggregant administration 
Antiplatelet administration 
Cell specificity MSCs and C17.2 
MNPs specificity Dextran-MNPs and PluronicF127-MNPs 
Serum reactivity In vitro aggregation 
 
Table 10: Approaches to elucidate the mechanism of cellular 
entrapment after intra-arterial delivery.  
 224 
 
On one hand, cells could be aggregating before being 
injected. To avoid this, we change the cellular 
concentration in PBS before injection changing total 
injected volume from 300 μL to 1 mL. What we found is that 
cell distribution for 1 mL was similar to 300 μL but an 
important brain edema after injection was observed for 1 
mL.  
In this way, and maintaining 300μL of injection, instead of 
performing the administration by manual injection a micro-
infusion-pump was used for stem cell delivery. Injection was 
performed for 15 minutes but following a constant delivery 
that could overcome the bolus-like manual injection. No 
differences were observed between manual and pump-
controlled administration. 
Other approach we also considered was the possibility of 
cell precipitation into the syringe.  Because the duration of 
the injection was 15 minutes and the length of the catheter 
was 20cm, we hypothesized that cells could precipitate in 
the syringe, aggregate and what we were actually 
injecting were cell aggregates instead of a single-cell 
suspension. To overcome this we have used a 2 m length 
catheter and prior to injection it was filled up with the cells 
in PBS. However, no differences were observed changing 
the length of the catheter.  
We have also evaluated if the passage number of the 
injected cells could have an influence onto the cellular 
retention in brain, but no differences were observed 
between passage number 7 and 18.  
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Figure 88: T2* weighted images 4h after 0.5x106 labeled MSCs intra-arterial 
injection of (A) Wistar rat 4h after onset of cerebral ischemia with 
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magnet, (B) Wistar rat 4h after onset of cerebral ischemia without 
magnet.  
After all these changes related to cellular status before 
injection and no differences observed between them, we 
thought that maybe was not a consequence of cellular 
aggregation prior to injection, but a reaction after being 
injected. To prove this hypothesis, 3 different experiments 
were performed. Our first hypothesis was coagulation 
problems mostly due to the injection surgery, but also for 
using PBS for cell delivery, although most of cellular 
administration studies use this vehicle for injecting the 
cells.[117,182,259,260] Cells were dispersed in heparinized 
PBS and injected following the intra-arterial delivery 
procedure, however 4h after injection it was possible to 
observe cells in the rat brain in MR T2* weighted images. 
Secondly, we thought about the possibility of platelet 
aggregation as a consequence of the injection. To 
overcome this fact, animals were pretreated with 
antiplatelets (Adiro) and labeled cells in PBS were intra-
arterially administered. Once more, no differences in 
cellular detection through MRI were observed after 
antiplatelet pre-administration.  
So far, we have tested all these hypothesis of cellular 
detection 4h after injection using mesenchymal stem cells 
labeled with dextran-coated superparamagnetic 
nanoparticles. In order to demonstrate if the entrapment 
effect is dependent on the type of injected cells we 
evaluated the injection of neural stem cells C17.2 labeled 
with dextran-coated MNPs already characterized in 
Chapter 6. No differences were observed between C17.2 
and MSCs in MR T2* weighted images 4h after an intra-
arterial injection.  
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Moreover, in section 3, we have demonstrated that for the 
labeling protocol used,[227] all magnetic nanoparticles for 
cell labeling are inside the cell, not attached to the surface, 
so MNPs should not be a parameter which explains the 
entrapment. However, we also used MSCs labeled with 
Pluronic F127-coated MNPs to confirm this hypothesis. No 
differences of cellular entrapment in the animal brain were 
observed between MSCs labeled with dextran or pluronic 
F127 coated MNPs, so it was also verified that the type of 
MNPs does not have an influence on injected cell 
detection.   
Finally, considering that the MSCs we have used are from a 
donor rat, it could be that injected cells are reacting with 
animal serum once injected, as it was reported in other 
study.[263] To prove this hypothesis, we cultured MSCs and 
C17.2 cells in IMDM and DMEM respectively using 20% Wistar 
serum or 20% FBS. Pictures of all groups were taken and no 
aggregation was observed for any group after 1 and 6 
hours, concluding that MSCs either C17.2 aggregates in 
Wistar serum (data not shown).  
In light of these results, magnetic vectorization after an 
intra-arterial delivery of labeled mesenchymal stem cells in 
an animal with cerebral ischemia is not needed. For those 
animal models that cells not always end up in the brain, 
magnetic vectorization resulted not effective, and for those 
that cells always end up in the brain, magnetic cell 
guidance did not increase the amount of cells in the brain. 
We have also studied several factors that could influence 
the cell entrapment in the brain; however none of the 
investigated approaches gave us an explanation of the 
mechanism. In order to elucidate this natural vectorization, 
it would be necessary to study MSCs administration in 
healthy animals to evaluate if molecular ischemic processes 
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have an influence on the entrapment, and this will be one 
of the objectives of the next chapter.  
8.3.4. Monitoring of cerebral blood flow for an 
intra-arterial injection of labeled 
mesenchymal stem cells in healthy rats 
So far, we have reported the most efficient and the safest 
route for intra-arterial administration, and also that 
magnetic vectorization does not increase the amount of 
cells in brain from a macroscopic point of view. However, it 
is still necessary to demonstrate if the injection of labeled 
cells can affect the CBF.  
We have observed that for several tMCAO & intra-arterial 
injection procedures cells can migrate into the cerebellum 
producing an ischemic lesion that can be early observed in 
T2 weighted images (Figure 81). We assume that the 
hyperintense signal in the cerebellum was a consequence 
of the injection, because tMCAO occlusions do not affect 
that territory.  
In non-ischemic animals and following the last injection 
procedure “d”, we would evaluate the cell entrapment in 
healthy brains. We would also assess if MSCs provoke 
multifocal ischemias by monitoring the CBF during the 
injection and studying T2 weighted images 24h after cell 
delivery.  At this point, because stem cell administration is 
going to be performed in healthy animals, if MRI reveals 
ischemic lesions, they would be a consequence from the 
MSCs injection unambiguously.  
Thus, 6 healthy animals were used for studying the CBF 
changes as consequence of the injection, and 3 different 
conditions were evaluated: PBS; 1x106 MSCs and 0.25x106 
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MSCs. For an optimal monitoring, prior to injection 3 doppler 
probes were placed onto the squamosal bone in the skull 
and cannulation surgery was performed as previously 
described following “d” condition. (Figure 89)  
CBF was monitored during all procedure. 24h after MSCs 
administration MR T2 weighted images were acquired to 
assess focal/multifocal ischemias due to the intra-arterial 
cellular injection. Results of transcranial Doppler flow 
measurements and T2 weighted images 24h after the 
injection are shown in Figure 90, Figure 91 and Figure 92 for 
PBS, 1x106 MSCs and 0.25x106  MSCs respectively.  
 
Figure 89: Lateral view of the skull of a rat (adapted from[264]). Color 
dots shows the different Doppler probes position onto the squamosal 
bone for monitoring CBF before, during and after the mesenchymal stem 
cell intra-arterial administration.  
The measurement of the CBF in three different regions was 
performed following the same procedure for all animals. 
(Figure 89) 
In order to evaluate the safety of the procedure, first group 
of study was an intra-arterial delivery of 300 μL of vehicle 
(PBS). As it can be noted in the graph of Figure 90, CBF was 
constant during all procedure for all of the 3 probes used. 
All profiles did not show peaks and valleys during the 
injection and after it either. MR T2 weighted images were 
performed 24h after injection, and no hyperintensities were 
observed along the brain (Figure 90), confirming the safety 
of this intra-arterial administration route.  
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Figure 90: CBF for 3 Doppler probes (D1, D2, D3) measured before, during 
and after the injection of PBS; and MR T2 weighted images of several 
slices 24h after the injection.  
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In previous sections we had reported that most of animals 
which had been injected with 1x106 cells after tMCAO, died 
short after stem cell delivery. In order to elucidate if injected 
cells can provoke ischemic lesions and consequently the 
animal death, 2 healthy animals were considered for these 
injections. One of them died 6h after the injection and the 
other survived 24h. CBF monitoring of this animal is shown in 
the graph of Figure 91. Unlike PBS administration, for one 
million cell delivery it is possible to observe peaks and 
valleys during the injection for all Doppler measurements. 
What is also interesting in this graph is the CBF reduction 
that can be observed in the three of them after the cell 
administration; however it is more evident for the upper 
profile line (going from approximately 150 to 100). CBF was 
monitored for 40 minutes more after finishing the cell 
delivery, but no changes were observed after it. 
Considering these Doppler profiles, it would be expectable 
to observe hyperintensities in MR T2 weighted images 24h 
after the injection. In effect, in Figure 91 it is possible to 
observe multifocal ischemic regions (hyperintensity in T2 
weighted images) distributed along the brain. Most of them 
were found in the hemisphere where the cannulation and 
administration was performed, however due to the circle of 
Willis some hyperintensities were also observed in the 
contralateral hemisphere. For an injection of one million 
cells, Doppler flow monitoring showed a reduction in the 
CBF which was further confirmed by the presence of 
multifocal ischemic lesions in T2 weighted images 24h after 
the mesenchymal stem cells administration.  
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Figure 91: CBF for 3 Doppler probes (D1, D2, D3) measured before, during 
and after the injection of 106 MSCs; and MR weighted images of several 
brain slices 24h after the cell delivery. 
 233 
 
We have already reported that no animals with cerebral 
ischemia died after an intra-arterial injection of 0.25x106 
mesenchymal stem cells. In this section we have studied if 
those injections can vary the CBF in 3 healthy rats. In regard 
to Doppler measurements in Figure 92, in this animal it is also 
possible to observe peaks and valleys during the injection; 
however no reduction in CBF was measured after stem cell 
delivery. For the upper CBF monitoring, baseline is more 
horizontal than for the other two, however the slope 
observed for these last ones seems to be originated in the 
measurement itself and not as a consequence of the 
injection. MR T2 weighted images of this animal 24h after the 
injection showed big subcortical ischemic lesions in the 
same hemisphere and cortical lesions in the contralateral 
side of the brain. So, for this animal laser Doppler 
measurements did not report a reduction in the CBF but 
ischemic events were observed 24h later. This 
underestimation took place because Laser Doppler 
flowmetry has an excellent temporal resolution but not 
sufficient spatial resolution. CBF monitoring is limited to the 
proximity of the probe, in surface and also in depth, being 
the subortical region out of the range of measurement. 
Thus, deep ischemic lesions could not be detected by this 
technique.  
However, not all animals injected with 0.25x106 MSCs 
showed significant ischemic events. In Figure 93 it is possible 
to observe one animal 24h after 0.25x106 MSCs intra-
arterially delivered. Hyperintensities noted with green arrows 
correspond to a lesion consequence of one Doppler probe 
positioning, and orange arrows point out 3 focal ischemias 
that could be produced by the cell injection. Comparing 
Figure 92 with Figure 93, the degree of ischemic events after 
0.25x106 cells injection is quite different, which could point 
out the big influence of the circle of Willis structure on the 
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cell distribution and even multifocal ischemias due to the 
intra-arterial delivery of MSCs.  
Hence, this procedure for intra-arterial delivery route is 
highly reproducible and safe for vehicle injection, however 
for mesenchymal stem cell administration multifocal injuries 
were observed in MR T2 weighted images in all groups. 
Animals which were injected with 1x106 MSCs showed 
bigger lesions or died, while animals injected with 0.25x106 
mesenchymal stem cells had variable size multifocal 
ischemias along the brain. Moreover, laser Doppler 
flowmetry is a good technique to monitor CBF in a specific 
region onto the brain surface; however it is not enough to 
elucidate deep ischemic lesions after an intra-arterial stem 
cell delivery.   
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Figure 92: CBF for 3 Doppler probes measured before, during and after 
the injection of 0.25x106 MSCs; and MR T2 weighted images of several 
brain slices 24h after the cell delivery. 
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Figure 93: MR T2 weighted images 24h after 0.25x106 MSCs intra-arterial 
delivery. Green arrows point lesion induced by positioning the Doppler 
probes and orange arrows point ischemic lesions produced by 0.25x106 
cells intra-arterially administrated.   
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8.4. Conclusions 
This chapter shows the different combinations of animal 
models of ischemic stroke and intra-arterial administration 
routes for mesenchymal stem cells delivery. In order to 
elucidate which model was the most efficient and the 
safest for an intra-arterial injection, we have used 
mesenchymal stem cells labeled with our dextran-coated 
superparamagnetic nanoparticles characterized in 
previous chapters. By using them, we have observed the 
circle of Willis compensating flow adaptation after an 
ischemic event and the great importance of the tMCAO 
procedure for a successful intra-arterial administration.  
Thus, for an efficient intra-arterial delivery, during tMCAO 
surgery is necessary to maintain intact the contralateral 
common carotid artery and, after perfunding the occluded 
middle cerebral artery of ipsilateral side, ipsilateral common 
carotid must be also opened. Intra-arterial stem cell 
delivery will be produced through the ipsilateral external 
carotid and heart pumping will carry the delivered cells to 
the brain territory.  
These injected cells can be detected in the ischemic brain 
for more than 4h after injection, and their presence is not 
increased by the use of external magnetic fields, as 
magnetic vectorization. Moreover, we have demonstrated 
that monitoring of CBF by transcranial laser Doppler is not 
enough to assess the safety of the intra-arterial delivery,  
and healthy animals injected with 0.25x106 MSCs showed 
multifocal ischemic lesions 24h after the stem cell 
administration, evidencing that injected cells could be 
inducing focal ischemias.  
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9. Cell tracking of 
mesenchymal stem cells 
9.1. Hypothesis 
In previous sections we have developed dextran-coated 
superparamagnetic nanoparticles for cell labeling and 
further cell tracking for MRI. This system, cell-MNPs, let us to 
monitor the cells once being injected and was used to 
assess the efficiency for intra-arterial administration after 
tMCAO.  
The aim of this chapter is to track labeled mesenchymal 
stem cells following intra-arterial (i.a.) and intravenous (i.v.) 
routes in healthy and ischemic animals to assess if ischemic 
condition has an influence on the biodistribution of the 
injected cells, evaluated by MRI and histological 
techniques.  
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9.2. Materials & Methods 
9.2.1. Cell labeling preparation 
9.2.1.1. Cell lines 
All experiments were performed using Mesenchymal Stem 
Cells (MSCs) purchased from Cultrex, Trevigen and were  
cultured in IMDM (78%), Fetal bovine serum (10%), Horse 
serum (10%), Penicillin-Streptomycin (1%) all from Gibco 
Invitrogen, and Amphotericin-B (1%) from Sigma-Aldrich. 
Cell passage numbers between 7 and 18 were used in 
these experiments.  
9.2.1.2. Dextran-coated superparamagnetic nanoparticles 
Dextran coated MNPs (D-MNPs) were synthesized in the 
Clinical Neuroscience Research Laboratory following the in 
situ protocol described in chapter 4.  
9.2.1.3. Preparation of Poly-L-lysine hydrobromide-coated 
D-MNPs 
1.5μg/mL of Poly-L-lysine hydrobromide (PLL) (Sigma-
Aldrich) was used. One hour prior to cell incubation, D-
MNPs were mixed with cell medium and with 1.5 μg/mL PLL 
and vigorously shaken.  
9.2.1.4. Cell labeling with PLL-coated D-MNPs and CFSE 
MSCs were labeled following the protocol described 
elsewhere[227] with slight modifications. Cells were 
incubated with 1.5 g/mL PLL and 100 μg/mL of D-MNPs for 
24h. The MNP containing medium was removed and the 
cells were 3 times washed with 1.5 mL of Phosphate 
Buffered Saline (PBS without Mg2+ and Ca2+, Gibco 
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Invitrogen) to remove non-attached MNPs. After washing, 
the cells were left overnight (12h) in 1mL of fresh medium.  
The following day the medium was removed, and CFSE 
(Carboxyfluorescein succinimidyl ester) labeling was 
performed following the manufacture instructions 
(CellTrace CFSE Cell Proliferation Kit for flow cytometry, 
LifeTechnology). Then, cells were washed once with 1.5mL 
of PBS and 0.5mL of EDTA-trypsin (Gibco Invitrogen) was 
added to detach the cells from the well. The trypsin was 
neutralized with fresh medium and the detached cells were 
collected in a Falcon tube. After a mild centrifugation, the 
supernatant was discarded and the cells were resuspended 
in PBS 1x. Cell count was performed with Trypan Blue 
staining and a Neubauer chamber. Samples were diluted 
1:5 with PBS and 1:2 with Trypan Blue. 0.5x106 labeled cells 
were injected in order to study the cell tracking following 
different administration routes.  
9.2.2. Animal management 
In this study we have used 8 Wistar rats (Harlan) with a 
weight of 288±9 g. Animals were kept at controlled 
conditions of temperature (22±1 °C) and humidity (60±5%), 
with a 12/12 hours light/dark cycle, and granting free 
access to food (commercial chow pellets) and tap water. 
For surgery and MRI, rats were anesthetized with sevoflurane 
(3% in 70% N2O and 30% O2). Rectal temperature was 
monitored and maintained at 37±0.5 °C with a feedback 
controlled heating system (1025 system, SA Instruments). At 
the end of the procedures animals were sacrificed under 
deep anesthesia (8% sevoflurane). Experimental protocols 
were approved by the local Animal Care Committee 
according to the Spanish and European Union (EU) rules 
 242 
 
(86/609/CEE, 2003/65/CE, 2010/63/EU, RD 1201/2005 and 
RD53/2013). 
9.2.3. Model of focal transient ischemia in the rat 
Transient focal ischemia was induced in rats by intraluminal 
occlusion of the middle cerebral artery (tMCAO), 
performed as previously described[171] with several 
modifications. In order to monitor the relative cerebral 
blood flow (CBF) during the surgery, a laser-Doppler flow 
probe (tip diameter 1 mm) attached to a flow meter 
(PeriFlux 5000; Perimed AB) was located over the thinned 
skull, over the middle cerebral artery territory 
(approximately 4 mm lateral to bregma). Only animals with 
a CBF reduction higher than 60% and with reperfusion after 
occlusion were included in the studies. To perform tMCAO, 
both vertebral arteries and contralateral common carotid 
artery remained intact all surgical procedures.  
Under a surgical microscope, common carotid, external 
carotid, and the internal carotid arteries of the left side 
were dissected from connective tissue through a midline 
neck incision. Left external carotid and pterygopalatine 
arteries were separated and tied permanently with 6-0 silk 
sutures, showing a CBF reduction of 20% measured by laser 
Doppler. A silicon rubber-coated monofilament 
(403512PK5Re; Doccol Corporation) was inserted through 
the external carotid into the left common carotid artery 
and advanced into the internal carotid 17-20 mm from the 
bifurcation to occlude the origin of the MCA. The 
intraluminal filament was removed after 45 minutes of 
occlusion. Common carotid artery was perfunded 
immediately after removing the intraluminal filament.  
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9.2.4. Intraparenchymal injections in healthy rats 
Labeled cells with CFSE and labeled cells with dextran-
coated superparamagnetic nanoparticles and CFSE were 
injected in each hemisphere following stereotactic 
injections in 3 healthy animals (Figure 94).  Under 
sevofluorane anesthesia (3%), 100.000 mesenchymal stem 
cells in sterile PBS (total volume of 10 μL) were administered 
to the rat brain hemispheres at the locations of 0.6 mm 
posterior, 2.9 mm lateral to the bregma, and 5.0 mm deep 
to the skull surface in a rat stereotactic apparatus, after 
drilling a hole in the parietal bones. The injection was 
performed using a 30G needle in 10 min, MSCs were 
delivered at a rate of 1 μL/min using a micro-pump, and the 
needle was kept in this position for an additional 10 min and 
then retrieved slowly out of the brain.  
 
Figure 94: Representative scheme of intraparenchymal injection of MSCs 
labeled cells.  
9.2.5. Systemic administration delivery routes 
Cells were administrated 4h after the perfusion of the ACM 
in those animals that went under tMCAO. 
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9.2.5.1. Intra-arterial injection 
Cannulation for intra-arterial delivery of labeled MSCs is 
performed in the left side following the same procedure for 
healthy and ischemic rats. Animals that went under tMCAO 
have already pterigopalatin and external carotid arteries 
closed, however it is necessary to tie these arteries in 
healthy rats.  
Ipsilateral common carotid is temporally ligated to insert the 
cannula for the MSCs intra-arterial delivery. A 0.28 mm ID & 
0.61 mm OD catheter (Smiths) connected to a 30G needle 
and a 1 mL syringe was inserted into the stump of ECA 
through an incision on the vessel under the operation 
microscope, and was tightened to ECA by a 6-0 silk suture. 
The catheter went forward into ICA till reach the branch of 
common and internal carotid. This tube was filled with 
heparinized physiological saline to prevent air bubble and 
coagulation. Common carotid is opened and a small blood 
reflux in the catheter can be observed. The syringe was 
filled with labeled cells in PBS and using slow hand injection 
over 15 minutes, 0.5x106 labeled cells in 300 μL of PBS were 
delivered into the internal carotid.  When the injection is 
finished, common carotid is temporally ligated to remove 
the catheter. EC is tied and common carotid is opened 
again.  
9.2.5.2. Intravenous injection 
Intravenously administration was performed through the 
jugular vein. A 0.5 cm incision was made in the animal’s 
neck just above the clavicle 1 cm to both left and right of 
the midline. Subcutaneous fat was cut and the jugular vein 
was revealed. A 30G gauge needle was used for every 
injection since after withdrawal; the puncture rapidly closes 
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preventing bleeding. One million cells in 300 μL of PBS were 
administered manually in less than 1 min.  
9.2.6. Magnetic resonance imaging in vivo 
Cell tracking was assessed by magnetic resonance 
imaging. Magnetic resonance imaging studies were 
conducted on a 9.4-T horizontal bore magnet (Bruker 
BioSpin, Ettligen, Germany) with 20 cm wide actively 
shielded gradient coils (440 mT/m). Radio-frequency 
transmission was achieved with a birdcage volume 
resonator; signal was detected using a four-element 
surface coil, positioned over the head of the animal, which 
was fixed with a teeth bar, earplugs, and adhesive tape. 
Transmission and reception coils were actively decoupled 
from each other. Gradient-echo pilot scans were 
performed at the beginning of each imaging session for 
accurate positioning of the animal inside the magnet  
T2-weighted images were acquired using a multislice 
multiecho spin-echo sequence with the following 
acquisition parameters: FOV 19.2 x 19.2 mm2, image matrix 
192 x 192 (isotropic in-plane resolution of 100 μm/pixel x 100 
μm/pixel), 14 consecutive slices of 1mm thickness, repetition 
time of 3 s, and 16 echoes with 9 ms of echo time. T2-
weighted images were acquired 24h after the onset of the 
ischemia. 
T2*-weighted images were acquired using a multi gradient 
echo sequence with the following acquisition parameters: 
FOV 19.2 x 19.2 mm2, image matrix 192 x 192 (isotropic in-
plane resolution of 100 μm/pixel x 100 μm/pixel), 14 
consecutive slices of 1mm thickness, repetition time of 1.5 s, 
and 16 echoes with 2.9 ms for the first echo time and 3.28 
ms of echo spacing.  
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Post-processing of all images was performed using ImageJ 
software (Rasband, W. NIH). 
9.2.7. Tissue processing 
Rats were anesthetized under sevofluorane (8%), perfused 
transcardiacally with 4% paraformaldehyde (PFA) in 0.1 M 
PBS, the brains were removed, postfixed (4% PFA, 4°C, 24 h), 
and included in paraffin. 
9.2.7.1. Tissue processing for Prussian Blue staining and CFSE 
detection 
Prussian Blue staining was performed to colocalize D-MNPs 
with the CFSE labeled cells. Paraffin sections of 10 μm were 
deparaffinized in xylol and rehydrated in graded alcohol 
series. The sections were then washed with phosphate 
buffer saline (PBS 1X) and incubated for 20 minutes with a 
mix of equal parts of aqueous solution of 20% HCl 
(Hydrochloric acid fuming 37% extra pure, Merk) and 
aqueous solution of 10% Potassium ferrocyanide Trihydrate 
(KFe(CN)6.3H2O, FW 422.2, Sigma-Aldrich). After incubation, 
slides were washed 3 times with PBS and were mounted 
with fluorescence mounting medium (Life Technologies). 
Photographs were taken using an inverted microscope 
(Olympus IX51). 
9.2.7.2. Tissue processing for fluorescence optical 
microscopy 
Paraffin sections of 10 μm were deparaffinized in xylol and 
rehydrated in graded alcohol series. The sections were then 
washed with phosphate buffer saline (PBS 1X), heated at 
99ºC in Citrate buffer (Dako) for 20 min and washed again 
with PBS 1x. Slides were incubated first with Rabbit 
polyclonal antibody to CD31 (Abcam) (1:25), normal horse 
 247 
 
serum (15%), Trition X-100 (0.2%) and PBS overnight. The 
slides were then incubated at room temperature for 1h with 
biotinylated horse anti-Rabbit IgG antibody (Vector) (1:200) 
and PBST. After 3 washes with PBST, slides were incubated 
with dylight 594 streptavidin (Vector) (1:500) and PBST. And 
finally for nucleus staining, 10 μL of Hoechst (Invitrogen) in 
60mL of PBS 1x were added to the slides and incubated for 
15 min and washed afterwards with PBS. Slides were 
mounted with fluorescence mounting medium (Life 
Technologies). Photographs were taken using an inverted 
microscope (Olympus IX51). 
9.2.7.3. Tissue processing for transmission electronic 
microscopy 
Rats were sacrificed under sevofluorane anesthesia (8%) 
and samples of brain cortex and striatum were taken 
immediately after the animal death. Fixation and 
postfixation were carried out in 2% glutaraldehyde in 
sodium cacodylate buffer and in 1% OsO4 in the same 
buffer. Inclusion was done in Spurr’s epoxy resin. Semithin 
sections (0.5 μm) were stained with Toluidine blue and 
examined under optical microscope to select brain regions 
for further TEM analysis and ultrathin sections (100 nm) were 
stained with uranyl acetate and lead citrate.  
9.3. Results & Discussion 
Stem cells offer tremendous potential to treat stroke and 
other neurological diseases; however the translation from 
pre-clinical to clinical studies presents several challenges 
and one of them is the selection of an adequate 
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administration route for cell delivery. Monitoring cell 
localization and study the fate after administration is 
essential to elucidate underlying mechanisms of stem cell 
therapy. 
In this chapter we will monitor the fate of labeled cells 
following two types of administration routes; intra-arterial 
delivery, following the procedure described in the previous 
chapter and, intravenous administration route through 
jugular vein. As we have mentioned before, MRI is the best 
technique to monitor injected cells due to the soft tissue 
contrast and non-invasiveness of the procedure, however a 
complementary technique would be useful to demonstrate 
that MR hypointensities in T2* weighted images correspond 
to labeled cells and not to free particles. 
Immnunohistochemistry will assess the co-localization of 
cells and magnetic nanoparticles ex vivo.  
Because there is not a specific marker for MSCs that let us 
an unequivocal identification of the administered cells, 
MSCs will be labeled with a fluorescent cell staining dye 
prior to be injected. CFSE is a fluorescent dye, used for in 
vitro and in vivo labeling of cells to trace multiple 
generations; however in this work the dye will be used to 
distinguish between injected cells and host cells in brain 
tissue ex vivo. This dye labeling is performed in vitro, prior to 
the injection, diffusing easily into cells and binding 
covalently to intracellular amines in vitro, resulting in stable 
and well-retained fluorescent staining. Apart from CFSE, 
MSCs will be also labeled with our synthesized dextran-
coated superparamagnetic nanoparticles, which will 
provide MRI contrast as well Prussian blue staining for ex 
vivo detection. Thus, we will be able to correlate in vivo MRI 
signal with Prussian blue and CFSE signal ex vivo. In vitro 
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assessing of D-MNPs and CFSE labeling of MSCs is shown in 
Figure 95.   
 
Figure 95: MSCs labeled with D-MNPs and CFSE (A) Phase contrast 
microscopy; (B) Prussian blue staining of D-MNPs through bright field 
optical microscopy and (C) fluorescent microscopy for observing CFSE 
labeling. 
9.3.1. Intraparenchymal administration route 
So as to assess the efficacy of these different labels on 
mesenchymal stem cells, our first in vivo approach was an 
intraparenchymal injection. Actually, this administration 
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route was one of the early delivery routes and was also 
used for stem cell therapy, however due to the high 
invasiveness of the technique we will consider stereotactic 
injections to co-localize cells and D-MNPs, and not as an 
administration route for cell tracking studies or further stem 
cell therapy experiments.  
In this way, MSCs labeled with CFSE were injected in the left 
brain hemisphere, and MSCs labeled with CFSE and D-MNPs 
in the right hemisphere of a healthy animal (Figure 94). After 
the injection, the animal was scanned in MRI and T2* and T2 
weighted images were acquired, corresponding to Figure 
96 and Figure 97 respectively. As we expected, only cells 
labeled with D-MNPs can be detected after the injection in 
MRI. Moreover, it is possible to note in T2 and T2* weighted 
images the needle track for cell delivery in the left 
hemisphere, corresponding to CFSE labeling (green arrow), 
being this trace attributed to a small bleeding due to the 
injection itself. Collateral effects from craniotomy and 
intraparenchymal injection can be also noted in T2 and T2* 
(red asterisks). D-MNPs labeled cells can be easily observed 
in both sequences due to the high concentration of cells in 
a reduced brain volume producing similar hypointensities in 
both sequences, however blooming effect for T2* weighted 
images can be noted.  
In the previous chapter we had demonstrated that cells 
labeled with D-MNPs can be visualized by MRI after an 
intra-arterial administration. In this section we have seen 
that non-labeled cells do not present hypointensities in T2 or 
T2*, while D-MNPs labeled cells following the same route of 
administration do present negative contrast in both 
sequences, making them visible in MRI 4h after being 
injected. 
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Figure 96: MR T2* weighted images of an intraparenchymal injection of 
MSCs. Left hemisphere was injected with MSCs labeled with CFSE and 
right hemisphere was injected with MSCs labeled with CFSE and D-MNPs. 
Green arrow shows the needle trajectory for MSCs with CFSE and red 
asterisks point out the craniotomy/wound effect. 
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Figure 97: MR T2 weighted images of an intraparenchymal injection of 
MSCs. Left hemisphere was injected with MSCs labeled with CFSE and 
right hemisphere was injected with MSCs labeled with CFSE and D-MNPs. 
Green arrow shows the needle trajectory for MSCs with CFSE and red 
asterisks point out the craniotomy/wound effect. 
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Immediately after MRI scanning and therefore 4h after 
intraparenchymal delivery, these animals were perfunded 
and brain tissue sections were processed and fixed in 
paraffin. Brain slices of 10 μm were obtained, processed for 
Prussian blue staining and mounted. Bright field and 
fluorescence optical images of left hemisphere and right 
hemisphere were taken to co-localize Prussian blue and 
CFSE. Figure 98(A) and (B) corresponds to the injection of 
MSCs labeled exclusively with CFSE in the left hemisphere. 
No staining for Prussian blue is observed in bright field 
microscopy (Figure 98 (A)) and CFSE labeled cells can be 
noted (Figure 98 (B)). This result is in accordance with MR T2 
and T2* of left hemisphere where no cells were detected 
and no Prussian blue either because MSCs are exclusively 
labeled with CFSE. (Figure 96 and Figure 97)  
On the other hand, Figure 98 from C to F corresponds to 
MSCs labeled with D-MNPs and CFSE. Prussian blue and 
CFSE staining are observed. Different region of same 
hemisphere is shown in  Figure 98 (E) and (F) where a single 
cell can be examined, noting that CFSE and Prussian blue 
are well delimited in the cell and correspond to one single 
labeled cell. This result of positive staining for Prussian blue is 
in accordance with MR T2 and T2* of right hemisphere where 
hypointensities were detected. (Figure 96 and Figure 97)  
Overall, we can conclude that for MSCs labeled with D-
MNPs and CFSE, three measurable signals were detected, in 
vivo contrast in MRI, and ex vivo Prussian blue and CFSE 
staining.  
So far in this part we have demonstrated that we can label 
MSCs with a fluorescent dye and detect those cells ex vivo 
after being injected following the intraparenchymal route. 
In the same way, we have observed that if the 
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administered cells are also labeled with D-MNPs, those 
nanoparticles are still in the cell at least 4h after the 
injection and, that the detected hypointensities in MRI 
would correspond with D-MNPs labeled cells and not to free 
D-MNPs. We have also confirmed that for non-D-MNPs 
labeled cells, no signal is observed in MRI and in Prussian 
blue either; however CFSE labeled cells can be detected 
by histochemistry techniques.   
 
Figure 98: Intraparenchymal injection of (A) and (B) MSCs labeled 
exclusively with CFSE; (C), (D), (E), (F), MSCs labeled with CFSE and D-
MNPs. Left column corresponds to bright field optical microscopy and 
right column optical fluorescence microscopy.   
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9.3.2. Intravenous and intra-arterial administration 
routes 
We have assessed the feasibility of an intraparenchymal 
injection of labeled MSCs for cell detection following 
several techniques however, this administration route is 
highly invasive and in an ischemic animal multiple injections 
would be required to cover all ischemic regions. In order to 
minimize the invasiveness of the administration, the most 
used delivery routes for stem cell therapy are intravenous 
and lately, intra-arterial administration routes. Within 
intravenously injection several body sites have been used, 
tail, penile, jugular and femoral veins,[265] nevertheless 
most common are tail and jugular, while intra-arterial 
delivery is normally performed in the internal carotid 
through the external carotid artery.  
To study intravenous and intra-arterial delivery routes, 
healthy animals and animals with cerebral ischemia were 
considered. All rats were injected with 0.5x106 MSCs labeled 
with CFSE and D-MNPs, and one healthy animal was 
injected intra-arterially with MSCs labeled exclusively with 
CFSE to evaluate possible differences due to the D-MNPs.   
9.3.2.1. Intravenous administration route 
Following intravenous jugular injection, no hypointensities in 
T2* weighted images in healthy and ischemic animal brains 
were observed (Figure 99). Since MSCs are injected, till they 
could reach the brain, the organ they have to pass through 
is the lung. Several studies have described the lungs as the 
major obstacle for intravenous cell delivery and because of 
this, a reduced proportion of injected cells could reach the 
arterial circulation and therefore the brain. Cell size and 
receptor-mediated adhesion and/or stem cell type appear 
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to be crucial variables for pulmonary stem cell passage. 
[114,266]   
Considering that MRI did not detect labeled MSCs in brain 
slices, animals were sacrificed and brain, heart and lungs 
were processed for further histological CFSE analysis. No 
CFSE labeled cells were detected in brain and heart using 
fluorescence optical microscopy; however CFSE labeled 
cells were observed along the lungs (Figure 100). All studied 
lung slices showed dispersed labeled MSCs.  
Our results are in concordance with previous studies which 
have demonstrated that most of the mesenchymal stem 
cells injected intravenously get trapped inside the lungs, 
mostly because of the size of the cells. Histochemistry 
techniques are indispensable to assess lung entrapment 
because lung tissue appears as hypointense signal in MR 
images due to its weak proton density and the 
heterogeneity of the tissue (air-tissue interfaces), making not 
possible to track D-MNPs labeled cells with this technique. 
However, at this point it is important to mention that for 
tissue processing, the animal is perfused. In order to wash 
the blood and fix the tissues PBS and paraformaldehyde 4% 
are used, nevertheless lungs are difficult organs to prefund 
so still some blood can be observed in lungs. This is 
traduced in a background of blood for microscopic 
analysis and therefore of iron, which makes Prussian blue 
tissue staining non-specific of MNPs.  Overall, we have 
observed that after a jugular administration of labeled 
MSCs cells are retained in the lungs and no cells were 
detected in the brain or heart.  
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Figure 99: MR T2* weighted images of 3 brain slices 4h after intravenously 
delivery of MSCs labeled with D-MNPs and CFSE in a (A) healthy animal 
and (B) in a ischemic animal. 
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Figure 100: Representative fluorescence optical microscopy of rat lung 
slices where MSCs labeled with CFSE can be observed after jugular 
delivery.   
9.3.2.2. Intra-arterial administration route 
So far, we have studied the fate of labeled cells injected 
intraparenchymally and intravenously, and in this section 
we will track labeled cells which have been injected intra-
arterially.  
The timing of administration was the same as intravenously, 
i.e. 4h after the onset of the stroke in the case of ischemic 
animals, and MRI was performed 4h after the injection for 
ischemic and non-ischemic animals. Thus, following intra-
arterial injection, Figure 101 shows MR T2* weighted images 
4h after intra-arterial delivery of (A) MSCs labeled 
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exclusively with CFSE in a healthy animal, (B) MSCs labeled 
with CFSE and D-MNPs in a healthy animal and (C) MSCs 
labeled with CFSE and D-MNPs in an animal 8h after the 
onset of the cerebral ischemia. 
Differences between groups can be easily observed. 
Ischemic animal after intra-arterial delivery (C) presents 
more hypointensities and therefore more MSCs in the brain 
than the healthy animal (B) after being injected with the 
same number of cells. This observation could be explained 
by the disruption of the BBB and the tissue damage after 
the ischemic process, which could be retaining more cells 
in the brain. However, the healthy animal (B) with an intact 
BBB still presents labeled MSCs along the brain; the 
distribution pattern is more spread than ischemic brain, 
nevertheless cells can still be detected 4h after the 
injection. Figure 101 (A) does not display hypointensities, 
because injected cells were labeled exclusively with CFSE. 
Histochemistry evaluation of the tissue will elucidate MSCs 
distribution along these brains to compare with MRI.  
After MRI scanning, animals were perfused and brain, heart 
and lungs were processed for further histological analysis. 
From one extra animal, kidneys, spleen and liver were also 
processed in order to evaluate cell migration towards those 
organs. Microscopic results revealed that no cells were 
found in kidneys, spleen, liver, heart and lungs, however all 
brain slices showed CFSE labeled cells. MSCs were found 
distributed mostly along the right hemisphere of the brain, in 
agreement with MRI T2* weighted images cell distribution 
(Figure 102).  
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Figure 101: MR T2* weighted images of 3 brain slices 4h after intra-arterial 
delivery of (A) MSCs labeled with CFSE in a healthy animal, (B) MSCs 
labeled with CFSE and D-MNPs in a healthy animal and (C) MSCs labeled 
with CFSE and D-MNPs in an animal 8h after the onset of the cerebral 
ischemia. 
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Figure 102: Fluorescence optical microscopy of brain slices after a intra-
arterial delivery of MSCs (A) labeled exclusively with CFSE in a healthy 
animal, (B) labeled with CFSE and D-MNPs in a healthy animal and (C) 
labeled with CFSE and D-MNPs in a ischemic animal.  
From fluorescence optical microscopy images (Figure 102) 
we can observe that CFSE positive cells show tubular-like 
configuration for all injected animals. This result together 
with the fact that intra-arterial delivery of MSCs provoke 
multifocal ischemias (see previous chapter), could mean 
that injected MSCs are in the vessels, adopting the tubular-
like structure observed, and at the same time occluding 
those vessels.  
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In order to elucidate if the injected cells are in the vessels or 
they have migrated into the brain parenchyma, we 
investigated by immunohistochemistry techniques the 
expression of CD31, which is used primarily to mark 
endothelial cells in histological tissue sections. The 
combination of vessels labeled with CD31 and MSCs 
labeled with CFSE will let us elucidate ex vivo where 
injected cells are. Besides CD31 and CFSE, cell nucleuses 
were stained with Hoechst dye (Figure 104 and Figure 105).  
Figure 103 is a representative brain region image of an 
animal injected with CFSE and D-MNPs labeled MSCs. 
Hoechst nucleuses and CD31 vessels staining are observed 
along all tissue section. After the co-localization (merge) no 
cells were detected out of vessels in this picture, but also in 
other regions of the brain. Moreover, in Figure 103, it is easy 
to note that the coincident vessel and CFSE labeled MSCs 
have a small and similar caliber. It will be interesting to 
observe what would happen if vessel diameter is wider than 
cell size to discriminate if the cells are adhered to the vessel 
wall or stacked there because of their similar size.  
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Figure 103: Injected MSCs labeled with CFSE are localized in the vessel. 
CFSE is co-localized with CD31 and Hoechst. (Scale bar 100μm). 
In Figure 104 a representative brain region where small and 
big vessels can be examined is shown. We can observe that 
the big vessel of the image do not present CFSE positive 
cells, however smaller vessels do display labeled MSCs. 
Small vessels with positive CFSE staining are zoomed in 
Figure 105 and once again, the diameter of the vessel is 
similar to cell dimensions for both cells. Thus, in all brain slices 
studied, all CFSE positive cells were found in the vessels of 
small caliber (Figure 104 and Figure 105) and no cells were 
observed for wider vessels. This finding of MSCs localized in 
the small vessels could explain why intra-arterial injection of 
MSCs provokes multifocal ischemias. 
However at this point we should take into account the 
observer effect. In science, the term “observer effect” refers 
to changes that the act of observation will make on a 
phenomenon being observed. This is often the result of 
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instruments that, by necessity, alter the state of what they 
measure in some manner. This effect in our experiments is 
reflected on the tissue processing protocol used for 
immunohistochemistry analysis. In order to eliminate the 
blood and therefore minimize background fluorescence, 
animals were perfunded with PBS and paraformaldehyde 
4%. The perfusion is performed by injecting transcardially 
these substances, washing the animal blood. This process 
could alter the cell localization because the infusion 
parameters from the pump will be different from the heart 
pumping blood parameters, inducing variability on the cell 
positioning. However, inmunohistochemistry techniques 
require perfunded organs for an efficient marking and clear 
discrimination between structures. According to this, what 
we need is a technique which let us to study the distribution 
of the cells after being injected with the best possible 
resolution and without inducing changes in the tissue. The 
appropriate candidate to study cell positioning after 
injection minimizing tissue processing is the transmission 
electron microscopy.  
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Figure 104: Injected MSCs labeled with CFSE can be found in the small 
vessels. CFSE is co-localizatized with CD31 and Hoechst. (Scale bar 
10μm).  
 
Figure 105: Magnification of Figure 39 for the two positive CFSE cells [1] 
and [2].  
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9.3.3. Transmission electron microscopy (TEM) of 
brain slices after intra-arterial delivery of D-
MNPs labeled MSCs 
Ultrastructural examination of tissues, cells and 
microorganisms plays a vital role in diagnostic pathology 
and biologic research. TEM is used to study the morphology 
of cells and their organelles,[267] which makes this 
technique appropriate for studying cell distribution once 
cells are injected.  
In order to study if the injected cells are in the vessels or 
dispersed in the brain parenchyma, injected MSCs were 
labeled with D-MNPs. In Section 3 we have assessed that 
MSCs labeled with D-MNPs in vitro can be visualized by TEM, 
which makes possible to distinguish between non-labeled 
MSCs and D-MNPs labeled MSCs because of their MNPs 
endosomes encapsulation. This detection ability together 
with the fact that the TEM fixation protocol used lets us to 
keep the brain intact after the animal sacrifice, make this 
technique suitable for elucidating where the injected cells 
are. However, results of this section may be taken carefully 
because so far only one animal was used for TEM 
examination.  
One healthy animal was selected for TEM brain 
examinations 4h after intra-arterial delivery of 1x106 D-MNPs 
labeled MSCs. Administration procedure was performed as 
previously reported, and 4h after cell delivery, MR T2* and T2 
weighted images were acquired to assess MRI cell 
distribution. In previous chapters we have shown that most 
of ischemic animals which have been injected with one 
million cells died within 24h and healthy animals presented 
large multifocal ischemias. However, the study of the stem 
cell administration in a healthy animal was more interesting 
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due to its undamaged vessel structure and intact blood 
brain barrier which could let us understand the interaction 
between MSCs and the brain structures under a non-
pathologic condition. Besides, we have injected 1x106 
labeled cells to make easier the cell detection in the animal 
brain.  
Thus 4h after the intra-arterial injection, MRI scanning was 
performed and T2* weighted images were acquired. All 
right hemisphere and several regions of the left one 
displayed a hypointense dotted pattern as it can be 
observed in Figure 106. After MRI, the animal was sacrificed 
(not perfunded) and several sections (blue squares in Figure 
106) of approximately 3 mm x 3 mm x 3 mm were extracted 
and immediately immersed in fresh glutaraldehyde for 
tissue fixation.  
Electron micrographs of the cortex in a healthy rat injected 
with 1x106 MSCs labeled with D-MNPs revealed the 
presence of the injected cells in the brain parenchyma, a 
representative cell can be observed in Figure 107. This 
micrograph shows one isolated MSC which had travelled 
from the vessels to the parenchyma and is in direct contact 
with the neuropil, where somas and cellular processes can 
be observed.[267] Not only the background color of the 
injected MSC is different from the surrounding, the presence 
of dark endosomes let us its identification as MSC (yellow 
arrows in Figure 107). Zoom of one endosome is shown in 
Figure 108, where it is possible to note the dark dotted 
pattern inside the wrapping endosome membrane. 
Distribution, size and morphology are similar to those 
observed in vitro in Chapters 5 and 6. Close to this 
endosome, 4 mitochondria can be also identified by their 
cristae, demonstrating the well-being of this mesenchymal 
stem cell 4h after being injected.      
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Figure 106: MR T2* weighted images of the healthy rat injected with one 
million D-MNPs labeled MSCs. Blue squares represent the extracted 
sections for further TEM examination.  
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Figure 107: Electron micrograph of rat brain cortex 4h after intra-arterial 
delivery of D-MNPs labeled MSCs, showing one single MSC labeled with 
D-MNPs (yellow arrows) and surrounded by neuropil (NePi). Yellow 
rectangle is zoomed in next figure.   
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Figure 108: Electron micrograph of rat brain cortex 4h after intra-arterial 
delivery of D-MNPs labeled MSCs. Detail of Figure 107, showing D-MNPs 
contained in one endosome (yellow arrow) and several mitochondria 
(green arrows).   
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Labeled cells were found in the brain parenchyma, 
assessing that after an intra-arterial injection of a healthy rat 
MSCs can cross the BBB. However, it was also observed that 
some cells could be producing micro-embolus, as can be 
noted in Figure 109. A vessel surrounded by neuropil can be 
observed. Blue arrow points out the dilatation and magenta 
arrows denote normal vessel morphology before and after 
it. This vessel widening can be observed in more detail in 
Figure 110. Mainly 3 different cell types appeared in this 
expansion; red blood cells (RB), several platelets nucleus 
(P), one entire mesenchymal stem cell (A) and two 
disrupted MSCs (B and C). It is possible to note dotted 
hypointensities pointed with a yellow arrow in this picture; 
however it will be necessary to zoom in to compare them 
with previous in vitro/in vivo D-MNPs dotted patterns. In 
Figure 111 a magnification of these hypointensities can be 
observed more in detail. Magenta asterisks indicate the 
boundary of the cell membrane of MSC “A”, in which 
cytoplasm some endosomes containing D-MNPs can be 
recognized. Close to this cell, MSC “B” has a diffuse cell 
membrane boundary and scattered dotted pattern is 
pointed out with cyan arrows. Because the spread 
hypointensities are not contained in an endosome but still 
localized in this cell, and the cell membrane boundary is 
not well-defined, we could think that this MSC is in 
apoptosis. However, our assumption is based on cell-
endosome structure and membrane morphology because 
we do not have information about the state of its 
mitochondria. Apart from the well-being of these MSCs, the 
mechanism that is provoking this vessel broadening must be 
analyzed, and for this task it is necessary to examine also 
the morphology after/before the clot. A section of the non-
expanded vessel is shown in Figure 112. Neuropil surrounds 
the vessel and in the inside a tubular-fiber structures can be 
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observed. This is fibrin, a fibrous, non-globular protein 
involved in the clotting of blood. It is formed by the action 
of the protease thrombin on fibrinogen which causes the 
latter to polymerize and the polymerized fibrin together with 
platelets forms a clot. In Figure 112 dispersed platelets 
nucleus and two tubular structures corresponding to fibrin 
fibers at the entrance of the extension can be noted. Thus 
gathering all electron microscopy images related to the 
dilatation, fibrin fibers (Figure 110 ), nucleus of the platelets 
(Figure 112) and MSCs, all are forming the clot, which is 
expanding the vessel in the scanned region.  
This fibrin reaction could be the reason of the multifocal 
ischemias observed in MRI for healthy animals injected with 
MSCs. In the cannulation procedure we have followed in 
this work, we have always administered antiaggregants 
prior to cell delivery to prevent blood clotting, however 
Heparin concentration administered may not be enough to 
prevent clot formation or the injected mesenchymal stem 
cells may have an influence in this fibrin reaction. Moreover, 
in the previous chapter we have studied the influence of 
the heparin in the classical administration and in the 
magnetic vectorization in an ischemic brain; however we 
did not find any macroscopic difference in brain cell 
retention through MRI after using this antiaggregant drug.  
So, attending to TEM results, most of MSCs observed in 
ultrathin sections are in the brain parenchyma, however it 
was also possible to observe one vessel occlusion where 
MSCs were also involved. This last fact could explain the 
multifocal ischemias observed in MRI after cell 
administration however TEM experiments were performed 
by injecting 1x106 instead 0.25x106 MSCs which was the 
compromise we have established between safety and 
efficiency for injection. In addition, it is important to take 
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into account that only one animal has been injected and 
examined through electron microscopy, and these results of 
parenchyma migration and vessel occlusion may be taken 
carefully. Further studies are needed to confirm these 
preliminary results.   
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Figure 109: Electron micrograph of rat brain cortex 4h after intra-arterial 
delivery of D-MNPs labeled MSCs. It can be observed a neuron nucleus 
(Ne), surrounded by neuropil (NP). Magenta arrows point out a vessel 
with an expansion (blue arrow) due to MSCs presence.  
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Figure 110: Electron micrograph of rat brain cortex 4h after intra-arterial 
delivery of D-MNPs labeled MSCs, zoom of Figure 109. Red blood 
corpuscles (RB), Platelets nucleus (P), mesenchymal stem cells (A, B, C) 
and yellow arrows point out D-MNPs.  
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Figure 111: Electron micrograph of rat brain cortex 4h after intra-arterial 
delivery of D-MNPs labeled MSCs, zoom of Figure 110. Endosomes of “A” 
MSC containing D-MNPs (yellow arrows), boundary of cellular membrane 
of MSC “A” denoted with magenta asterisks, Opened endosomes of a 
dead MSC “B” (cyan arrows).  
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Figure 112: Electron micrograph of rat brain cortex 4h after intra-arterial 
delivery of D-MNPs labeled MSCs, zoom of Figure 109. A vessel 
surrounded by neuropil (NePi) is observed. Fibrin  
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9.4. Conclusions 
Cell tracking of labeled MSCs following different 
administration routes is essential for a further understanding 
of the interaction between injected and host cells. In 
previous chapters, we had demonstrated the efficient 
labeling of MSCs with D-MNPs for in vivo MRI cell tracking. In 
this chapter we have assessed the feasibility of tagging 
MSCs with D-MNPs and also with CFSE, which let us not only 
in vivo cell tracking, ex vivo MSCs identification as well.  
In order to assess the efficiency of this double labeling, 
intraparenchymal injections for MSCs delivery were 
performed. Ex vivo histology demonstrated that injected 
cells were still labeled with D-MNPs 4h after the injection 
and no particles were found out of the cells assessed by 
CFSE and Prussian blue staining, therefore MRI in vivo signal 
corresponds to labeled MSCs and not to free particles.  
Intraparenchymal injection is a feasible administration 
route, however it is not the preferred for stem cell delivery 
due to the high invasiveness of the technique. Less invasive 
routes for stem cell delivery are intravenous and intra-
arterial injection. We have studied the fate after the 
injection of labeled cells through jugular vein and through 
the internal carotid artery and we have found important 
differences between them. On one hand, we have 
assessed by MRI and/or histochemistry techniques that cells 
injected through jugular vein were found in the lungs and 
no cells were detected in the brain, for healthy and 
ischemic animals.  On the other hand, following the intra-
arterial route we have demonstrated that, for ischemic or 
non-ischemic animals, injected MSCs are found in the brain 
and no cells can be detected in other organs, opening a 
big window for further stem cell therapy administration. 
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Because of the blood brain barrier integrity in healthy 
animals and its disruption in ischemic ones, we also studied 
the localization of the injected cells by 
immunohistochemistry techniques after an intra-arterial 
administration. By CD31 staining and CFSE labeling it was 
possible to assess that injected cells are found in small 
vessels along the brain while large ones do not express CFSE 
positive cells. This selective intra-vessel localization could 
explain the multifocal ischemias observed in ischemic and 
non-ischemic intra-arterial injected rats, however because it 
is necessary to perfuse de animal to perform 
immunohistochemistry, other technique for corroborating 
this result was studied.  
Preliminary results of electron microscopy have shown that  
MSCs labeled with D-MNPs are able to migrate into brain 
parenchyma in a healthy animal after an intra-arterial 
delivery of one million cells. However, TEM images of same 
animal also revealed vessel occlusions with MSCs and fibrin 
reaction associated which could explain previous results of 
multifocal ischemias.  
In conclusion, for a non invasive brain localization of 
injected MSCs, intra-arterial injection is the most efficient 
administration route. On the other hand, MSCs delivered 
following intra-jugular injection results in cell entrapment in 
the lungs, and no cells reach the brain.  
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10. Neuroreparation 
study in an animal 
model of ischemic stroke 
using mesenchymal 
stem cells labeled with 
Dextran-coated 
superparamagnetic 
nanoparticles 
10.1. Hypothesis 
In previous chapters we have assessed the fate and the 
kinetics of labeled mesenchymal stem cells after an intra-
arterial (ia) and intravenous (iv) administration routes. In this 
chapter, MSCs were ia and iv delivered during the acute 
phase in a cerebral ischemia model to investigate whether 
the cell distribution, and therefore administration route may 
improve the therapeutic outcome. MRI studies, behavioral 
tests, histological examinations and blood serum 
determinations were performed to evaluate the 
therapeutic benefits of the treatment.  
 284 
 
10.2. Materials & Methods 
10.2.1. Cell labeling preparation 
10.2.1.1. Cell lines 
All experiments were performed using Mesenchymal Stem 
Cells (MSCs) purchased from Cultrex, Trevigen and were  
cultured in IMDM (78%), Fetal bovine serum (10%), Horse 
serum (10%), Penicillin-Streptomycin (1%) all from Gibco 
Invitrogen, and Amphotericin-B (1%) from Sigma-Aldrich. 
Cell passage numbers between 7 and 18 were used in 
these experiments.  
10.2.1.2. Dextran-coated superparamagnetic 
nanoparticles 
Dextran coated MNPs (D-MNPs) were synthesized in the 
Clinical Neuroscience Research Laboratory following the in 
situ protocol described in Chapter 4.  
10.2.1.3. Preparation of Poly-L-lysine hydrobromide-
coated D-MNPs 
1.5 μg/mL of Poly-L-lysine hydrobromide (PLL) (Sigma-
Aldrich) was used. One hour prior to cell incubation, D-
MNPs were mixed with cell medium and with 1.5 μg/mL PLL 
and vigorously shaken.  
10.2.1.4. Cell labeling with PLL-coated D-MNPs 
MSCs were labeled following the protocol described 
elsewhere[227] with slight modifications. Cells were 
incubated with 1.5 g/mL PLL and 100 μg/mL of D-MNPs for 
24h. The MNP containing medium was removed and the 
cells were 3 times washed with 1.5 mL of Phosphate 
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Buffered Saline (PBS without Mg2+ and Ca2+, Gibco 
Invitrogen) to remove non-attached MNPs. After washing, 
the cells were left overnight (12h) in 1 mL of fresh medium. 
Cells were washed once with 1.5 mL of PBS and 0.5 mL of 
EDTA-trypsin (Gibco Invitrogen) was added to detach the 
cells from the well. The trypsin was neutralized with fresh 
medium and the detached cells were collected in a Falcon 
tube. After a mild centrifugation, the supernatant was 
discarded and the cells were resuspended in PBS 1x. Cell 
count was performed with Trypan Blue staining and a 
Neubauer chamber. Samples were diluted 1:5 with PBS and 
1:2 with Trypan Blue.  
10.2.2. Animal management 
In this study we have used 53 Wistar rats (Harlan) with a 
weight of 288±9 g. Animals were kept at controlled 
conditions of temperature (22±1 °C) and humidity (60±5%), 
with a 12/12 hours light/dark cycle, and granting free 
access to food (commercial chow pellets) and tap water. 
For surgery and MRI, rats were anesthetized with sevoflurane 
(3% in 70% N2O and 30% O2). Rectal temperature was 
monitored and maintained at 37±0.5 °C with a feedback 
controlled heating system (1025 system, SA Instruments). At 
the end of the procedures animals were sacrificed under 
deep anesthesia (8% sevoflurane). Experimental protocols 
were approved by the local Animal Care Committee 
according to the Spanish and European Union (EU) rules 
(86/609/CEE, 2003/65/CE, 2010/63/EU, RD 1201/2005 and 
RD53/2013. 
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10.2.3. Model of focal transient ischemia in the rat 
Transient focal ischemia was induced in rats by intraluminal 
occlusion of the middle cerebral artery (tMCAO), 
performed as previously described[171] with several 
modifications. In order to monitor the relative cerebral 
blood flow (CBF) during the surgery, a laser-Doppler flow 
probe (tip diameter 1 mm) attached to a flow meter 
(PeriFlux 5000; Perimed AB) was located over the thinned 
skull, over the middle cerebral artery territory 
(approximately 4 mm lateral to bregma). To perform 
tMCAO, both vertebral arteries and contralateral common 
carotid remained intact all surgical procedures.  
Under a surgical microscope, common carotid, external 
carotid, and the internal carotid of the left side were 
dissected from connective tissue through a midline neck 
incision. Left external carotid and pterygopalatine arteries 
were separated and tied permanently with 6-0 silk sutures, 
showing a CBF reduction of 20% measured by laser 
Doppler. A silicon rubber-coated monofilament 
(403512PK5Re; Doccol Corporation) was inserted through 
the external carotid into the left common carotid artery 
and advanced into the internal carotid 17-20 mm from the 
bifurcation to occlude the origin of the MCA. The 
intraluminal filament was removed after 45 minutes of 
occlusion. Common carotid artery was perfunded 
immediately after removing the intraluminal filament.  
Only animals with a CBF reduction measured by laser 
Doppler higher than 60% and with reperfusion after 
occlusion, MCA occluded on MR angiography and a 
infarct volume during the occlusion between 25-45% of the 
hemisphere measured on ADC maps were included in this 
study. 
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10.2.4. Administration delivery routes 
Cells were administrated 4h after the perfusion of the ACM. 
10.2.4.1. Intra-arterial injection 
Cannulation for intra-arterial delivery of labeled MSCs is 
performed in the left side where pterigopalatin and external 
carotid arteries were already sutured during tMCAO 
procedures.  
Ipsilateral common carotid is temporally ligated to insert the 
cannula for the MSCs intra-arterial delivery. A 0.28 mm ID & 
0.61 mm OD catheter (Smiths) connected to a 30G needle 
and a 1 mL syringe was inserted into the stump of ECA 
through an incision on the vessel under the operation 
microscope, and was tightened to ECA by a 6-0 silk suture. 
The catheter went forward into ICA till reach the branch of 
common and internal carotid. This tube was filled with 
heparinized physiological saline to prevent air bubble and 
coagulation. Common carotid is opened and a small blood 
reflux in the catheter could be observed. The syringe was 
filled with labeled cells in PBS and using slow hand injection 
over 15 minutes, 0.25x106 labeled cells in 300 μL of PBS were 
delivered into the internal carotid.  When the injection is 
finished, common carotid artery is temporally ligated to 
remove the catheter. EC is tied and common carotid artery 
is opened again.  
10.2.4.2. Intravenous injection 
Intravenously administration was performed through the 
jugular vein. A 0.5 cm incision was made in the animal’s 
neck just above the clavicle 1 cm to both left and right of 
the midline. Subcutaneous fat was cut and the jugular vein 
was revealed. A 30G gauge needle was used for every 
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injection since after withdrawal; the puncture rapidly closes 
preventing bleeding. . One million cells in 300 μL of PBS were 
administered manually in less than 1 min. 
10.2.5. Magnetic resonance imaging 
Infarct size, angiography and cell tracking were assessed by 
magnetic resonance imaging. Magnetic resonance 
imaging studies were conducted on a 9.4-T horizontal bore 
magnet (Bruker BioSpin, Ettligen, Germany) with 20 cm wide 
actively shielded gradient coils (440 mT/m). Radio-
frequency transmission was achieved with a birdcage 
volume resonator; signal was detected using a four-
element surface coil, positioned over the head of the 
animal, which was fixed with a teeth bar, earplugs, and 
adhesive tape. Transmission and reception coils were 
actively decoupled from each other. Gradient-echo pilot 
scans were performed at the beginning of each imaging 
session for accurate positioning of the animal inside the 
magnet bore.  
Apparent diffusion coefficient maps were acquired using a 
spin-echo echo-planar imaging sequences with the 
following acquisition parameters: FOV 24 x 16 mm2, image 
matrix 96 x 64 (in plane resolution 200mm/pixel x 
200mm/pixel), 14 consecutive slices of 1mm thickness, 
repetition time 4 s, 4 averages, echo time 26.91 ms, spectral 
bandwidth 200.000 Hz and 7 diffusion b values: 0; 300; 600; 
900; 1200; 1600 and 2000. Diffusion-weighted images were 
acquired during the ACM occlusion.  
To evaluate the status of the ACM occlusion in a 
noninvasive manner, the TOF-MRA was performed.  The 
MRA scan was performed with a 3D Flash sequence with 
the following acquisition parameters: FOV 30.72 x 30.72 x 14 
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mm3, image matrix 256 x 256 x 58 (in plane resolution 120 
mm/pixel x 120 mm/pixel x 241 mm/pixel), repetition time 15 
ms, 2 averages and echo time 2.5 ms. MRA was performed 
during ACM occlusion and 24h, 1, 3, 7 and 14 days after the 
ischemia. 
T2-weighted images were acquired using a multislice 
multiecho spin-echo sequence with the following 
acquisition parameters: FOV 19.2 x 19.2 mm2, image matrix 
192 x 192 (isotropic in-plane resolution of 100 μm/pixel x 100 
μm/pixel), 14 consecutive slices of 1mm thickness, repetition 
time of 3 s, and 16 echoes with 9 ms of echo time. T2-
weighted images were acquired 24h, 1, 3, 7 and 14 days 
after the onset of the ischemia. 
T2*-weighted axial images were acquired using a multi 
gradient echo sequence with the following acquisition 
parameters: FOV 19.2 x 19.2 mm2, image matrix 192 x 192 
(isotropic in-plane resolution of 100 μm/pixel x 100 μm/pixel), 
14 consecutive slices of 1mm thickness, repetition time of 
1.5 s, and 16 echoes with 2.9 ms. T2*-weighted images were 
acquired 4h after the MSCs administration and 24h, 1, 3, 7 
and 14 days after the onset of the ischemia. 
Post-processing of all images was performed using ImageJ 
software (Rasband, W. NIH). 
10.2.6. Functional test: Cylinder test 
The Cylinder test is designed to evaluate locomotor 
asymmetry in rodent models of CNS disorders. As the animal 
moves within an open-top, clear plastic cylinder, its forelimb 
activity while rearing against the wall of the arena is 
recorded. Forelimb use is defined by the placement of the 
whole palm on the wall of the arena, which indicates its use 
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for body support. Forelimb contacts while rearing are 
scored with a total of 10 contacts recorded for each 
animal. The number of impaired and non-impaired forelimb 
contacts is calculated as a percentage of total contacts. 
Cylinder test was performed prior to tMCAO and 7 and 14 
days after the ischemia. 
10.2.7. Blood serum determinations: Vascular 
endothelial growth factor (VEGF) and 
interleunkin-6 (IL-6) 
Venous blood was collected from the tail vein prior to 
tMCAO, 4h, 8h, 24h, 1day, 3 days, 7 days and 14 days after 
the onset of the ischemia. Blood serum was obtained and 
stored at -80ºC for further VEGF and IL-6 determinations. 
ELISA assays were performed using Quantikine ELISA Rat 
VEGF kit (R&D Systems, Inc.) and Quantikine ELISA Rat IL-6 kit 
(R&D Systems, Inc.) respectively.  
10.2.8. Immunohistochemistry processing 
Rats were anesthetized under sevofluorane (8%), perfused 
transcardiacally with 4% paraformaldehyde (PFA) in 0.1 M 
PBS, the brains were removed, postfixed (4% PFA, 4°C, 24 h), 
cryopreserved (Sucrose 35%), included in OCT and stored at 
-80ºC. 15 μm thick axial sections were cut by a cryostat and 
dried in an oven at 38ºC for 4h. Slices were rehydrated in 
PBS, exposed to Citrate buffer (0.01 M, pH 6.0) (Dako) for 20 
min at 99ºC and washed with PBS 1x. 
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10.2.8.1. Immunohistochemistry processing for Ki-67 and 
CD31 staining dyes 
Slides were incubated first with Rabbit polyclonal antibody 
to CD31 (Abcam) (1:25), Mouse monoclonal antibody to ki-
67 (Dako) (1:30), normal horse serum (15%), normal goat 
serum (15%), Triton X-100 (0.2%) and PBS overnight. The slides 
were then incubated at room temperature for 1h with 
biotinylated horse anti-Mouse IgG antibody (Vector) 
(1:200), DyLight 488 Goat anti-Rabbit IgG antibody (Vector) 
(1:100), Triton (0.2%) and PBS. After 3 washes with PBST, slides 
were incubated with dylight 594 streptavidin (Vector) 
(1:500), Triton (0.2%) and PBS. Then, 10 μL of Hoechst 
(Invitrogen) in 60 mL of PBS 1x were added to the slides, 
incubated for 15 min and washed afterwards with PBS. 
Slides were mounted with fluorescence mounting medium. 
Photographs were taken using a Leica DMI 6000 B and 
processed using LAS AF V.1.0.0 software (Leica 
Microsystems). 
10.2.8.2. Immunohistochemistry processing for Ki-67 and 
doublecortin (DCX) staining dyes 
Slides were incubated first with Rabbit polyclonal antibody 
to DCX (1:25), Mouse monoclonal antibody to ki-67 (Dako) 
(1:30), normal horse serum (15%), normal goat serum (15%), 
Triton X-100 (0.2%) and PBS overnight. The slides were then 
incubated at room temperature for 1h with biotinylated 
horse anti-Mouse IgG antibody (Vector) (1:200), DyLight 488 
Goat anti-Rabbit IgG antibody (Vector) (1:100), Triton (0.2%) 
and PBS. After 3 washes with PBST, slides were incubated 
with dylight 594 streptavidin (Vector) (1:500), Triton (0.2%) 
and PBS. Then, 10 μL of Hoechst (Invitrogen) in 60 mL of PBS 
1x were added to the slides, incubated for 15 min and 
washed afterwards with PBS. Slides were mounted with 
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fluorescence mounting medium. Photographs were taken 
using a Leica DMI 6000 B and processed using LAS AF 
V.1.0.0 software (Leica Microsystems)  
10.2.9. Statistical analysis 
The statistical analyses of the data were performed using 
GraphPad Prism 5.01 (GraphPad Software, Inc). For 
descriptive analyses, means and standard deviations were 
calculated for the normally distributed continuous variables. 
For confirmatory analyses one-way ANOVA was performed 
to calculate overall p-values for the comparison of the 
different groups for each variable. The global significance 
level for all statistical test procedures was chosen as =0.05. 
10.2.10. Timeline of the study 
In order to evaluate the therapeutic properties of different 
administration routes for of MSCs in an animal model of 
ischemic stroke, 4 groups were studied: 
o Control 1 (n=6): tMCAO 
o Control 2 (n=6): tMCAO which were injected i.a. with 
300 μL of PBS 4h after the onset of the ischemia. 
o MSCs ia (n=6): tMCAO which were injected i.a. with 
0.25x106 of MSCs labeled with D-MNPs dispersed in 
300 μL of PBS 4h after the onset of the ischemia. 
o MSCs iv (n=6): tMCAO which were injected i.v. with 
1x106 of MSCs labeled with D-MNPs dispersed in 300 
μL of PBS 4h after the onset of the ischemia. 
Experimental procedures diagram can be observed in 
Figure 113.  
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Figure 113: Timeline evaluation of the therapeutic benefits of the different 
routes for MSCs administration in an animal model of ischemic stroke.  
 
Cylinder test was performed prior to tMCAO to assess the 
locomotor symmetry of the animals and on the days 7th and 
14th to assess the symmetry/asymmetry due to the stem cell 
administration. The infarct size and brain edema follow-up 
were performed during the occlusion by a MR-DWI 
sequence and by a T2-weighted images on the 1st, 3rd, 7th 
and 14th day after the ischemia induction. Moreover, T2*-
weighted images were acquired to track the injected cells 
and to evaluate hemorrhagic lesions 8h, 1 day, 3 days, 7 
days and 14 days after the ischemia. We have also 
included MR angiography to evaluate the occlusion during 
the tMCAO and to study morphologic changes on the 
vessels during the following-up of the animals.  Venous 
blood samples were collected during the occlusion, 4h, 8h, 
1 day, 3 days, 7 days and 14 days after the onset of the 
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insult for further VEGF and IL-6 determinations. And finally, 
on the 14th day, animals were transcardiacally perfused 
and their brains processed as described previously for 
further histology analysis.  
10.3. Results 
10.3.1. Cell tracking after intra-arterial 
administration 
D-MNPs labeled MSCs were easily detected by MR T2* 
weighted images 4h, 24h and 3 days after the injection.. 
Next timepoint is 7 days, and it was not possible to observe 
labeled cells in all animals scanned (Figure 114).  
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Figure 114: MR T2* weighted images of one ischemic animal 
injected with 0.25x106 D-MNPs labeled MSCs at different 
timepoints. 
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10.3.2. Effects on ischemic lesion volume 
Infarct volume sizes were measured on ADC maps, 
calculated  from MR DWI, acquired during the occlusion 
(t=0), and on T2 maps, obtained from T2 weighted images at 
days 1, 3, 7 and 14 after the induction of the ischemia. In 
Table 11 and Figure 115, infarct volume sizes are expressed 
in percentage respect the hemisphere volume corrected 
by edema factor. 
 Control 1 Control 2 MSCs ia MSCs iv 
 Mean SD Mean SD Mean SD Mean SD 
0 (tMCAO) 32 6 33 6 35 2 35 7 
Day 1 25 5 30 10 32 3 27 7 
Day 3 30 5 37 11 36 3 32 10 
Day 7 20 8 22 11 22 3 18 11 
Day 14 15 5 19 11 19 4 15 10 
 
Table 11: Infarct volumes (% hemisphere) measured from MR ADC and T2 
maps for all groups.  
 
Figure 115: Infarct volumes (% hemisphere) measured from MR ADC and 
T2 maps for all groups.   
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No infarct volume reduction compared to control was 
observed 14 days after the onset of the ischemia and 
mesenchymal stem cell administration in any group (Figure 
116). Infarct volumes for intra-arterial administration of PBS 
or MSCs are slightly increased respect to control or 
intravenous administration of MSCs, however results are not 
statistically significant.  
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Figure 116: Representative MRI of each group at different time points. 
tMCAO corresponds to ADC maps and 24h, 3days, 7days and 14days to 
T2 weighted images.  
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10.3.3. Effects on edema formation 
Brain edema volume sizes were measured on T2 maps, 
obtained from T2 weighted images at days 1, 3, 7 and 14 
after the induction of the ischemia. Edema volumes were 
calculated as the increase of ipsilateral hemispheric volume 
respect to contralateral hemispheric volume expressed in 
percentage (Table 12 and Figure 117). 
 Control 1 Control 2 MSCs ia MSCs iv 
 Mean SD Mean SD Mean SD Mean SD 
Day 1 7 3 9 5 12 3 7 3 
Day 3 9 3 11 5 13 2 10 5 
Day 7 2 3 1 2 2 1 1 2 
Day 14 -4 1 -4 2 -4 1 -4 2 
 
Table 12: Edema volume formation (% of the increase of ipsilateral 
hemispheric volume respect to contralateral hemispheric volume).  
 
Figure 117: Edema volume (% of the increase of ipsilateral hemispheric 
volume respect to contralateral hemispheric volume). 
No edema volume reduction was observed after MSCs 
intra-arterial or intravenous administration in the acute 
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phase of the cerebral ischemia. 24h after the ischemia and 
cell delivery, a significant increment of the edema volume 
formation following intra-arterial delivery of mesenchymal 
stem cells was observed (*p<0.05).  
10.3.4. Cylinder test 
Cylinder test was performed prior to tMCAO (Pre-ischemia) 
and 7 and 14 days after the ischemia by counting the 
number of forelimb contacts. The number of impaired and 
non-impaired forelimb contacts is calculated as a 
percentage of total contacts (Table 13 and Figure 118). 
 Control 1 Control 2 MSCs ia MSCs iv 
 Mean SD Mean SD Mean SD Mean SD 
Pre-isch 48 2 50 5 51 4 50 4 
Day 7 65 19 63 8 62 15 57 13 
Day 14 64 17 63 6 73 13 58 5 
 
Table 13: Edema formation (% of the increase of ipsilateral hemispheric 
volume respect to contralateral hemispheric volume). 
 
Figure 118: Use of impaired forelimb (%) in the cylinder test. 
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No significant differences in functional recovery determined 
by cylinder behavioral test were observed between groups. 
Attending to the obtained results, i.v. administration of MSCs 
shows a reduction on the use of impaired forelimb, however 
not statistically significant.  
10.3.5. Blood serum determinations: VEGF and IL-6 
Blood serum samples were evaluated for detectable levels 
of VEGF and IL-6 with its respective ELISA kit and all samples 
measured showed lower levels than the detectable for 
both assays. (31.2 pg/mL for VEGF ELISA kit and 62.5 pg/mL 
for IL-6 ELISA kit) 
10.3.6. Immunohistochemistry 
Subventricular region of the contralateral and ipsilateral 
ventricles were examined with doublecortin (DCX) and Ki-
67 staining in order to evaluate the neurogenesis. In Figure 
119 a representative image of each group is shown. DCX 
and Ki-67 co-localization seemed to be higher for the 
treated groups compared to control, and specially the DCX 
staining, marking neuronal precursor cells and immature 
neurons, however we did not perform a quantification. 
(Figure 119)   
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Figure 119: Immunohistochemistry of subventricular zone to evaluate the 
neurogenesis by using DCX and Ki-67. Representative pictures of the 
different groups corresponding to the red rectangle in the scheme. 
(Scale bar 50 μm) 
Infarct and peri-infarct regions were observed for 
angiogenesis evaluation by studying the co-localization of 
CD31 and DCX. No differences in Ki-67 and CD31 were 
observed, therefore, no differences in angiogenesis were 
seen between groups. (Figure 120).  
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Figure 120: Immunohistochemistry of peri-infarct region to evaluate the 
angiogenesis by using CD31 and Ki-67. Representative pictures of the 
different groups corresponding to red rectangles in the scheme. (Scale 
bar 50 μm) 
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10.4. Discussion 
Mesenchymal stem cells have received special attention 
last years as a therapeutic candidate for stroke due to their 
possible multi-mechanistic effects on the damaged brain. 
However, several parameters as therapeutic window, cell 
dosage or administration route are still under discussion. In 
previous chapters we have reported the relationship 
between safety and cell dosage for intra-arterial and 
intravenous delivery routes and moreover, we have studied 
the fate of these injected cells by using superparamagnetic 
nanoparticles. In this chapter, we have compared the 
outcome after intra-arterial and intravenous injection of 
labeled mesenchymal stem cells in terms of functional 
recovery, reduction of ischemic lesion size, edema 
formation and also evaluating the neurogenesis and 
angiogenesis 14 days after the ischemia.  
Several groups have studied the therapeutic window for 
stem cells administration in animal models of cerebral 
ischemia, suggesting that an early intervention could 
reduce lesion size and improve functional 
outcome.[119,268] Considering these results we have 
injected D-MNPs labeled MSCs 4h after the onset of the 
ischemia. Cell dosage for i.a. delivery route is limited by the 
safety of the injection reported in the previous chapter. 
Thus, 0.25x106 D-MNPs were i.a. injected, while we 
considered 1x106 for iv administration. 
We have assessed that after an intra-arterial injection of D-
MNPs labeled MSCs it is possible to track administered cells 
in vivo with MRI. We have observed that all animals injected 
following intra-arterial route with labeled cells displayed 
brain hypointensities for the 3 days after the administration 
and, on the other hand, in the animals injected 
 305 
 
intravenously it was not possible to detect labeled cells in 
brain. These two facts have demonstrated that the fate 
after delivery is determined by the injection site and also, it 
opened the possibility to compare ia and i.v. administration 
routes of MSCs for cerebral ischemia therapy.  
In this chapter we have studied the neuroreparation after 
an ischemic event by measuring the infarct volume, edema 
formation and functional recovery. No significant 
differences in infarct volume reduction and edema 
formation were observed for treated and non-treated 
animals, although i.a. delivery has shown bigger infarct 
volumes and edema formation than control or i.v. 
administration. On the other hand, a slightly improvement in 
functional recovery was observed for i.v. administered cells, 
but not statistically significant. These results are in 
consonance with previous studies that have reported that 
stem cell therapies improved neurological function 
recovery without the reduction of lesion volume.[269-271]  
Parameters such as stem cell type, dose, therapeutic 
window, and administration route have shown high 
influence on infarct volume reduction studies however, 
most of them cannot be compared because the initial 
conditions are different.[261,268,269,272,273] But favorable 
effects on behavioral outcomes after an ischemic insult are 
normally associated with regenerative processes onto the 
microenvironment, as neurogenesis and angiogenesis. 
[62,274,275]   
Thus, in our study we have assessed that treatment with 
MSCs significantly increased the number of Ki-67 and DCX 
immunoreactive area in the ipsilateral subventricular zone 
suggesting that MSC treatment enhanced endogenous 
neurogenesis, but no differences between intra-arterial and 
intravenous administration were found. On the contrary, 
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CD31 combined with Ki-67 did not show an increase in the 
angiogenesis process in treated animals compared to 
control 14 days after cerebral ischemia.  
Furthermore, VEGF and IL-6 were analyzed in blood serum 
samples. VEGF is an angiogenic and neuroprotective factor 
that increase axonal outgrowth, block neuronal apoptosis 
and increase neurogenesis, thus promoting neuroprotection 
from stroke.[156] In this work we have previously 
demonstrated that D-MNPs labeled MSCs secrete same 
levels of VEGF than non-labeled cells. Thus, at this point the 
study of VEGF levels after MSCs administration was crucial 
for further understanding of the stem cells therapeutic 
mechanism. However, blood serum samples showed lower 
levels than the detectable by ELISA technique. Other 
studies have determined VEGF levels by measuring brain 
sections by ELISA instead by blood serum.[276] Besides 
VEGF, IL-6 was determined in blood serum samples because 
its demonstrated relationship with pro- and anti-
immflamatory effects following focal ischemia. Serum levels 
measurements of IL-6 were lower than the resolution limit of 
the ELISA kit. As happened before with VEGF determination, 
brain sections would report values for measuring using ELISA 
assays.     
Collectively, our data indicates that intravenous 
administration of 1x106 MSCs slightly improve functional 
outcome after cerebral ischemia, and that the intra-arterial 
or intravenous delivery of mesenchymal stem cells 
promotes neurogenesis measured 14 days after the 
injection.  
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10.5. Conclusions 
In this study we have compared intra-arterial and 
intravenous administration of MSCs for the therapy of focal 
cerebral ischemia. Only cells injected i.a. reached the brain 
and were detectable for 3 days after the delivery, 
guaranteeing the cellular proximity to the injury site.  
Under our experimental conditions and by using dextran-
coated superparamagnetic nanoparticles, we have 
assessed that the local effect of MSCs injected following i.a. 
route did not improve the outcome after a cerebral 
ischemia compared to a systemic administration following 
the i.v. route.  
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General conclusions 
1. Three types of superparamagnetic nanoparticles 
coated with different polymers, dextran, pluronic F127 
and tetronic 908, have been developed and 
characterized for further biological and biomedical 
applications as MRI contrast agents.   
2. The optimization procedure and in vitro validation of 
our synthesized superparamagnetic nanoparticles have 
been performed in mesenchymal stem cells and neural 
stem cells assessing the biocompatibility of these 
nanoparticles for cell labeling.  
3. We have assessed in vitro the feasibility of label and 
detect mesenchymal stem cells after proliferation when 
labeled with dextran- coated superparamagnetic 
nanoparticles without harmful effects. In addition, it is 
possible to vectorize these labeled cells with magnetic 
fields in vitro. 
4. We have demonstrated that MSCs labeled with D-MNPs 
can be visualized in vivo by T2 and T2* weighted images 
in MRI, and the hypointensities observed correspond to 
labeled cells and not to free superparamagnetic 
nanoparticles. 
5. A model of intra-arterial administration of stem cells with 
low associated risks and high brain delivery efficiency 
has been developed for further cerebral ischemia 
treatment studies. 
6. The doses of mesenchymal stem cells for intra-arterial 
administration as a potential treatment for ischemic 
stroke are determined by the presence of multifocal 
ischemias, being 2.5x105 cells the highest administrable 
dose. 
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7. We have assessed that the brain targeting with labeled 
mesenchymal stem cells has not been increased by the 
use of the magnetic vectorization in vivo.  
8. We have observed that after an intravenous 
administration of labeled mesenchymal stem cells, no 
cells were found in the brain while cells were detected 
in the lungs.  
9. Dextran-coated superparamagnetic nanoparticles 
labeling has also allowed the visualization of injected 
cells for electron microscopy ex vivo analysis. Our first 
results suggested that some labeled MSCs remained in 
the vessels and some crossed to the brain parenchyma 
4h after an intra-arterial administration.  
10. Superparamagnetic nanoparticles are a valuable tool 
for distinguishing the fate between injected cells 
following intra-arterial and intravenous administration in 
an animal model of stroke.  
11. Under our experimental conditions, we have not 
observed that the intra-arterial administration of 
mesenchymal stem cells presents more advantages 
than an intravenous delivery in terms of safety and 
outcome after cerebral ischemia.  
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Conclusiones generales 
1. Hemos desarrollado y caracterizado 3 tipos de 
nanopartículas superparamagnéticas recubiertas de 
diferentes polímeros, dextran, pluronic F127 y tetronic 
908 para uso biomédico como agentes de contraste 
de resonancia magnética nuclear. 
2. Estas nanopartículas se han probado en cultivos 
celulares de células madre mesenquimales y de células 
madre neurales, demostrando su alta 
biocompatibilidad y sus posibles aplicaciones para 
seguimiento celular.  
3. Las células madre mesenquimales marcadas con 
nanopartículas recubiertas de dextran han sido 
examinadas tras diversas divisiones celulares 
asegurando que sus propiedades no se ven afectadas 
por el marcaje. Además, la vectorización magnética 
de estas células no sólo es posible sino que no afecta a 
su viabilidad en estudios in vitro. 
4. Diversos experimentos in vivo, han puesto de manifiesto 
que es posible la visualización de las células marcadas 
tras ser inyectadas, y que las hipointensidades 
observadas por resonancia magnética se 
corresponden a células marcadas y no a 
nanopartículas libres.  
5. Hemos desarrollado un modelo de administración intra-
arterial de células en animales con isquemia cerebral 
que minimiza los riesgos asociados a la inyección y que 
asegura la presencia de células en el cerebro. 
6. Las dosis de células madre mesenquimales 
administradas intra-arterialmente como futura opción 
terapéutica en la isquemia cerebral, están limitadas 
por la posibilidad de inducción de isquemias 
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multifocales, siendo 2.5x105 la dosis máxima 
administrable encontrada. 
7. Los experimentos in vivo de vectorización magnética 
han evidenciado que no es posible incrementar el 
número de células madre mesenquimales marcadas 
por la acción de campos magnéticos bajo nuestras 
condiciones experimentales.  
8. Las células madre mesenquimales marcadas y 
administradas a través de la vena yugular han sido 
detectadas en los pulmones, sin que se haya 
observado migración de las mismas al cerebro del 
animal. 
9. El marcaje con  nanopartículas superparamagnéticas 
recubiertas de dextran ha permitido la discriminación 
entre células inyectadas y células del cerebro del 
animal mediante técnicas de microscopía electrónica. 
Nuestros resultados sugieren que las células madre 
mesenquimales en algunos casos han permanecido en 
el interior de los vasos, mientras que en otros, han 
cruzado al parénquima cerebral de un animal sano 4h 
tras ser administradas. 
10. Hemos demostrado que las nanopartículas 
superparamagnéticas desarrolladas en este trabajo 
son la herramienta idónea para estudiar la migración 
celular a nivel cerebral con células administradas tanto 
i.a. como i.v.  
11. Bajo nuestras condiciones experimentales, no hemos 
observado que la administración intra-arterial suponga 
una mejora en términos de riesgo beneficio respecto la 
administración intravenosa de células madre 
mesenquimales.  
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In this section we present several moments of beauty in our 
day-to-day research. Maybe results of those experiments 
were not what we were looking for, however the images 
remain beautiful. 
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Figure 121: TEM micrograph of a mesenchymal stem cell labeled with 
Tetronic 908-coated superparamagnetic nanoparticles. Apart from 
spherical-shape particles, one fiber was wrapped with the polymer and 
the cell also included it.  
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Figure 122: Magnification of Figure 121, where it is possible to observe 
how the Tetronic 908-wrapped fiber is fully internalized. 
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Figure 123: Optical image of dextran-labeled mesenchymal stem cells 
after 2D vectorization stained with Prussian Blue. One magnet was 
placed below the Petri-dish, cells were vectorized to that region and got 
attached to the surface. 
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Figure 124: Optical image of dextran-labeled mesenchymal stem cells 
after 2D vectorization stained with Prussian Blue. Two magnets were 
placed below the Petri-dish close enough to observe their attraction on 
the distribution of the attached cells.  
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Figure 125: MR T2 weighted image of one brain slice of a Wistar rat 7 days 
after the onset of the cerebral ischemia. Black and white ring 
inhomogeneities were observed at the last part of the internal carotid 
artery. T2* weighted image and MR angiography of this animal is shown in 
Figure 126 and Figure 127 respectively. 
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Figure 126: MR T2* weighted image of one brain slice of a Wistar rat 7 
days after the onset of the cerebral ischemia. White density surrounded 
by a black ring was observed at the last part of the internal carotid 
artery. Hemorrhagic event was discarded due to the white density 
observed. MR angiography of this animal is shown in Figure 127. 
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Figure 127: (A) Brain slice of MR angiography of one brain slice of a Wistar 
rat 7 days after the onset of the cerebral ischemia where it is possible to 
note that anterior cerebral artery is expanded. (B) Z-Projection of MR 
angiography where the aneurism can be observed.  
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Figure 128: MR T2* weighted image of one brain slice of a Wistar rat 8h  
after the onset of the cerebral ischemia and 4h after the intra-arterial 
administration of 106 Mesenchymal stem cells labeled with dextran 
coated superparamagnetic nanoparticles.  
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Figure 129: TEM micrograph of a brain capillary wall. (From the left to the 
right) Black shape corresponds to a red blood cell inside the vessel. The 
wall of the vessel is composed by endothelial cells, basal membrane, 
smooth muscle cells, basal membrane and astrocytic processes.  
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Figure 130: Two mesenchymal stem cells can be observed inside a 
capillary transversally observed by TEM micrograph. Their membranes 
allow its differentiation, and black hypointensities point out the nature of 
these cells.  
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Summary 
Cerebrovascular diseases are the second cause of death 
and the first cause of disability in developed countries. 
However, despite their social and economical importance, 
therapies for these diseases are quite limited. The most 
common etiology of stroke, ischemic stroke, consists in the 
reduction of blood flow in a brain area after the occlusion 
of a cerebral artery. This process triggers a series of events 
at molecular and cellular levels that leads to energy 
depletion in the affected area, yielding on a quick process 
of cell death by necrosis. This area is called the infarct core. 
The surrounding zone, usually called the ischemic 
penumbra but probably better defined as the peri-infarct 
area, it is constituted by hypo-perfused tissue. Here, blood 
flow is reduced to maintain electric activity, but cerebral 
tissue is still viable. This area is subjected to a wave of 
deleterious metabolic processes that propagate from the 
ischemic core to the neighboring tissue, including 
excitotoxicity, spreading depression, oxidative stress, and 
inflammatory response, all of them leading to the expansion 
of the ischemic core into the peri-infarct region, and 
subsequent worsening of the clinical outcome. 
So far, pharmacological thrombolysis or mechanical 
reperfusion are the strategies that report higher benefits in 
the acute phase for the patients, in terms of neurological 
outcome, being the recombinant tissue plasminogen 
activator (rt-PA) the most common thrombolytic agent. 
However, only 3-7% of stroke patients are currently treated 
by these procedures due to the narrow therapeutic window 
(4.5h after the onset of the symptoms) and due to the risks 
associated to this pharmacological therapy. One of the 
most important associated risks is the high rate of 
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hemorrhagic events induced by the reperfusion of the 
arteries. The efficiency of neuropretective strategies during 
the acute phase of the stroke is conditioned by the 
maintenance of the blood brain barrier, fluid homeostasis 
and disabling free radicals after a reperfusion treatment. 
Thus, several therapies have emerged with a 
neuroprotective aim while others are based on their 
neurorepair possible approaches. 
Neuroprotection is the term that includes all therapies 
aimed to reduce cell death after an ischemic process 
without influencing tissue reperfusion during the acute 
phase of the stroke. So far experimental studies of 
neuroprotective drugs have shown promising results, 
however they have failed once were applied in clinical 
trials.  
On the other hand, neurorepair strategies have a wider 
therapeutic window than the acute phase of stroke. These 
strategies involve the restoration of brain function, either by 
regeneration of damaged cerebral tissue 
(neuroregeneration) or by the establishment of alternative 
neuronal pathways or synapses (brain plasticity).  In this 
way, neurorepair therapies are not restricted to neurons, 
since the repair of the neurovascular unit includes also 
procedures focused in the enhancement of angiogenesis 
and synaptogenesis. Neurorepair treatments may include 
pro-neurogeinc, pro-angiogenic and pro-synaptogenic 
drug administration, but stem cell therapies as well.  
Cell based therapies have emerged as a promissing 
approaches to conventional pharmacological treatments 
due to their multipotential action mechanisms. Integration 
in the host, immunomodulation processes or growth factors 
secretion are the possible ways of action, however 
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fundamental questions related to cell type, 
characterization and dosage, therapeutic timing versus 
toxicity or the relationship between biodistribution, fate and 
outcome must be elucidated. Several types of stem cells 
have demonstrated beneficial effects in preclinical studies 
of ischemic stroke, including Embrionic Stem cells (ESCs), 
Neural Stem Cells (NSCs), Induced Pluripotent Stem Cells 
(iPSCs) and Mesenchymal Stem Cells (MSCs) among others, 
and different administration time points and delivery routes 
have been studied.  
MSCs are one of the best candidates for regenerative 
therapies, also in stroke, not only due to their 
multipotentiality, but mainly because of their ability of 
releasing growth factors and their immunomodulatory 
properties. Several mechanisms of action of these cells in 
the ischemic brain have been described, mechanisms like 
transdifferentiation into cells of neural lineage, induction of 
neurogenesis, angiogenesis, synaptogenesis, activation of 
endogenous restorative processes by producing cytokines 
and trophic factors, regulating the cerebral blood flow and 
the blood brain barrier and other neuroprotective 
mechanisms like the reduction of apoptosis, immflamation, 
demyelination and the increase of astrocyte survival. 
Moreover, several studies have reported functional 
recovery and infarct volume reduction after ischemic stroke 
following different administration routes of MSC delivery. A 
large number of preclinical and clinical trials have used 
systemic infusion of these cells, nevertheless it is still 
necessary to understand if transplanted MSCs can home to 
and engraft at ischemic and injured sites in the brain to 
exert their therapeutic effects. On one hand, brain 
intraparenquimal and intraventricular administration routes 
are invasive and it would be necessary several injection 
sites to cover the ischemic region. On the other hand, tail, 
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jugular or femoral intravenous administrations are less 
invasive but most of cells remain trapped in lungs, liver and 
spleen. In spite of this, intra-arterial administration route 
would be the best candidate to direct most of the injected 
cells to the brain, especially on the region of the ischemic 
injury. Some studies have shown that approximately 21% of 
the delivered cells after an intra-arterial injection were 
found in the ipsilateral hemisphere, while a recent study has 
reported that 24h after injection, 95% of the delivered cells 
were found in the spleen, however, administration 
procedures for intra-arterial delivery in these studies were 
different. Thus, due to the high variability reported in 
preclinical studies of stem cell therapy in animal models of 
ischemic stroke, the fate of the injected cells following the 
intra-arterial delivery route remains unknown. 
Several imaging techniques combined with cellular labeling 
agents have been developed to monitor the fate of 
injected cells following different administration routes. 
However, for stem cell therapy the goal of imaging 
techniques is double. On one hand is crucial to determine 
where and when the cells are, but on the other hand 
imaging modality is also important to evaluate the 
pathological progress of the target organ as well. 
Nowadays, magnetic resonance imaging (MRI) is one of 
the most powerful medical diagnostic tools available due 
to the high resolution images, but also because of the non-
invasive and no ionizing radiation nature of the technique. 
Moreover, MRI is the gold standard not only in the acute 
phase of the stroke; as well to evaluate the progression of 
the pathology. Nevertheless, administered cells are too 
small to be detectable in MRI. In order to overcome this 
limitation, the use of biocompatible contrast agents to label 
injected cells leads us to an in vivo real time monitoring of 
delivered cells without harmful side effects. Thus, 
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superparamagnetic nanoparticles (MNPs) are an excellent 
tool for stem cell labeling, not only for the high quality of the 
MRI image, for the low toxicity and the ease for tagging as 
well.  
MNPs for biological applications are basically composed by 
a magnetic core of nanocrystalline magnetite or 
maghemite, which provides MRI signal, and this core is 
wrapped with a polymeric coating, which not only gives 
colloidal stability and protects the core from degradation, 
but will condition the future biological application as well. 
Particularly, MNPs for cell tracking must be specific of the 
studied type of cell, detectable at low concentrations, 
reasonable clearing period, stable and the associated 
toxicity must be low. In addition to these tagging properties, 
cells labeled with MNPs could be guided by using external 
magnetic fields due to the magnetic nature of the core of 
these contrast agents, enabling not only the detection, but 
the vectorization of the stem cell therapy as well.   
Overall, in this work we have hypothesized that it is possible 
to synthesize biocompatible   superparamagnetic 
nanoparticles for in vivo cell tracking. Superparamagnetic 
nanoparticles-tagged cells can be monitored in vivo by MRI 
and guided with magnetic fields without harmful effects, 
providing information of the cellular fate after different 
routes of administration. Moreover, the nanoparticle 
labeling will allow us to study therapeutic effects in an 
animal model of ischemic stroke based on the localization 
of the cells after delivery.  
In order to synthesize biocompatible MNPs, coprecipitation 
method was used. The main advantages of coprecipitation 
procedure are the ease for the synthesis and the high 
amount of MNPs obtained. Thus three types of coated 
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superparamagnetic nanoparticles were synthesized and 
characterized in this study. 
Dextran is one of the most widely polymers used as 
magnetic nanoparticle coating due to its reported 
biocompatibility. The synthesis of dextran coated MNPs (D-
MNPs) was performed by following a one step procedure, 
i.e. the magnetite is formed under the presence of this 
polymer. The characterization of the dextran-coated 
superparamagnetic nanoparticles was performed 
attending to the magnetic core and to the coated MNP. 
On one hand, magnetic cores of synthesized D-MNPs have 
a spherical shape with a mean size of 3.7±0.8 nm measured 
by TEM and 4.8±0.5 nm measured with X-ray diffraction 
analysis (XRD), and with regard to the composition, the D-
MNPs synthesized magnetic cores were found to be a 
combination of magnetite and maghemite as showed the 
lattice parameter measured by XRD (8.33±0.02 Å). The 
magnetic characterization of the D-MNPs reported that at 
300K these MNPs exhibit superparamagnetic behavior. In 
addition, Fourier-transform infrared spectroscopy (FTIR) and 
thermal gravimetric analysis (TGA) reported the polymer 
absorption onto the surface of the MNPs, demonstrating 
that magnetic cores are wrapped by dextran coating. 
Moreover, the mean size of these coated MNPs measured 
by dynamic light scattering (DLS) was 94±3 nm and they are 
negatively charged -11±3 mV determined by Z-Potential. 
MR T2-weighted images of D-MNPs phantoms were 
acquired, evidencing that dextran- coated 
superparamagnetic nanoparticles feasibility as contrast 
agents for MRI. 
Apart from dextran, other polymers can be also used as 
MNPs coating. This is the case of the poloxamers and 
poloxamines, which their use have been approved by FDA 
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and EMEA for several applications in food, pharmaceutical 
and agricultural industries. Among all of them, Pluronic F127 
and Tetronic 908 were also used in this work as MNPs 
coatings. The synthesis procedure for Pluronic F127- and 
Tetronic 908-coated superparamagnetic nanoparticles (P-
MNPs and T-MNPs respectively) was a two step method. 
First, after the formation of the magnetic cores by following 
the coprecipitation method, a surrounding layer of oleic 
acid was created on the cores surface for further polymer 
anchoring. After this first step, magnetic core mean sizes 
were 8.6±1.4 nm determined by TEM, 7.7±0.8 nm measured 
by DLS and 7.7±0.8 nm by XRD. Moreover, XRD data have 
shown that magnetic cores are composed by magnetite 
and maghemite with an associated lattice parameter of 
8.361±0.004 Å, and VSM data reported that MNPs exhibit 
superparamagnetic behavior at 300K. The second step for 
P-MNPs and T-MNPs synthesis was the polymer 
functionalization, FTIR and TGA data demonstrated the 
presence of oleic acid and polymers in each MNP 
formulation and P-MNPs mean size was 120±6 nm measured 
by DLS while T-MNPs was 154±6 nm. Both Z-Potentials were 
found negative, -18±3 mV for P-MNPs and -24±3 mV for T-
MNPs. MR T2-weighted images of P-MNPs and T-MNPs 
phantoms were acquired, evidencing the feasibility of 
Pluronic F127 and Tetronic 908- coated superparamagnetic 
nanoparticles as contrast agents for MRI. 
Physicochemical characterization of D-MNPs, P-MNPs and 
T-MNPs suggested the suitability for being used as contrast 
agents for cell tracking in MRI. However, an in vitro study of 
cell labeling, biocompatibility and MRI signal detection was 
needed prior to in vivo cell tracking studies.  
Several studies have reported the need of different 
techniques for an efficient cell tagging, and among all of 
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them transfect agents (TA) as poly-l-lysine (PLL) are the most 
used. Preliminary experiments using dextran-, Pluronic F127- 
and Tetronic 908- coated MNPs have shown that only D-
MNPs needed PLL to tag cells, while P-MNPs and T-MNPs 
were internalized without the use of TA. Experimental data 
revealed that 1.5 μg/mL of PLL combined with D-MNPs 
ensured a full internalization of MNPs without harmful effects 
for the cells. 
In order to study the biocompatibility and elucidate which 
was the best superparamagnetic nanoparticle for cell 
tagging, D-MNPs combined with PLL, P-MNPs and T-MNPs 
were evaluated in vitro by using rat MSCs and a mice multi-
potent neural progenitor cell line C17.2. Several parameters 
as incubation time and MNPs concentration were also 
studied. The observed uptake mechanism for D-MNPs was 
different from P-MNPs and T-MNPs; the first one was 
conditioned by the concentration and incubation time, 
while for P-MNPs and T-MNPs the internalization depended 
mostly on the MNP concentration in the cell medium. MNPs 
influence on the cellular wellbeing depended on the 
internalized iron; thus proliferation and viability was reduced 
for those cells with more than 28 pg of iron/cell. Moreover, 
the combination of MRI and TEM techniques showed that 
MNPs were fully internalized, and MR T2 and T2* weighted 
images showed that labeled cells could be properly 
detected in MRI, providing promising results for further in 
vivo applications. Overall, considering the MNPs distribution 
in the cell, amount of internalized iron, proliferation and 
viability, D-MNPs were pointed as the best candidates for 
cell labeling.  
However, the biocompatible study of D-MNPs with different 
types of cells was performed just after labeling. Prior to go 
into in vivo studies of cell tracking, a long term evaluation of 
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labeled cells and how the cellular proliferation rate 
influenced the MR signal was evaluated.  
Because of the multi-potential abilities of MSCs and with the 
aim of a future stem cell therapy in an animal model of 
ischemic stroke, the long term biocompatibility study and 
the evaluation of the MRI signal clearance with the 
proliferation was performed in MSCs. Experimental results 
showed that labeled cells did not differ from control cells in 
terms of proliferation rate and viability after 5 days, as well 
as the maintenance of CD45-, CD90+ and CD73+ cellular 
phenotype. Angiogenesis capacity was not altered by the 
presence of internalized D-MNPs, as well as vascular 
endothelial growth factor (VEGF) release measurements did 
not exhibit differences between control and labeled cells. 
Under the labeling conditions studied and for cell tracking 
applications, MRI can easily detect labeled cells in a 
phantom 3 days after being tagged. From then, MRI signal 
is affected by the clearance of the internalized D-MNPs due 
to proliferation, being only possible to detect MNPs loaded 
cells by ICP techniques.  
In addition to MRI cell detection, dextran coated 
superparamagnetic nanoparticles could be combined with 
magnetic fields for enhancing targeted delivery of stem 
cells. In this work the in vitro efficacy of cellular magnetic 
vectorization in a liquid environment without harmful effects 
for future targeted delivery of stem cells has been 
demonstrated. However, in a non-liquid environment the 
use of external magnetic fields for labeled cell vectorization 
showed no cellular migration. 
Overall, the in vitro validation of synthesized 
superparamagnetic nanoparticles suggest that MSCs 
loaded with D-MNPs were a promising tool for cell tracking 
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and cellular magnetic vectorization in vivo without cellular 
harmful effects. 
In order to elucidate if labeled cells could be detected in 
vivo and to corroborate that MRI signal corresponded to 
labeled cells and not to free particles, the 
intraparenchymal injection was the best approach. 
Moreover, in addition to MNPs labeling, MSCs can be 
tagged also with CFSE, which let us not only in vivo cell 
tracking, ex vivo MSCs identification as well. In order to 
assess the efficiency of this double labeling, 
intraparenchymal injections for MSCs delivery were 
performed. Histology demonstrated that injected cells were 
still labeled with D-MNPs 4h after the injection and no 
particles were found outside of the cells assessed by CFSE 
and Prussian blue staining. Therefore, MRI in vivo signal 
corresponded to labeled MSCs and not to free particles. 
Animal models of cerebral ischemia are designed to 
generate reproducible infarcts with a minimum of surgical 
manipulation; however therapeutic approaches have to 
be also optimized for each disease. Thus, optimal conditions 
for applying stem cell therapies for cerebral ischemia are 
still under discussion, fundamental questions related to cell 
type, characterization and dosage, administration route, 
therapeutic timing, toxicity, or the relationship between 
biodistribution, fate and outcome are still on the bench. 
Administration routes of labeled cells was a crucial 
parameter to take into account not only for cell tracking, 
but for stem cell therapy as well.  
For intra-arterial delivery route, different combinations of 
animal models of ischemic stroke and intra-arterial 
administration routes of MSCs were studied. In order to 
elucidate which model was the most efficient and the 
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safest for an intra-arterial injection, MSCs labeled with D-
MNPs were used. The optimization of the method for 
transient middle cerebral artery occlusion (tMCAO) and 
intra-arterial delivery of tagged cells was performed by 
using D-MNPs labeled MSCs. Thus, for an efficient intra-
arterial delivery, after tMCAO surgery the common carotid 
artery must be perfused and also during and after the cell 
administration (that is performed through the external 
carotid artery) so the heart pumping would help on 
carrying the delivered cells to the brain territory.  
These intra-arterial injected cells could be detected in the 
ischemic brain for more than 4h after injection, and their 
presence was not increased by the use of external 
magnetic fields, as magnetic vectorization. Moreover, the 
monitoring of cerebral blood flow (CBF) by transcranial laser 
Doppler was not enough to assess the safety of the intra-
arterial delivery,  and healthy animals injected with 2.5x105 
MSCs showed multifocal ischemic lesions 24h after the stem 
cell administration, evidencing that injected cells could be 
inducing focal ischemias.  
Tracking of administered cells is important to understand 
the relationship between possible therapeutic mechanisms 
and cell localizations. Intraparenchymal injection is a 
feasible administration route, however it is not the preferred 
for stem cell delivery due to the high invasiveness of the 
technique. Less invasive routes for stem cell delivery are 
intravenous and intra-arterial injection. We have studied the 
fate after the injection of labeled cells through jugular vein 
and through the internal carotid artery and we have found 
important differences between them. On one hand, we 
have assessed by MRI and/or histochemistry techniques 
that cells injected through jugular vein were found in the 
lungs and no cells were detected in the brain, both in 
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healthy and ischemic animals.  On the other hand, 
following the intra-arterial route we have demonstrated 
that, for ischemic or non-ischemic animals, injected MSCs 
were found in the brain and no cells can be detected in 
other organs, opening a big window for further stem cell 
therapy administration. 
Because of the blood brain barrier integrity in healthy 
animals and its disruption in ischemic ones, we also studied 
the localization of the injected cells by 
immunohistochemistry techniques after an intra-arterial 
administration. By CD31 staining and CFSE labeling it was 
possible to assess that injected cells were found in small 
vessels along the brain while large ones do not express CFSE 
positive cells. This selective intra-vessel localization could 
explain the multifocal ischemias observed in ischemic and 
non-ischemic intra-arterial injected rats, however because it 
was necessary to perfuse de animal to perform 
immunohistochemistry, other technique for corroborating 
this result was studied.  
Preliminary results of electron microscopy have shown that  
MSCs labeled with D-MNPs were able to migrate into brain 
parenchyma in a healthy animal after an intra-arterial 
delivery of one million cells. However, TEM images of same 
animal also revealed vessel occlusions with MSCs and fibrin 
reaction associated which could explain previous results of 
multifocal ischemias. Nevertheless, more studies of intra-
arterial administration of D-MNPs labeled MSCs at different 
time points are needed for a better understanding of these 
mechanisms.  
Thus, intra-arterial injection was found as the most efficient 
administration route for brain targeting, and also MSCs 
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delivered following intra-jugular injection resulted in cell 
entrapment in the lungs, with no cells reaching the brain.  
Finally, MSCs were intra-arterially and intravenously 
delivered during the acute phase in a cerebral ischemia 
model to investigate whether the cell distribution, and 
therefore administration route may improve the therapeutic 
outcome. MRI studies, behavioral tests, histological 
examinations and blood serum determinations were 
performed to evaluate the therapeutic benefits of the 
treatment. Experimental results showed that only cells 
injected intra-arterially reached the brain and were 
detectable for 3 days after the delivery, guaranteeing the 
cellular proximity to the injury site. Under our experimental 
conditions and by using D-MNPs, we have assessed that the 
local effect of MSCs injected following intra-arterial route 
did not improve the outcome after a cerebral ischemia 
compared to a systemic administration following the 
intravenous route. 
In summary, we have synthesized biocompatible   
superparamagnetic nanoparticles for in vivo cell tracking. 
Superparamagnetic nanoparticles-tagged mesenchymal 
stem cells can be monitored in vivo by MRI without harmful 
effects, providing information of the cellular fate after 
different routes of administration. Moreover, the 
nanoparticle labeling allowed us the study of therapeutic 
effects in an animal model of ischemic stroke based on the 
localization of the cells after delivery.  
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Resumen 
Las enfermedades cerebrovsculares son la segunda causa 
de muerte y la primera de discapacidad en países 
desarrollados. Sin embardo, a pesar de su importancia 
socio-económica, las terapias disponibles son limitadas. La 
etiología más frecuente del ictus, el ictus isquémico, 
consiste en la reducción localizada del flujo cerebral tras la 
oclusión de una arteria cerebral. Este proceso 
desencadena una serie de eventos a nivel molecular y 
celular que culminan con un fallo energético en el área 
afectada, seguida de un proceso de muerte celular por 
necrosis. Esta área recibe el nombre de core isquémico. La 
región circundante, llamada penumbra isquémica pero 
normalmente definida como región peri-infarto, está 
constituida por tejido hipoperfundido. En esa región el flujo 
cerebral se encuentra reducido para mantener la 
actividad eléctrica, pero el tejido es todavía viable si se 
establece el flujo cerebral. Esta área se encuentra además 
sometida a una serie de procesos metabólicos que se 
propagan desde el core isquémico al tejido circundante, 
incluyendo procesos de exitotoxicidad, estrés oxidativo, 
respuesta inflamatoria, condicionando el pronóstico 
clínico.  
La trombolisis farmacológica o la reperfusión mecánica son 
las estrategias que reportan mejores beneficios a los 
pacientes, en términos de pronóstico neurológico, siendo el 
activador tisular del plasminógeno recombinante (rt-PA) el 
más común de todos ellos. Sin embargo, solo entre el 3 y el 
7% de los pacientes con un ictus pueden beneficiarse de 
esta terapia debido principalmente la estrecha ventana 
terapéutica de aplicación (4.5h tras el comienzo de los 
síntomas) y también debido a los riesgos asociados a esta 
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terapia farmacológica. Uno de los riesgos más relevantes 
es el alto grado de transformación hemorrágica inducida 
por la reperfusión de las arterias. Así, el mantenimiento de 
la barrera hematoencefálica, la homeostasis de los fluidos, 
y el bloqueo de los radicales libres tras el tratamiento de 
reperfusión constituyen algunas de las principales 
estrategias neuroprotectoras durante la fase aguda del 
ictus. 
 La neuroprotección es un término que incluye a todas las 
terapias dirigidas a reducir la muerte celular tras un proceso 
isquémico sin ejercer ningún tipo de influencia en la 
reperfusión del tejido durante la fase aguda del ictus. Hasta 
ahora, algunos fármacos han mostrado resultados 
prometedores en estudios experimentales, pero una vez 
trasladados a ensayos clínicos no han demostrado su 
eficacia. 
Por otro lado, las estrategias neurorreparadoras cuentan 
con una ventana terapéutica mayor que la fase aguda del 
ictus. Estas estrategias incluyen la restauración de la 
función cerebral, ya sea bien por regeneración del tejido 
cerebral dañado (neurorregeneración) o bien por la 
creación de nuevas conexiones neuronales o sinapsis 
(plasticidad cerebral). De esta forma, las terapias de 
neurorreparación no están exclusivamente dirigidas a 
neuronas, ya que la restauración de la unidad 
neurovascular incluye también procedimientos enfocados 
a la potenciación del a angiogénesis y sinaptogénesis. Los 
tratamientos neurorreparativos incluyen pues la formación 
de nuevas neuronas, sinapsis, y vasos, ya sea por la 
aplicación de nuevas terapias farmacológicas o bien por 
tratamiento con células madre.  
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La terapia celular ha surgido como una estrategia 
prometedora frente a tratamientos farmacológicos 
convencionales debido a sus múltiples y potenciales 
mecanismos de acción, entre los cuales se han destacado 
la integración de las células administradas en los tejidos, 
procesos de inmunomodulación o secreción de factores 
de crecimiento. Sin embargo, otros aspectos como el tipo 
celular, dosis, ventana terapéutica, toxicidad o la relación 
entre biodistribución y pronóstico deben ser todavía 
estudiadas en profundidad. En cuanto a la estirpe celular, 
varios tipos celulares han demostrado efectos beneficiosos 
en estudios preclínicos de isquemia cerebral, incluyendo 
células madre embrionarias, células madre neurales, 
células madre pluripotentes inducidas y células madre 
mesenquimales (MSCs) entre otras. En numerosos estudios 
también se han evaluado diferentes tiempos y rutas de 
administración con prometedores resultados.  
Las MSCs han sido descritas como son unas de las 
candidatas favoritas para terapias regenerativas no sólo en 
el campo de la isquemia cerebral. Esto se debe no sólo a  
que son multipotentes, sino también a sus capacidades 
inmunomoduladoras y de secreción de factores de 
crecimiento. En los últimos años se han descrito varios 
mecanismos de acción de esas células en el cerebro 
isquémico, como su diferenciación a células de estirpe 
neural, inducción de la neurogénesis, angiogénesis, 
sinaptogénesis, activación de procesos endógenos, 
regulación del flujo sanguíneo cerebral, y otros 
mecanismos neuroprotectores como la reducción de la 
apoptosis, de la inflamación o incremento de la 
supervivencia astrocitaria, entre otros. Además, algunos 
estudios preclínicos en roedores han encontrado 
recuperación funcional y reducción del volumen de infarto 
siguiendo diversas rutas de administración de éstas células. 
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Aunque la administración sistémica es la preferida para la 
mayoría de estos ensayos in vivo con células madre hasta 
el momento, no está claro todavía si las células 
administradas van a ejercer su efecto terapéutico desde el 
cerebro o desde otra parte del cuerpo.  
Las inyecciones intraparenquimal e intraventricular 
aseguran una localización cerebral de las células 
inyectadas, pero esta técnica es altamente invasiva y 
requeriría de múltiples inyecciones para abarcar la lesión 
isquémica. Siguiendo rutas de administración sistémicas y 
por tanto menos invasivas, en diversos estudios se ha 
observado que la mayoría de las células administradas 
intravenosas en cola, yugular o vena femoral se han 
encontrado en pulmones, hígado o bazo, y muy pocos 
estudios apuntan a una migración cerebral. Por otro lado, 
la inyección intra-arterial está descrita como la mejor vía 
para dirigir células al cerebro, especialmente a la región 
isquémica. Algunos trabajos han demostrado que 
aproximadamente un 21% de las células administradas 
intra-arterialmente fueron halladas en el hemisferio 
ipsilateral, mientras que un estudio más reciente ha 
observado que 24h tras la administración, el 95% de las 
células inyectadas se encontraban en el bazo; esta 
variedad de resultados podría residir en que los 
procedimientos de administración celular intra-arterial son 
diferentes entre estudios. Así, todavía se necesitan más 
trabajos de seguimiento tras la administración intra-arterial 
de células madre en modelos animales de ictus isquémico. 
Para estudiar la biodistribución, se han desarrollado varias 
técnicas de imagen combinadas con marcajes  celulares 
específicos siguiendo distintas rutas de administración. Estas 
técnicas aplicadas a terapia celular tienen un papel doble; 
el de seguimiento celular tras la inyección en tiempo real, y 
 349 
 
el de evaluación de la progresión de la patología. Hoy en 
día, la resonancia magnética nuclear (RMN) es una de las 
mejores herramientas de diagnóstico disponibles, no solo 
por la alta resolución de sus imágenes, sino también por su 
carácter no invasivo y radiación no ionizante. Además, la 
RMN es el gold standard no sólo en la fase aguda del ictus, 
sino también como herramienta para evaluar la progresión 
de la enfermedad. Sin embargo, las células inyectadas son 
demasiado pequeñas para poder ser visualizadas por RMN. 
Para su detección y estudio es necesario el uso de agentes 
de contraste que marquen esas células y que permitan 
una monitorización en tiempo real de las células 
administradas sin efectos colaterales, tanto para las células 
como para el paciente. En esta línea, las nanopartículas 
superparamagnéticas (MNPs) son una herramienta idónea 
para marcaje celular, no sólo por el alto contraste que 
generan en RMN, sino también por la reducida toxicidad y 
sencillez en el proceso de marcaje.  
Las MNPs para aplicaciones biológicas están compuestas 
básicamente por un núcleo de magnetita o maghemita, 
que proporciona la señal en RMN, el cual está rodeado por 
una cubierta normalmente polimérica, que no sólo 
proporciona estabilidad coloidal, sino que también lo 
protege de la degradación y condiciona las futuras 
aplicaciones biomédicas. Las nanopartículas destinadas al 
seguimiento celular por RMN han de tener ciertas 
características especiales, como ser específicas para cada 
tipo celular, detectables a concentraciones bajas, estables 
y de toxicidad reducida. Además de esas propiedades de 
seguimiento, las células marcadas con MNPs poseen 
también propiedades de vectorización magnética, es 
decir, pueden ser guiadas mediante campos magnéticos 
externos debido a la naturaleza magnética del núcleo de 
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las MNPs, posibilitando no sólo la detección celular por 
RMN sino también la vectorización de la terapia celular.  
Así, la hipótesis de este trabajo se basó en la síntesis de  
nanopartículas superparamagnéticas biocompatibles para 
seguimiento celular in vivo. Las células marcadas con estas 
nanopartículas superparamagnéticas pueden ser 
monitorizadas in vivo por técnicas de RMN y guiadas 
mediante campos magnéticos externos sin dañar a las 
células y proporcionando información de la biodistribución 
celular siguiendo distintas rutas de administración. Además, 
este marcaje nos permitirá el estudio de los efectos 
terapéuticos en un modelo animal de isquemia cerebral 
dependiendo de la localización de las células tras la 
administración.  
La síntesis de MNPs biocompatibles se llevó a cabo 
mediante el procedimiento de coprecipitación química.  
Es un método simple que proporciona gran cantidad de 
nanopartículas en pocos pasos. En este trabajo se 
sintetizaron 3 tipos de nanopartículas con distintos 
recubrimientos poliméricos.  
El dextrano es uno de los polímeros más utilizados como 
recubrimiento de nanopartículas debido a su alta 
biocompatibilidad. La síntesis de nanopartículas recubiertas 
de dextrano (D-MNPs) se llevó a cabo mediante un 
procedimiento de un solo paso (one step), donde la 
magnetita se forma en presencia del polímero. Según la 
técnica empleada, ha sido posible la caracterización 
independiente de los núcleos y del conjunto núcleo y 
recubrimiento. Por un lado, los núcleos presentaron una 
morfología esférica con un tamaño medio de 3.7±0.8 nm 
medido mediante TEM y 4.8±0.5 nm medido por X-ray 
diffraction analysis (XRD). La composición de los núcleos 
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fue una mezcla de magnetita y maghemita, como muestra 
el lattice parameter medido por XRD (8.33±0.02 Å). La 
caracterización magnética de las D-MNPs ha puesto de 
manifiesto que a 300K el comportamiento es 
superparamagnetico. Además, los resultados obtenidos por 
Fourier-transform infrared spectroscopy (FTIR) y thermal 
gravimetric analysis (TGA) han mostrado que el polímero se 
encuentra en la superficie de las MNPs, demostrando que 
los núcleos están envueltos por una cubierta de dextrano. 
Los tamaños medios de las nanopartículas recubiertas 
medidos por dynamic light scattering (DLS) fueron 94±3 nm 
and y estaban cargadas negativamente (-11±3) mV. Y en 
último lugar, las imágenes de RMN con peso T2 de los 
phantoms de D-MNPs demostraron que estas 
nanopartículas podían ser usadas como agentes de 
contraste de resonancia magnética nuclear.  
Además del dextrano, otros polímeros pueden ser usados 
como recubrimiento de MNPs. Es el caso de los poloxamers 
y poloxamines, cuyo uso ha sido aprobado por la FDA y 
EMEA para diversas aplicaciones en comida, e industrias 
farmacéutica y agrícola. Entre todos ellos, el  Pluronic F127 
y el Tetronic 908 fueron los elegidos como cubiertas 
poliméricas en este trabajo. El procedimiento de síntesis 
para Pluronic F127 y Tetronic 908 (P-MNPs and T-MNPs 
respectivamente) es un método de dos etapas (two step). 
Primero, y tras la formación de los núcleos magnéticos 
siguiendo el proceso de coprecipitación química, se creó 
una capa de ácido oleico en la superficie del núcleo que 
fué posteriormente utilizada para anclaje polimérico. Tras 
este primer paso, el tamaño medio de los núcleos 
recubiertos de ácido oleico fue 8.6±1.4 nm determinado 
mediante TEM, 7.7±0.8 nm determinado mediante DLS y 
7.7±0.8 nm medido por XRD. Además, los núcleos están 
compuestos por una mezcla de magnetita/maghemita tal 
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como muestra el lattice parameter, 8.361±0.004 Å, y los 
resultados de VSM muestran que el comportamiento de 
estas nanopartículas a 300K es superparamagnético. El 
segundo paso en la síntesis de estas nanopartículas fue la 
funcionalización de su superficie con una cubierta 
polimérica de Pluronic F127 y Tetronic 908. Los resultados 
experimentales de FTIR and TGA demostraron la presencia 
de ácido oleico y polímero en cada formulación de MNPs, 
y que el tamaño medio de P-MNPs fue 120±6 nm 
determinado por DLS mientras que para T-MNPs fue 154±6 
nm. Ambos potenciales Z fueron negativos y de valor 
medio -18±3 mV para P-MNPs y -24±3 mV para T-MNPs, y las 
imágenes de resonancia con peso T2 de ambos tipos de 
nanopartículas corroboraron su futura aplicación como 
agentes de contraste para RMN.  
La caracterización fisicoquímica de las D-MNPs, P-MNPs y T-
MNPs han puesto de manifiesto las grandes  capacidades 
de estas nanopartículas como agentes de contraste para 
seguimiento celular por RMN. Sin embargo, fue necesario el 
estudio in vitro de biocompatibilidad, marcaje celular y 
detección por RMN antes de pasar a estudios de 
seguimiento in vivo.  
Para mejorar la eficiencia de transfección con 
nanopartículas, diversos estudios han publicado la 
necesidad de diferentes técnicas, y entre todos ellos el uso 
de agentes transfectantes como la poly-L-lysine (PLL) son 
los más utilizados. Experimentos preliminares en cultivos 
celulares con D-MNPs, P-MNPs y T-MNPs han puesto de 
manifiesto que sólo fue necesario el uso de PLL para el 
marcaje con D-MNPs, mientras que las células incubadas 
con P-MNPs y T-MNPs internalizaron directamente estas 
nanopartículas. Así, es necesaria la utilización de 1.5 μg/mL 
PLL para una internalización completa de D-MNPS.  
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Con el fin de estudiar la biocompatibilidad y verificar cuál 
es la nanopartículas superparamagnética más idónea 
para marcaje celular, se llevaron a cabo experimentos de 
marcaje con dos tipos celulares, MSCs de rata y multi-
potent neural progenitor cell line C17.2 de ratón y con los 3 
tipos de MNPs, D-MNPs combinadas con PLL, P-MNPs y T-
MNPs. También se estudiaron varios parámetros como el 
tiempo de incubación y la concentración de 
nanopartículas en el medio. El mecanismo de inclusión 
observado para las D-MNPs fue diferente del de P-MNPs y T-
MNPs; en el primero la captación de MNPs está 
mayormente condicionada por la concentración y el 
tiempo de incubación, mientras que para P-MNPs y T-MNPs 
la internalización depende en mayor medida de la 
concentración de nanopartículas en el medio. En cualquier 
caso, solo aquellas células que internalizaron más de 28 pg 
de hierro/célula expresaron proliferación y viabilidad 
reducidas. La combinación de imágenes de TEM y RMN ha 
verificado que todas las nanopartículas están 
internalizadas en el citoplasma celular, y que por tanto, la 
señal observada por RMN se corresponde con MNPs 
intracelulares. Además, las imágenes de RMN con peso T2 y 
T2* mostraron que las células marcadas pueden ser 
detectadas fácilmente por RMN, proporcionando 
resultados prometedores para futuros experimentos 
preclínicos. Así, a la vista de estos resultados de distribución 
de MNPs en las células, proliferación y viabilidad, las D-
MNPs fueron seleccionadas como las mejores candidatas 
para marcaje celular. 
Sin embargo, la evaluación de la biocompatibilidad de D-
MNPs con distintos tipos de células ha sido llevada a cabo 
inmediatamente tras el marcaje celular. Así, y antes de 
aplicar su uso in vivo fue necesario un estudio a más largo 
plazo que asegure la viabilidad celular y que además 
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proporcione información de la evolución de la señal de 
RMN con la proliferación celular.  
Considerando una futura terapia celular en un modelo 
animal de isquemia cerebral, y debido a sus múltiples 
capacidades regenerativas, el estudio in vitro de 
biocompatibilidad celular y de evolución de señal de RMN 
a largo plazo se llevó a cabo en MSCs. Su seguimiento a 
largo plazo (5 días tras la internalización de las MNPs) fue 
condicionado por la señal en RMN ya que el fin último de 
las D-MNPs es seguimiento celular por RMN.   
Los resultados experimentales mostraron iguales valores de 
proliferación y viabilidad de las células marcadas con D-
MNPs y las no marcadas tras 5 días de seguimiento, al igual 
que se mantuvo inalterada la expresión de marcadores de 
MSCs como CD45-, CD90+ and CD73+. La capacidad 
angiogénica no se encontró alterada en aquellas células 
que estaban marcadas, al igual que la secreción de 
vascular endothelial growth factor (VEGF). Considerando 
las condiciones de marcaje estudiadas y para aplicaciones 
de seguimiento celular, fue posible detectar por RMN en un 
phantom células que han sido marcadas hasta 3 días tras 
el marcaje. A partir del tercer día no fue posible detectar 
por RMN estas células ya que la cantidad de MNPs/célula 
se ha reducido debido a la proliferación celular, aunque 
los valores de ICP demostraron que todavía había 
nanopartículas internalizadas.  
Además de la detección por RMN, las D-MNPs combinadas 
con campos magnéticos externos podrían incrementar la 
presencia de MSCs en ciertas regiones de interés, como 
podría ser el cerebro en patología isquémica cerebral. Dos 
aproximaciones de vectorización magnética de MSCs 
marcadas con D-MNPs fueron estudiadas en este trabajo; 
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por un lado se estudió la vectorización en un entorno 
líquido, demostrando que esta aproximación es no sólo 
posible sino que no afecta a la viabilidad celular, y por otro 
lado, la vectorización magnética fue también evaluada en 
un entorno tridimensional, usando Matrigel como soporte. 
En este último caso no se observó migración celular.  
En general, la validación in vitro llevada  a cabo sugirió que 
las MSCs marcadas con D-MNPs  son una herramienta 
prometedora en el campo del seguimiento celular por 
RMN y para la vectorización magnética in vivo sin daños 
asociados a las células marcadas.  
Para corroborar que las células administradas pueden ser 
detectadas in vivo, y que la señal de RMN se corresponde 
a células marcadas y no a nanopartículas libres, se llevaron 
a cabo inyecciones intraparenquimales en rata sana. Las 
células administradas se marcaron con D-MNPs y también 
con CFSE, una sonda fluorescente que permitirá la 
identificación histológica de las células inyectadas. Así, los 
estudios histológicos con tinción de Prussian Blue y CFSE 
demostraron que las nanopartículas seguían internalizadas 
en las células, y que no se observaron nanopartículas libres, 
con lo que la señal de RMN observada in vivo se 
correspondió exclusivamente a células marcadas. 
Para llevar a cabo estudios fiables preclínicos de ictus 
isquémico se necesita un modelo animal de isquemia 
cerebral que proporcione lesiones isquémicas 
reproducibles y cuya cirugía sea mínimamente invasiva. Sin 
embargo también es necesaria la optimización de las 
estrategias terapéuticas para cada patología. Así, las 
condiciones óptimas para terapia celular en la isquemia 
cerebral todavía no han sido establecidas. La ruta de 
administración es un parámetro crucial, no sólo para 
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estudiar la biodistribución celular, sino también para el 
estudio de los mecanismos involucrados en la terapia 
celular.  
La administración intra-arterial está íntimamente 
relacionada con el modelo animal de ictus isquémico. La 
optimización del modelo de isquemia cerebral y de 
inyección celular se llevó a cabo atendiendo a la 
seguridad y a la eficiencia de la administración y mediante 
el uso de MSCs marcadas con D-MNPs.  Así, y tras varias 
configuraciones de las cirugías se observó que tras la 
oclusión transitoria de la arteria cerebral media (tMCAO), 
es necesario reperfundir la arteria común carótida, y que 
ésta también ha de permanecer abierta durante la 
administración de las MSCs (que se hace a través de la 
arteria carótida externa), para que la sangre procedente 
del corazón colabore en el transporte estas células al 
cerebro. Las células administradas intra-arterialmente 
pudieron ser detectadas en el cerebro isquémico durante 
más de 4h tras la inyección.  
Además, la vectorización magnetica llevada a cabo con 
un imán de 1T demostró no incrementar la presencia de 
MSCs marcadas con D-MNPs en el cerebro, desde el punto 
de vista macroscópico de imagen por RMN. Lo que sí se 
observó fue que la administración intra-arterial de 2.5x105 
MSCs en animales sanos cuyo flujo cerebral fue 
monitorizado con laser doppler transcraneal produjo 
isquemias multifocales 24h tras la administración, 
evidenciando que las mediciones por laser Doppler no son 
suficientes para asegurar el mantenimiento del flujo 
cerebral.   
El seguimiento celular es crucial para estudiar la relación 
entre localización celular y posibles mecanismos 
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terapéuticos. Las inyecciones intraparenquimales han sido 
utilizadas al comienzo de la aplicación de la terapia 
celular, sin embargo su carácter altamente invasivo hace 
que poco a poco haya caído en desuso. La administración 
intra-arterial e intravenosa son técnicas menos invasivas y 
por tanto más atractivas para terapia celular, y en este 
trabajo se ha estudiado la biodistribución de MSCs 
marcadas con D-MNPs siguiendo estas vías por RMN y/o 
técnicas histoquímicas. Así, se observó que las células 
administradas en animales sanos e isquémicos a través de 
la vena yugular se encontraban en los pulmones y no en el 
cerebro, mientras que tras una administración intra-arterial 
sólo se detectaron células en el cerebro y no en otros 
órganos. Estos resultados han abierto una vía de estudio 
que relacione la función terapéutica frente a localización 
de las células madre administradas.  
Además, se ha estudiado histológicamente mediante el 
marcaje de vasos con CD31 y el marcaje de CFSE de las 
MSCs administradas, la localización de las células 
inyectadas intra-arterialmente debido a las diferencias en 
integridad de la barrera hematoencefálica de animales 
sanos e isquémicos. Estos estudios mostraron que las células 
administradas se encontraban en pequeños vasos, 
mientras que vasos de mayor calibre no mostraron células. 
Esta presencia selectiva de pequeños vasos podría explicar 
las isquemias multifocales observadas en animales sanos e 
isquémicos tras la administración celular, sin embargo dado 
que para llevar a cabo estos estudios histológicos fue 
preciso perfundir el animal, sería adecuado utilizar otra 
técnica que confirmase estos resultados.  
Los primeros resultados de microscopía electrónica 
muestran que las MSCs marcadas con D-MNPs pueden 
migrar al parénquima cerebral en un animal sano tras una 
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administración intra-arterial de 106 de células. Sin embargo, 
imágenes de TEM del mismo animal en otra región cerebral 
evidenciaron una oclusión en un capilar producida por las 
MSCs administradas y donde también se observó una 
reacción de fibrina, lo cual explicaría así las isquemias 
multifocales observadas en este trabajo con otras técnicas. 
Estos resultados de TEM no son concluyentes, pues se 
necesitaría evaluar la migración en más animales y estudiar 
el perfil temporal de migración y/o oclusión tras la 
administración.  
Finalmente, se estudió las capacidades terapéuticas de las 
MSCs administradas intravenosas e intra-arteriales, y por 
tanto, la influencia de la distribución celular en la mejora 
tras la isquemia cerebral en un modelo animal. Para 
determinar los efectos beneficiosos de esta terapia se 
llevaron a cabo estudios de RMN, test de comportamiento, 
análisis histológico, y determinaciones en suero sanguíneo. 
Los resultados experimentales de seguimiento celular 
mostraron que sólo las células inyectadas intra-
arterialmente fueron detectadas en el cerebro del animal 
durante los 3 días siguientes a su administración. Además, 
bajo las condiciones experimentales utilizadas en este 
estudio y mediante el marcaje con D-MNPs, los animales 
tratados con MSCs administradas intra-arterialmente no 
mejoraron significativamente respecto de los tratados con 
MSCs administradas intravenosamente.      
En resumen, hemos sintetizado nanopartículas 
superparamagneticas biocompatibles para seguimiento 
celular in vivo. Las células madre mesenquimales marcadas 
con estas nanopartículas superparamagneticas pueden ser 
monitorizadas in vivo por resonancia magnética nuclear sin 
afectar a su viabilidad, proporcionando información de la 
biodistribución celular tras ser administradas siguiendo 
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distintas vías de administración. Además, el marcaje celular 
nos ha permitido el estudio de los efectos terapéuticos en 
un modelo animal de ictus isquémico basándonos en la 
localización de las células tras la administración.  
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